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1. Einleitung:  
Der gegenwärtige Mangel an Spenderorganen führt zum Rückgang der Transplantationszahlen. Die 
Rate an postmortalen Organspenden sank in Deutschland dabei von 15,8 im Jahr 2010 auf 10,7 pro 
eine Million Einwohner im Jahr 2014. In Österreich lag dieser Wert zuletzt bei 25,5 und in Spanien bei 
35,9 postmortalen Organspenden pro eine Million Einwohner (s. Abb.1). Die absolute Zahl der 
postmortal gespendeten Organe in Deutschland sank von 3200 (2010) auf rund 1900 Organe (2015), 
entsprechend einem Rückgang von über 40 %.    
                                                      
Abb.1: Postmortale Organspende in Deutschland im internationalen Vergleich, Quelle: DSO 
Im Jahr 2015 wurden in Deutschland 846 Lebern aus postmortalen Organspenden transplantiert. 
Demgegenüber standen rund 1300 Neuanmeldungen auf Wartelisten zur Lebertransplantation (12). 
Diese Diskrepanz wird durch Lebendspenden und Split-Lebertransplantationen nur unzureichend 
ausgeglichen.  
Infolge des Organmangels kommt es zu verlängerten Wartezeiten für eine Organtransplantation und 
zu einer erhöhten Wartelistenmortalität: Eine statistische Anfrage bei Eurotransplant ergab für den 
Verlauf des Jahres 2010 eine Letalität von 10,9 % unter den Patienten auf Wartelisten zur 
Lebertransplantation an deutschen Transplantationszentren. Darüber ist über die vergangenen Jahre 
ein schlechterer Gesundheitszustand der Organempfänger zu beobachten: Der durchschnittliche 
MELD-Score (model for endstage liver disease), der aus den Größen Kreatinin, Bilirubin und INR 
berechnet wird, liegt in Deutschland inzwischen bei einem Wert von >30 Punkten bei Standard-
Organallokationen an (36). Der MELD-Score dient als Maß für die zu erwartende Überlebensdauer 
von Patienten mit schweren Lebererkrankungen und dient als Grundlage der Organverteilung durch 
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Eurotransplant (17).  Ein schlechterer Gesundheitszustand der Organempfänger muss daher als eine 
Folge des Organmangels gewertet werden.  
Um den Organmangel auszugleichen müssen Organe mit reduzierter Qualität (sog. „marginale 
Organe“, englisch: extended criteria donors ECD) zur Transplantation verwendet werden (z.B. 
verfettete Organe, Spender mit hohem Alter oder mit kardiovaskulären Vorerkrankungen). Diese 
Organe weisen eine erhöhte Rate an Organdysfunktion sowie ein reduziertes Organüberleben auf 
(1;10;21;28;37).  
Als zentrale Ursache für schlechte Organfunktion und reduziertes Organüberleben gilt neben 
immunologischen Prozessen der Ischämie-Reperfusionsschaden (IRS), welcher bei Transplantation 
marginaler Organe verstärkt ausgeprägt ist (34;35).  
Der IRS ist ein primär allogen-unabhängiger inflammatorischer Prozess, der auf molekularer, 
zellulärer und klinischer Ebene gut charakterisiert ist. Während der Reperfusion verstärken sich 
während der Ischämie beginnende Prozesse, die durch proinflammatorische Zytokine (z.B. TNFα, IL6, 
etc.) und eine verstärkte endotheliale Interaktion mit zirkulierenden Zellen (Leukoyzyten, 
Thrombozyten) und ggf. deren Transmigration in das Gewebe die Freisetzung verschiedener radikaler 
Sauerstoffspezies (ROS) sowie durch Mikrozirkulationsstörungen eine lokale und systemische 
Entzündungsreaktion hervorrufen (11;15;19). Diese Schädigungsmechanismen führen je nach 
Ausprägung zu Organdysfunktion und im schwersten Fall zum Organverlust (34;35). Letzteres 
belastet durch die Notwendigkeit einer Retransplantation den knappen Organpool zusätzlich.   
Vor diesem Hintergrund müssen aktuelle Zahlen zum Organüberleben interpretiert werden, welche 
ein reduziertes 5-Jahres Organüberleben in Deutschland im Vergleich zum internationalen Mittel 
zeigen (s. Abb. 2; Quelle: DSO-Jahresbericht 2011 / CTS-Studie, Opelz G Transplantation 2013).   
Die Ursachen des Organmangels können von Medizinern nur begrenzt beeinflusst werden. Daher 
müssen Strategien entwickelt werden, um die Funktion marginaler Organe zu verbessern (z.B. durch 
eine Reduktion des IRS) und durch Nutzbarmachung zusätzlicher Organe eventuell eine 
Vergrößerung des Spenderpools zu erreichen. 
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Abb. 2:  
A) Postmortal entnommene Organe  B) Funktionsraten nach Lebertransplantation: 
in Deutschland                              Deutschland im internationalen Vergleich  
(Quelle: DSO - Deutsche Stiftung Organtransplantation) 
 
2. Ziel der Arbeit: 
Diese Arbeit soll Risikofaktoren bei Lebertransplantation und zugrundeliegende Pathomechanismen 
in experimentellen und klinischen Studien identifizieren.  Auf dem Boden dieser Erkenntnisse werden 
organprotektive Verfahren entwickelt, die insbesondere in marginalen Organen den IRS verbessern 
sollen. Dadurch könnte auch ggf. der limitierte Spenderpool erweitert werden. 
 
3. Forschungsarbeiten 
 
3.1 Klinische Risikofaktoren für den Ischämie-Reperfusionsschaden (IRS) 
Die Transplantation marginaler Lebern: Ein Ausweg aus dem Organmangeldilemma? Pratschke 
S, Loehe F, Graeb C, Jauch KW, Angele MK. Zentralbl Chir 2009 Apr;134(2):107-12. (28) 
Beim Organspender werden in der Literatur verschiedene Einflussgrößen beschrieben, mit denen 
eine potentiell verschlechterte Organfunktion nach Lebertransplantation assoziiert ist 
(Marginalitätskriterien, englisch: EDC – extended donor criteria).  Aus klinischer und 
wissenschaftlicher Sicht ist bislang keine eindeutige Definition von Marginalität für 
Transplantatlebern verfügbar. Je nach Publikation und Transplantationszentrum werden bis zu 15 
Kriterien (Extended Donor Criteria -  EDC) beschrieben (28). Die Daten aus der Literatur sind dabei 
zum Teil widersprüchlich, da die Ergebnisse der meistens Studien retrospektiv erhoben wurden und 
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schwierig vergleichbar sind auf Grund der unterschiedlichen Definitionen für marginale Organe. 
Zusätzlich erscheint der zum Teil sehr unterschiedliche Erhebungszeitraum für die Beurteilung der 
Ergebnisse problematisch. Die unklare Datenlage stellt auch ein ethisches Problem bei der Akzeptanz 
von marginalen Organen zur Transplantation dar, da die zu erwartende Sterblichkeit für einen 
individuellen Empfänger nicht ermittelt werden kann. 
Von der Bundesärztekammer wurde eine Definition marginaler Organe für Spenderlebern mit 
folgenden Kriterien erstellt (Bundesärztekammer: Richtlinien zur Organtransplantation gem. § 16 
TPG; Richtlinie gemäß § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG für die Wartelistenführung und 
Organvermittlung zur Lebertransplantation) (9):  Positive Serologie für HBV oder HCV, Sepsis mit 
positiver Blutkultur, Meningitis, extrahepatische Tumorerkrankungen, Drogenabusus, Spenderalter > 
65 Jahre, Fettleber > 40% (histologisch gesichert), Na >165 mmol/l, Intensivstation einschließlich 
Beatmung des Spenders > 7 Tage, Adipositas des Spenders mit BMI > 30, Kaltischämiezeit > 13 
Stunden, GOT od. GPT > 3x normal, Bilirubin > 3 mg/dl.  Auch von Eurotransplant wurde eine 
ähnliche Definition von erweiterten Spenderkriterien für Lebern erstellt (13).  
Unter Berücksichtigung dieser Definition betrug der Anteil von Organen mit mindestens einem 
Marginalitätskriterium in Deutschland zuletzt 70% (Quelle: Statistische Anfrage Eurotransplant). Die 
im klinischen Alltag häufigsten Marginalitätskriterien bei Spenderorganen sind eine ausgeprägte 
Leberverfettung, ein hohes Spenderalter sowie eine lange Kaltischämiezeit beim Spender.  In einer 
Auswertung der aktuellen Literatur und in Daten aus unserer Klinik konnte dabei am Beispiel der 
Leberverfettung gezeigt werden, dass das Vorhandensein von einem Marginalitätskriterium einen 
Risikofaktor für Organdysfunktion darstellt, daraus jedoch nicht zwingend ein verkürztes 
Organüberleben resultiert (1;28). Vielmehr scheint eine Kombination aus mehreren Risikofaktoren 
das Organüberleben negativ zu beeinflussen (21;34;37).   
Daher wurde in einer Übersichtsarbeit die Bedeutung verschiedener erweiterter Spenderkriterien 
anhand aktueller Literatur dargestellt (28). Die Transplantation marginaler Organe in Spender mit 
hohem MELD-Score erscheint mit einer höheren Sterblichkeit verbunden zu sein. Insbesondere für 
die Kombination aus hohem Spenderalter und langer Ischämiezeit oder aus fortgeschrittenem 
Spenderalter und Hepatitis-C-Infektion des Empfängers konnte eine signifikante Verschlechterung 
des Organüberlebens nachgewiesen werden. Angesichts des herrschenden Organmangels sollten 
Anstrengungen unternommen werden, durch Verkürzung der Kaltischämiezeit und die Entwicklung 
von therapeutischen Strategien die Funktion und Nutzbarmachung marginaler Organe zu erhöhen 
und dadurch den Spenderpool zu erweitern. Die Ablehnung marginaler Organe auf dem Boden von 
einzelnen EDC ohne Berücksichtigung des Empfängerstatus erscheint nach derzeitigem 
Kenntnisstand nicht adäquat.  
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Vor diesem Hintergrund müssen klinisch relevante und einfach zu bestimmende Marker zur 
Identifikation von Hochrisikoorganen entwickelt werden, um das perioperative Management bei 
Transplantation dieser Organe zu optimieren.    
 
Auswertung der chirurgischen Lebertransplantationsdatenbank am Klinikum der Universität 
München 
Um eine exaktere Identifikation von Risikofaktoren bei Organspendern und –empfängern zu 
erreichen, wurde die Lebertransplantationsdatenbank des Klinikums Grosshadern (n=448 
Lebertransplantationen) ausgewertet.   
In einer Univariatanalyse konnten u.a. folgende Parameter als statistisch signifikante 
Prognosefaktoren für das Organüberleben gezeigt werden (p < 0,05): Eine Retransplantation, ein 
LabMELD-Score ≥ 35, ein Bilirubinanstieg im postoperativen Verlauf um mehr als 20 % und ein DRI ≥ 
0,125 (29). Dabei wurde auch die positive Rolle eines intraoperativen portosystemischen Shunts 
sowie die prädiktive Bedeutung der intraoperativ gemessenen Blutflüsse in Leberarterie und 
Pfortader gezeigt (29;30) (s. 3.2 Beeinflussbare Prognosefaktoren bei Lebertransplantationon). 
Außerdem weisen Organe, die bei akutem Leberversagen und bei primär biliärer Zirrhose 
transplantiert werden, ein signifikant kürzeres Überleben auf als bei Transplantation bei malignen 
Grunderkrankungen, nutritiv-toxischer oder viral bedingter Leberzirrhose. In einer Multivariatanalyse 
konnte dabei die Bedeutung der Organqualität für das Ergebnis nach Lebertransplantation gezeigt 
werden: Es wurden unter anderem ein Donor Risk Index (DRI) (HRR [CI]: 3,2 [1,7–5,9], P<0,001), ein 
intraoperativer arterieller Blutfluss (A. hepatica) <100 ml/min (2.1 [1.3–3.2], P=0.001) als 
unabhängige Variablen identifiziert (29). 
 
 
3.2 Beeinflussbare Risikofaktoren bei Lebertransplantation 
Die Organperfusion spielt eine zentrale Rolle für die Transplantatfunktion nach Lebertransplantation.  
Während der Reperfusion auftretenden Mikrozirkulationsstörungen kommt eine Schlüsselrolle in der 
Pathogenese des Ischämie-Reperfusionsschadens zu (11;39).  Puhl et al. konnten eine Korrelation 
zwischen der initialen Mikrozirkulation und der frühen Organfunktion nach Lebertransplantation 
zeigen (32).  Gleichzeitig belegen Studien den Zusammenhang zwischen Mikrozirkulation und dem 
makrovaskulären Blutfluss der zuführenden Lebergefäße (41). Außerdem beeinflusst die systemische 
Hämodynamik die Leberdurchblutung, zum Beispiel der mittlere arterielle Druck oder der venöse 
Abfluss infolge technischer Probleme oder durch ein mögliches Rechtsherzversagen (8).   
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Einfluss der intraoperativen Makroperfusion auf Organfunktion und -überleben 
Arterial blood flow predicts graft survival in liver transplant patients. Pratschke S, Meimarakis G, 
Mayr S, Graeb C, Rentsch M, Zachoval R, et al. Liver Transpl 2011 Apr;17(4):436-45. (30) 
In einer klinischen Arbeit konnte als klinisch einfach durchführbare Methode zur Identifikation von 
Hochrisikoorganen die intraoperative Messung des Blutflusses von Pfortader und Leberarterie bei 
Lebertransplantation identifiziert werden (30).  Bei 290 Lebertransplantationen am Klinikum 
Grosshadern wurden hierzu intraoperativ nach Reperfusion die portalvenösen und arteriellen 
Blutflüsse gemessen und mit der Organfunktion und dem Organüberleben korreliert.  Als cut-off 
Punkte wurden mittels CRT-Analyse für den arteriellen Blutfluss 100 ml/min und 240 ml/min (ART I: 
<100 ml/min, ART II: 100-240 ml/min, ART III: ≥240 ml/min) bzw. 1300 ml/min (PV I: <1300 ml/min, 
PV II: ≥1300 ml/min für den portalvenösen Fluss identifiziert.   
Die Höhe des arteriellen und portalvenösen Blutflusses hatte keine Auswirkungen auf die akute 
postoperative Organfunktion und –schädigung (GOT, GPT als klinisches Maß für den IRS; Bilirubin, 
Quick) während der ersten sieben Tage nach Transplantation (P > 0,05). Dagegen führte 
insbesondere ein reduzierter arterieller Blutfluss zu einem signifikant schlechteren Organüberleben 
(s. Abb.3).  
Gleichzeitig waren niedrige intraoperative Flüsse assoziiert mit einem erhöhten Risiko für eine 
primäre Transplantat Nonfunktion (PNF), sowohl bei Pfortader (PV I: 7,1% vs. PV II: 2,1%; P=0.0487) 
als auch Leberarterie (ART I: 12,8%, ART II: 2,6%, ART III: 1,1%). Auch in der multivariaten Analyse 
zeigte sich ein signifikant erhöhtes Risiko für eine primäre Transplantat Nonfunktion (bei Patienten 
mit einem arteriellen Blutfluss < 100 ml/ min (HRR 7,4; CI [2,1-26,3]; P=0,002) und einem Gesamt-
Fluss < 1400 ml/ Minute (HRR 4,8; CI [1,3-17,6]; P=0,017).  
Die Retransplantationsrate korrelierte ebenfalls mit dem arteriellen Blutfluss (ART I: 21,3%, ART II: 
8,5%, ART III: 5,6%; P=0.010). Auch in der multivariaten Analyse war ein arterieller Fluss < 100 ml/ 
min ein Risikofaktor für Retransplantation (HRR 3,4; CI [1,4-7,9]; P < 0,005). 
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In der Multivariatanalyse erhöhte ein arterieller Blutfluss < 100 ml/min als unabhängige Variable das 
Risiko für Organversagen nach Transplantation um mehr als das doppelte mit einer hazard rate ratio 
von 2,5; CI [1,6-4,1]; P<0,001.   
Abb. 3: Kumulatives Transplantatüberleben 10 Jahre nach Lebertransplantation bezogen auf (A) 
Pfortaderfluss (B) arterieller Blutfluss (C) Pfortaderfluss (Patienten mit PNF ausgeschlossen) (D) arterielle 
Durchblutung (Patienten mit PNF ausgeschlossen)  
 
Eine intraoperative Blutflussmessung ist daher eine prädiktive und leicht durchführbare Methode zur 
Identifikation von Hochrisikoorganen bei Lebertransplantation (30).  Gleichzeitig müssen Therapien 
zur Verbesserung der Organperfusion entwickelt werden (s. 3.4 Prospektive klinische Studien).  
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Bedeutung eines intraoperativen portosystemischen Shunts für Organfunktion und -überleben 
 Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver 
transplantation? Pratschke S, Meimarakis G, Bruns CJ, Kaspar M, Prix N, Zachoval R, et al. 
Transpl Int 2013 Jan;26(1):90-8. (29) 
 Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce 
intraoperative blood loss and improve postoperative transaminases and renal function - a 
meta-analysis. Pratschke S., Rauch A., Albertsmeier M., Rentsch M., Kirschneck M., Andrassy J., 
et al. World J Surg. 2016 Dec;40(12):2988-2998. (31) 
Neben Messgrößen zur Identifikation von Risikoorganen wurde in bisherigen Arbeiten nach 
beeinflussbaren Faktoren gesucht, die mit einfach durchführbaren Maßnahmen zur Verbesserung 
der Funktion marginaler Organe beitragen können.   
Eine wichtige Rolle könnte hierbei die Anlage eines temporären, intraoperativen porto-cavalen 
Shunts bei Lebertransplantation spielen.  Während der anhepatischen Phase, nach dem Abklemmen 
der Pfortader, fördert die venöse Stase im Darm die Freisetzung von Endotoxin, das bei der 
Reperfusion zunächst über die Pfortader in die Leber und sekundär in die systemische Zirkulation 
gelangt (2).  Endotoxin aktiviert intrahepatische Kupfferzellen, die eine zentrale Rolle bei der 
Initiierung des hepatischen Ischämie-Reperfusionsschadens durch Freisetzung proinflammatorischer 
Zytokine und von Sauerstoffradikalen spielen (2;22). Bei der orthotopen „en bloc“ Transplantation 
wird die Leber inklusive der Vena Cava entnommen und es kommt zur kompletten venösen 
Abstromunterbrechung aus der unteren Körperhäfte. Daher wurde als Weiterentwicklung der „en 
bloc“ Transplantation, bei der die Leber inklusive der, die sog. Cava-erhaltende Lebertransplantation 
(z.B. „Piggy Back“) entwickelt (5;45). Dennoch kann auch durch diese Technik die mesenteriale Stase 
während des Abklemmens der Pfortader nicht vollständig verhindert werden. Daher wurde durch 
Belghiti ein zusätzlicher intraoperativer portosystemischer Shunt bei Cava-erhaltender 
Lebertransplantation durch eine temporäre End-zu-Seit Anastomose zwischen Pfortader und Vena 
Cava beschrieben (4) (s. Abb.4). Am Klinikum Grosshadern wird dieser Shunt als Kunststoffkatheter 
zwischen Pfortader und Vena femoralis angelegt (s. Abb.4). Die Indikation zur Anlage eines Shunts 
wird im Klinikum Grosshadern in Abhängigkeit von der individuellen Risikoeinschätzung der Spender-
Empfängerkonstellation und dem Vorhandensein adäquater portosystemischer Kollateralen durch 
den Operateur gestellt.  
In einer Untersuchung der Lebertransplantationsdatenbank des Klinikums Grosshadern wurden 448 
Lebertransplantationen (1/1997-6/2010) im Hinblick auf Organschädigung und -überleben mit oder 
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ohne Anlage eines porto-femoralen Shunts untersucht (Shunt n=274, kein Shunt n=174; mittlerer 
Nachbeobachtungszeitraum 50 Monate) (29).  
Als Maß für den Ischämie-Reperfusionsschaden diente der GOT- und GPT-Anstieg. Unter 
Berücksichtigung potenzieller Confounder (Alter, Geschlecht, Retransplantion) wurde eine univariate 
und multivariate Analyse hinsichtlich des Organüberlebens durchgeführt.   
 
 
Abb. 4: Temporärer intraoperativer Shunt. A: Portocavale End-zu-Seit Anastomose (Belghiti). B: 
Portofemoraler Katheter Shunt (Klinikum Grosshadern) 
 
Die Verwendung eines intraoperativen portofemoralen Shuntkatheters war mit einer signifikanten 
Verringerung der Transaminasen als klinischer Surrogatparameter des Ischämie-
Reperfusionsschadens bis zum 7. postoperativen Tag verbunden (s. Abb.5). 
 
Abb.5: Perioperative Organschädigung in Abhängigkeit von der Anlage eines portosystemischen Shunts; * P 
< 0,05 vs. kein Shunt (weiße Säulen: Kein Shunt, graue Säulen: Shunt) 
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Darüber hinaus war das mittlere Organüberleben bei Anlage eines Shunts signifikant verlängert (MW 
in Monaten ± SD): Shunt 106,8 [98,0-115,7] vs. kein Shunt (86,5 [73,5-99,5]; p=0,001 (Abb. 6). 
                                   
Abb. 6: Transplantatüberleben in Abhängigkeit von der Anlage eines portosytemischen Shunts  
Interessanterweise war dieser Effekt besonders ausgeprägt bei Empfängern von Organen mit 
reduzierter Qualität mit einem Donor Risk Index ≥ 1.25 (s. Abb.7 B).  
 
Abb. 7: A: Transplantatüberleben in Abhängigkeit von der Anlage eines portosystemischen Shunts und dem 
MELD-Score. B: Transplantatüberleben in Abhängigkeit von der Anlage eines portosystemischen Shunts und 
dem Donor Risk Index. 
In einer Multivariatanalyse fanden sich als unabhängige Prognosefaktoren für ein schlechtes Ergebnis 
nach Lebertransplantation die Transplantation ohne intraoperativen portosystemischen Shunt mit 
einer hazard rate ratio von 2,1 (p < 0,001), ein intraoperativ gemessener Fluss in der Leberarterie 
unter 100 ml/min (hazard rate ratio 2,1; p = 0,001) sowie ein Donor Risk Index über 1,25 mit einer 
hazard rate ratio von 3,2 (p < 0,001) (29). 
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In einer Metaanalyse anhand aktueller Literatur zu portosystemischen Shunts konnte gezeigt 
werden, dass diese Technik zu signifikant verringerten AST-Werten, weniger Bluttransfusionen und 
verbesserter postoperativer Nierenfunktion führt (P < 0,05). Gleichzeitig fanden sich keine statistisch 
signifikanten Unterschiede bei der primären Transplantat Nonfunktion, der Länge des 
Krankenhausaufenthaltes sowie der OP-Dauer (31).  
Die teilweise diskrepanten Ergebnisse zu diesem Thema verdeutlichen die Notwendigkeit 
prospektiver Daten zu diesem Thema. Eine randomisierte Studie zu portocavalen Shunts bei 
Lebertransplantation ist daher anzustreben. 
Insbesondere bei Hochrisiko Konstellationen aus marginalen Organen (hoher Donor Risk Index) und 
kranken Empfängern (hoher MELD-Score) könnte durch die Verwendung eines intraoperativen 
Shunts eine Verbesserung der Organfunktion und des Organüberlebens erzielt werden.   
 
3.3 Experimentelle Studien zu Pathomechanismen und Therapieformen des IRS 
 
Etablierung eines Schädigungsmodells bei experimenteller Lebertransplantation 
Zur Untersuchung von Schädigungsmechanismen marginaler Organe bei Ischämie und Reperfusion 
wurde ein orthotopes, arterialisiertes, syngenes Modell der Fettleber-Transplantation an Ratten 
etabliert. Als Spendertiere dienten hierbei Zuckerratten mit einem homozygoten Leptinrezeptor-
Defekt (Phänotyp: Fat) bzw. mit heterozygotem Leptinrezeptor-Defekt (Phänotyp: Lean). Bei 
Spendertieren mit homozygotem Leptinrezeptordefekt weisen die Lebern im Alter von 10 Wochen 
einen Verfettungsgrad von 40% auf. Die kalte Ischämiezeit in hypothermer (4°C) UW-Lösung 
(University of Wisconsin) betrug bei schlanken Lebern 24 Stunden, bei verfetteten Lebern 4 Stunden. 
Empfänger waren ausschließlich schlanke Tiere. 
Es konnte ein verstärkter Ischämie-Reperfusionsschaden auf dem Boden einer gesteigerten 
Produktion von Sauerstoffradikalen (ROS) im Vergleich zu Spenderlebern aus schlanken Zuckerratten 
mit heterozygotem Leptinrezeptor-Defekt (Phänotyp: Lean) anhand klinischer Parameter (ALT, AST, 
LDH) gezeigt werden. Dabei waren klinische Marker des IRS bei Transplantation dieser Organe 
gegenüber nicht verfetteten Lebern signifikant erhöht (P < 0,05) (24).  
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Experimentelle Therapien des IRS   
Untersuchung eines ROS Scavengers (Glutathion) bei Transplantation von Fettlebern 
GSH attenuates organ injury and improves function after transplantation of fatty livers. Pratschke S, 
Angele MK, Grutzner U, Tufman A, Bilzer M, Loehe F, et al. Eur Surg Res 2010;45(1):13-9. (24) 
In nicht-verfetteten Organen ist Glutathion (GSH) ein effizienter Fänger von ROS, was zu einem 
reduzierten IRS nach GSH-Gabe führt (29). Reaktive Sauerstoffspezies (ROS) spielen dabei eine 
Schlüsselrolle in der Pathogenese des Ischämie-Reperfusionsschaden der Leber (7;33).  
Ziel dieser Studie war es, zu untersuchen, ob GSH eine protektive Wirkung auf den Ischämie-
Reperfusionsschaden in verfetteten Transplantaten entfaltet.  Hierzu wurden die Empfängertiere von 
Fettlebern während der Reperfusion (120 min) systemisch intravenös mit GSH (200 mol/h/kg) oder 
mit Kochsalzlösung behandelt (jeweils n=5). Dabei wurden Parameter des hepatozellulären Schadens 
und der Gallefluss gemessen. Die Transplantation von verfetteten Lebern verstärkte den frühen 
Ischämie-Reperfusionsschaden im Vergleich zu nicht verfetteten Organen, was sich durch erhöhte 
AST-, ALT- und LDH-Spiegel äußerte (s. Abb.8A). Der Gallefluss als Maß für die exkretorische Funktion 
der Lebern war in steatotischen Transplantaten ebenfalls reduziert (s. Abb.8B; P < 0,05).  
Die intravenöse Verabreichung von GSH reduzierte dabei signifikant  
Leberschäden und führte zu einer verbesserten Exkretionsleistung (Gallefluss) bei Transplantation 
von Fettlebern (P<0,05) (24).  
  
 
 
 
 
 
 
Abb. 8 A: MW ± SD, one-way ANOVA. * P<0,05 vs.       B: MW ± SD, one-way ANOVA. * P<0,05 vs. 
Kontrolle Lean, # P<0,05 vs. Kontrolle fat        Kontrolle Lean, # P<0,05 vs. Kontrolle fat 
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Einfluss eines Calcineurin Inhibitors auf den IRS bei Lebertransplantation  
Tacrolimus Preconditioning of Rat Liver Allografts Impacts Glutathione Homeostasis and Early 
Reperfusion Injury. Pratschke S, Bilzer M, Grutzner U, Angele M, Tufman A, Jauch KW, et al. J 
Surg Res 2011 Aug 25. (26) 
Eine weitere experimentelle Studie untersuchte Effekte eines Immunsuppressivums auf den primär 
inflammatorischen Prozess des IRS. Die antiinflammatorische Wirkung von Calcineurininhibitoren 
(CNI, z.B. Tacrolimus, Cyclosporin, Sirolimus) auf ischämische Schädigungen verschiedener solider 
Organe ist dabei bekannt (3;16). In bisherigen Modellen wurden jedoch systemisch die Spender 
präkonditioniert, was die klinische Umsetzung solcher Therapien aufgrund der transnationalen 
Organallokation und einem daraus resultierenden unübersichtlichen Empfängerkreis behindert. Eine 
erfolgreiche Behandlung mit CNI zu einem späteren Zeitpunkt ist dagegen eine klinisch relevante 
Option zur Behandlung ischämischer Schädigungen. 
In der vorliegenden Versuchsreihe wurden nicht verfettete Transplantatlebern aus männlichen Lewis 
Ratten in einem Akut-Modell des IRS einmalig ex vivo mit Tacrolimus präkonditioniert. Nach 24-
stündiger kalter Ischämie (4°C) in University of Wisconsin (UW) Lösung wurden die Lebern am Ende 
der Kaltpräparation mit 20 ml verdünntem Tacrolimus perfundiert. Es wurden drei Gruppen (jeweils 
n=6) verglichen: Tacrolimus 50 ng/ml, Tacrolimus 10 ng/ml, NaCl 0,9% (Kontrolle). Die 
Reperfusionsdauer betrug 120 Minuten (26). 
Eine einmalige ex vivo Rinse der Transplantate unmittelbar vor Implantation mit Tacrolimus 
(Konzentration 10 bzw. 50 ng/ml) bewirkte eine relevante Organprotektion (ALT, AST, LDH, Bilirubin) 
120 Minuten nach Reperfusion einhergehend mit Veränderungen der Glutathion-Homöostase: Bei 
Verabreichung von Tacrolimus (10 ng/ml) verringerte sich der ALT-Spiegel im Serum auf 1740 ± 1169 
U/l vs. 3691 ± 1144 U/l (Kontrolle), P<0,05). Während die intrazelluläre GSH-Konzentrationen im 
Lebergewebe unverändert blieb, war GSSG, das Oxidationsprodukt von GSH, deutlich verringert in 
präkonditionierten Lebern (47,0 ± 10,4 nm/g vs. 71,8 ± 30,6 nm/g; P<0,05). Die Ursache hierfür 
könnte eine vermehrte Ausscheidung von GSSG in die Galle (0,19 ± 0,04 mm vs. 0,13 ± 0,04 mm 
(Kontrolle); P<0,05) sowie ins Plasma (2,4 ± 0,3 mM vs. 1,4 ± 0,2 mM (Kontrolle); P<0,05) sein (26). 
Diese Veränderungen sind relevant, da intrazelluläres GSSG in hohen Dosen zytotoxische 
Eigenschaften aufweist und somit u.a. für die beobachteten Effekte einer Tacrolimus Rinse 
verantwortlich sein könnte (14;26). Überraschenderweise waren die Effekte der Tacrolimus Rinse 
nicht dosisabhängig sondern stärker ausgeprägt in der niedrigeren Konzentration von 10 ng/ml 
gegenüber 50 ng/ml (Abb. 9).  
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Abb. 9: Transaminasen, Gallefluss 120 Minuten postoperativ: Sham, Kontrolle, Tacrolimus 50 / 10 ng/ml. 
*P<0,05 vs. Kontrolle 
 
3.4 Prospektive klinische Studien 
Organkonditionierung mit Nitroglycerin 
Die retrospektiv erhobenen Daten zur Bedeutung der Leberperfusion für die Transplantatfunktion 
und das Überleben (30) waren Anlass für eine Untersuchung mit einer vasoaktiven Substanz bei 
Lebertransplantation. Es wurde eine klinische Studie zur intraoperativen Gabe des NO-Donors 
Nitroglycerin mit dem Ziel einer verbesserten Organdurchblutung bei Lebertransplantation 
durchgeführt (nicht veröffentlichte Daten). Bei 44 konsekutiven Lebertransplantation wurden Organe 
mit einem Donor Risk Index (DRI) ≥ 1.9 mit 5 mg Nitroglyzerin (Injektion in Arteria hepatica) 
unmittelbar vor Implantation präkonditioniert. Diese Transplantationen wurden verglichen mit 44 
Lebertransplantationen ohne Gabe von Nitroglyzerin mittels matched pairs Analyse anhand der 
Lebertransplantationsdatenbank unserer Klinik. In die Untersuchung gingen ein der Lab-MELD-Score, 
der Donor Risk Index (DRI), die postoperative Leberschädigung (ALT, AST), Transplantatfunktion 
(Bilirubin, Quick), die intraoperativ gemessenen Blutflüsse in Leberarterie und Pfortader und das 
Organüberleben. Bei keinem der Parameter konnte ein Unterschied zwischen den Gruppen gefunden 
werden (P > 0,05). Trotz dieser Negativdaten sind weitere Untersuchungen mit vasoaktiven 
Substanzen erforderlich, um deren Interaktion mit dem Ischämie-Reperfusionsschaden zu 
untersuchen.  
 
TOP-Studie (Tacrolimus Organ Perfusion) 
 Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial 
to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex 
vivo tacrolimus perfusion. Pratschke S, Eder M, Heise M, Nadalin S, Pascher A, Schemmer P, 
Einleitende Zusammenfassung Habilitationsschrift Dr. med. Sebastian Pratschke 
 
17 
 
Scherer MN, Ulrich F, Wolters H, Jauch KW, Wöhling D, Angele MK. Transplant Res. 2013 Mar 
4;2(1):3. (27) 
 Results of the TOP Study: Prospectively randomized multicenter trial of an ex vivo Tacrolimus 
rinse prior to Transplantation in EDC Livers. Pratschke S, Arnold H, Zollner A, Heise M, Pascher 
A, Schemmer P, et al. Transplantation direct 2016 May 4;2(6):e76. (25) 
 The Authors' Reply. Pratschke S, Angele MK. Transplant Direct. 2017 Mar 28;3(4):e148. 2016. 
Auf dem Boden der experimentellen Vorarbeiten zu einer Tacrolimus Rinse bei Lebertransplantation 
an der Ratte (26) wurde eine IIT (investigator initiated trial) bei Lebertransplantation durchgeführt 
(27). Für die als Immunsuppressivum zugelassene Prüfsubstanz Tacrolimus wurden in 
experimentellen Arbeiten und in zwei klinischen Studien protektive Wirkungen auf den hepatischen 
IRS beschrieben (20;23;26). Jedoch fehlten bislang Aussagen zur Wirksamkeit einer solchen Therapie 
bei marginalen Organen, wo der Wirksamkeit von Tacrolimus besondere Bedeutung zukommt.   
Ziel der TOP-Studie (Tacrolimus Organ Perfusion) war, angesichts des herrschenden Organmangels 
und der daraus resultierenden Transplantation marginaler Organe, die Untersuchung einer 
medikamentösen Therapie mit Tacrolimus für den Ischämie-Reperfusionsschaden bei 
Transplantation von Lebern mit reduzierter Qualität.   
Studiendesign: 
Die Studie wurde durchgeführt als prospektive randomisierte Multicenterstudie (Phase III Studie), in 
der marginale Spenderorgane mit Tacrolimus perfundiert wurden (38). Teilnehmende Zentren waren 
neben München (LMU) Berlin, Heidelberg, Mainz und Regensburg. 
• Offene, nicht verblindete Studie 
• Zweiarmiges, Placebo-kontrolliertes Studiendesign:  
A: Ex vivo Perfusion marginaler Transplantatlebern mit Tacrolimus (20 ng/ml) gelöst in 1000 ml HTK: 
Sequenzielle arterielle (500 ml) und portalvenöse (500 ml) ex vivo Perfusion mit HTK vor Implantation 
nach Ende der Kaltpräparation 
B: Ex vivo Perfusion marginaler Transplantatlebern mit 1000 ml HTK  
Haupteinschlusskriterium war das Vorliegen von zwei oder mehr Marginalitätskriterien beim 
Organspender bei Lebertransplantation in Anlehnung an die Definition von Eurotransplant (s. Tab. 1): 
 Spenderalter > 65 Jahre  
 Makrovesikuläre Steatose > 40%  
 BMI > 30 
 Natrium >165 mmol/l 
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 Intensivstation und/ oder Beatmung  > 7 Tage 
 Kalte Ischämiezeit  > 13 Stunden 
 AST > 99 U/l 
 ALT > 105 U/l  
 Bilirubin > 3 mg/dl (> 51 µmol/l) 
 Gabe von Adrenalin  
Tab.1: Extended Donor Criteria (EDC) (nach: Eurotransplant manual (13)) 
Beim Empfänger waren die Einschlusskriterien erstmalige Organtransplantation, chronische 
terminale Leberinsuffizienz sowie ein Alter > 18 Jahre. 
Primärer Endpunkt der Studie waren die maximal gemessenen ALT-Spiegel im Serum als klinisches 
Maß für den Ischämie-Reperfusionsschaden.  
Sekundäre Endpunkte:  
 GPT, GOT postoperativ an den Tagen 1, 2, 4, 7 
 Transplantatfunktion (Quick, Bilirubin)  
 Organ- und Patientenüberleben  
 Biopsiegesicherte Abstoßungen  
 
Die maximalen ALT-Spiegel in den mit Tacrolimus behandelten Prüfungsteilnehmern wurden mittels 
nicht parametrischer Verfahren (Wilcoxon Rangsummentest) mit Placebo verglichen.  In Anlehnung 
an frühere Daten von Peter et al. (39) wurde eine Effektgröße von 0,7 angenommen.  Die statistische 
Power des Tests betrug 80% bei einem Signifikanzniveau von 0,05.  Eine Fallzahlschätzung 
(NQueryAdvisor 6.1) für zwei unverbundene Stichproben mittels Wilcoxon Rangsummentest 
erbrachte bei einer erwarteten drop-out Rate von 15% eine Population von 86 Studienteilnehmern 
(43 Tacrolimus vs. 43 Placebo).   
Ergebnisse:  
Es wurden 25 Prüfungsteilnehmer randomisiert und in die Studie eingeschlossen.  Ein 
Prüfungsteilnehmer (Zentrum 06, Mainz, Patient 003) wurde nach Studieneinschluss und 
Randomisierung aber noch vor Beginn der Studienbehandlung aus medizinischen Gründen nicht 
transplantiert.  Diesen Patienten eingerechnet betrug die drop-out rate 4 % (25). 
Die Dauer der Perfusion betrug im Median 19 (Range: 8-22) in der Tacrolimus/Intervention Gruppe 
und 15 (10-27) in der HTK/Placebo Gruppe (Wilcoxon rank-sum test, p=0,574).   
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Die ex vivo Perfusion von marginalen Lebern mit Tacrolimus (n=11; 20 ng/ml, gelöst in 1000 ml HTK) 
führte zu keinem statistisch signifikanten Effekt beim primären Endpunkt der Studie (p=0.207), dem 
maximal gemessenen GPT-/ ALT-Wert innerhalb der ersten beiden Tage nach Transplantation, 
gegenüber der Vergleichsgruppe (n=13), die mit 1000 ml HTK perfundiert worden war (U/l; Median 
(Range)):  812 (362; 3403) vs.  652 (147; 2034).  Der Hodges-Lehman Schätzer für das 95% 
Konfidenzintervall des Medianen Unterschieds war (-178; 1166). Durch den vorzeitigen 
Studienabbruch kann aufgrund der geringen Patientenzahl keine Aussage zu Unterschieden zwischen 
den Zentren getroffen werden.  
Der Vergleich der Behandlungsarme an den Tagen 1, 2, 4 und 7 mit Hilfe des multivariaten 
Rangsummentests nach O’Brien zeigte für die Parameter GPT, GOT, Quick und Bilirubin folgende p-
Werte: 0,100, 0,011, 0,553 und 0,815. 
Das Organ- und Patientenüberleben war gleich in beiden Behandlungsarmen. Die Anzahl der 
Abstoßungen war vergleichbar (p = 1,000).  
Um mögliche Auswirkungen einer Spülbehandlung zu untersuchen, wurden die Ergebnisse der 
vorliegenden Studie in einer matched pairs Analyse mit 24 konsekutiven Lebertransplantationen 
(Spender ≥ 2 EDC) aus der Lebertransplantationsdatenbank unserer Klinik verglichen. Die 
präoperativen ALT- und AST-Werte unterschieden sich nicht zwischen Patienten der Studie und 
Placebo (p > 0,05). Bei den postoperativen ALT- / AST-Werten (Tag 1, 2, 4, 7) fanden sich keine 
Unterschiede zwischen den Patienten der TOP-Studie und Placebo (keine Ex-situ Perfusion erhalten 
hatte Placebo (Mann-Whitney-U-Test, p > 0,05). 
Die Studie wurde daher 08/2013 bei fehlendem Nachweis der Wirksamkeit der Studienmedikation 
(Tacrolimus 20 ng/ml in 1000 ml HTK) gegenüber der Vergleichsgruppe (1000 ml HTK) beim primären 
Endpunkt der Studie (maximal gemessene GPT-/ALT-Werte an den ersten beiden postoperativen 
Tagen) vorzeitig beendet (25). 
Ob andere Dosierungen, Darreichungsformen oder Zeitpunkte der Anwendung von Tacrolimus zu 
einem protektiven Effekt bei Lebertransplantation führen, bleibt abzuwarten.  
 
4. Zusammenfassung 
Der hepatische IRS ist eine zentrale Ursache für schlechte Organfunktion sowie reduziertes 
Organüberleben und ist verstärkt ausgeprägt in marginalen Organen. Diese Transplantate werden 
aufgrund des herrschenden Organmangels verstärkt verwendet.  
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Die vorliegende Arbeit zeigt klinische Risikofaktoren für einen verstärkten IRS auf. Gleichzeitig 
konnten anhand der Lebertransplantationsdatenbank unserer Klinik beeinflussbare 
Prognosefaktoren nach Lebertransplantation identifiziert werden, z.B. der intraoperative Blutfluss 
der Leberarterie und der Pfortader. Ein hoher Fluss ist eine unabhängige Variable für längeres 
Transplantatüberleben in einer Multivariat-Analyse. Auch die Anlage eines intraoperativen 
portosystemischen Shunts scheint das outcome nach Lebertransplantation zu beeinflussen: 
Interessanterweise war dieser Effekt besonders ausgeprägt bei Empfängern von Organen mit einem 
erhöhten DRI. Diese einfache Technik scheint daher eine sinnvolle Möglichkeit zur Protektion 
marginaler Organe. 
Außerdem wurde ein experimentelles Modell der Lebertransplantation an der Ratte etabliert. Dabei 
wurde in einem Schädigungsmodell mit Fettlebern die Bedeutung von oxidativem Stress bei 
Transplantation dieser Organe gezeigt: Eine Behandlung mit dem ROS Scavenger Glutathion führte zu 
einer Reduktion der hepatozellulären Schädigung nach kalter Ischämie. Bei Transplantation nicht-
geschädigter Organe konnte eine Reduktion des akuten IRS durch eine einmalige ex vivo Perfusion 
mit Tacrolimus gezeigt werden.   
Diese Technik wurde übertragen in eine prospektive, randomisierte klinische Multicenter Studie (IIT) 
zur Behandlung marginaler Organe bei Lebertransplantation: Lebern mit ≥ 2 Marginalitätskriterien 
wurden vor Implantation mit Tacrolimus gespült. Diese Behandlung zeigte keinen Vorteil gegenüber 
Kontrolle, weswegen die Studie vorzeitig nach Einschluss von 25 Patienten abgebrochen wurde.   
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proved bile flow. Intravenous application of GSH effectively 
reduces early IRI in steatotic allografts and improves recov-
ery of these marginal donor organs following transplanta-
tion.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 In an attempt to overcome the discrepancy between 
liver organ availability and demand, livers with poor or-
gan quality are increasingly accepted for transplantation. 
In deceased organ donors, the prevalence of steatosis 
ranges from 13 to 28%, approaching 50% when sensitive 
histological techniques are used  [1, 2] . Demographic data 
suggest a strong increase of obesity in the population, 
which may have a negative impact on the quality of har-
vested allografts used for liver transplantation  [3] .
 Several human studies have demonstrated an in-
creased ischemia-reperfusion injury (IRI) following 
transplantation of steatotic liver grafts as evidenced by 
 Key Words 
 Fatty liver   Glutathione   Organ injury   Transplantation 
 Abstract 
 Ischemia-reperfusion injury (IRI) is increased after transplan-
tation of steatotic livers. Since those livers are increasingly 
used for transplantation, protective strategies must be de-
veloped. Reactive oxygen species (ROS) play a key role in he-
patic IRI. In lean organs, glutathione (GSH) is an efficient 
scavenger of ROS, diminishing IRI. The aim of this study was 
to evaluate whether GSH also protects steatotic allografts 
from IRI following transplantation. Fatty or lean livers were 
explanted from 10-week-old obese or lean Zucker rats and 
preserved (obese 4 h, lean 24 h) in hypothermic University of 
Wisconsin solution. Arterialized liver transplantation was 
then performed in lean syngeneic Zucker rats. Recipients of 
fatty livers were treated with GSH (200   mol/h/kg) or saline 
during reperfusion (2 h, n = 5). Parameters of hepatocellular 
damage and bile flow were measured. Transplantation of 
steatotic livers enhanced early reperfusion injury compared 
to lean organs as measured by increased aspartate amino-
transferase, alanine aminotransferase, and lactate dehydro-
genase plasma levels. Bile flow was also reduced in steatotic 
grafts. Intravenous administration of GSH effectively de-
creased liver damage in fatty allografts and resulted in im-
 Received: October 19, 2009 
 Accepted after revision: June 6, 2010 
 Published online: August 5, 2010 
 Martin Angele, MD,  Department of Surgery
Klinikum Grosshadern, Ludwig-Maximilians-University Munich 
 Marchioninistrasse 15,  DE–81377 Munich (Germany) 
 Tel. +49 89 7095 0, Fax +49 89 7095 5674
E-Mail Martin.Angele   @   med.uni-muenchen.de 
 © 2010 S. Karger AG, Basel
0014–312X/10/0451–0013$26.00/0 
 Accessible online at:
www.karger.com/esr 
S.P. and M.K.A. contributed equally to the manuscript.
D
ow
nl
oa
de
d 
by
: 
U
B
 d
er
 L
M
U
 M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 -
 7
/2
6/
20
16
 1
2:
08
:3
7 
P
M
 Pratschke/Angele/Grützner/Tufman/
Bilzer/Loehe/Jauch/Schauer 
Eur Surg Res 2010;45:13–19 14
elevated plasma liver enzyme levels and delayed organ 
function  [3, 4] . Zucker rats homozygotic for a leptine-re-
ceptor gene defect (fa/fa) develop macrovesicular hepatic 
steatosis. Studies have described increased reperfusion 
injury in fa/fa Zucker rats compared to animals with 
healthy livers following warm and cold ischemia  [5, 6] . 
Therefore, fa/fa Zucker rats may represent a suitable ani-
mal model of IRI following transplantation of non-alco-
holic fatty livers. Therefore, those rats may represent a 
suitable animal model of reperfusion injury following 
transplantation of non-alcoholic fatty livers.
 Although the precise sequence of events leading to IRI 
in liver transplants has not been completely described, 
the generation of reactive oxygen species (ROS) and dis-
turbances of the hepatic microcirculation may play key 
roles in the mechanisms following reperfusion injury  [7, 
8] . Administration of the antioxidant glutathione (GSH) 
has been shown to attenuate ischemia-reperfusion injury 
following warm ischemia or liver transplantation in 
healthy organs  [9, 10] . However, the effect of GSH on he-
patocellular damage caused by reperfusion of transplant-
ed fatty livers remains largely unknown. Recent work has 
demonstrated differences in the cellular and humoral re-
sponse in healthy and diseased livers following exposure 
to ischemia and reperfusion  [11] .
 The purpose of the present study is to test the efficacy 
of post-ischemic intravenous GSH administration in pre-
venting early reperfusion injury after transplantation of 
fatty livers. Despite promising results in several experi-
mental studies, no agent has made its way into clinical 
practice  [12] . This discrepancy between experimental 
studies and patient treatment may be in part due to the 
frequent use of healthy grafts in many animal studies  [13, 
14] . This is not representative of the clinical situation, in 
which organ shortage often necessitates the use of grafts 
of poor quality (i.e. steatotic grafts) from extended crite-
ria donors. Thus, the results of our study may provide a 
novel and clinically relevant therapeutic approach for the 
protection of steatotic organs, thereby increasing the pool 
of transplantable livers.
 Methods 
 Animals 
 Male syngeneic Zucker rats (Charles River Wiga, Sulzfeld, Ger-
many) aged 10–14 weeks were used in this study. Animals were 
housed in a temperature- and humidity-controlled room under a 
constant 12-hour light/dark cycle. Rats with a homozygote point 
mutation of codon 269 in the leptine receptor gene (fa/fa) develop 
massive obesity. In contrast, animals with a heterozygote defect of 
this gene (fa/–) remain lean. Donors (body weight: fa/fa 478  8 
63 g, fa/– 345  8 72 g) and recipients (fa/– 318  8 22 g) had free ac-
cess to water and rat chow (standard diet; Altromin, Lage, Ger-
many). Recipient rats were fasted 12 h prior to donor operation and 
liver transplantation. All procedures were carried out in accor-
dance with the guidelines of the Animal Welfare Act and the Guide 
for the Care and Use of Laboratory Animals from the National 
 Institutes of Health. The institutional animal care and use com-
mittee of the Government of Upper Bavaria and the Ludwig-Maxi-
milians-University (Munich, Germany) approved this project.
 Experimental Groups 
 Male Zucker rats were randomly assigned to three groups (n = 
5/group;  table 1 ). In group 1 (fa/– veh) livers were explanted from 
lean male Zucker rats and subjected to 24 h of cold ischemia (4  °  C) 
in University of Wisconsin solution. Orthotopic arterialized liver 
transplantation was then performed on lean male Zucker rats 
(fa/–). During reperfusion, 6 ml of saline 0.9% (vehicle) were in-
fused continuously at a rate of 3 ml/h starting 20 min before 
declamping of the portal vein and hepatic artery.
 In group 2 (fa/fa veh) and 3 (fa/fa GSH) steatotic livers were 
explanted from obese male Zucker rats (homozygote, fa/fa). After 
a cold ischemia period of 4 h these livers were transplanted into 
lean Zucker rats (fa/–). This reduction in ischemic time from 24 h 
in lean organs to 4 h in steatotic grafts was applied based on pre-
vious studies by Amersi et al.  [6] . During reperfusion, animals in 
group 2 received 6 ml saline (vehicle) by continuous infusion at a 
rate of 3 ml/h (vehicle), whereas animals in group 3 received GSH 
(Tationil 600, Roche, Italy) at a concentration of 200   mol/h/kg 
dissolved in 6 ml saline. Reperfusion time was 120 min in all 
groups.
 Surgical Procedures 
 Donor and recipient procedures were performed under spon-
taneous ether inhalation. For continuous monitoring of mean ar-
terial blood pressure and for substitution of plasma volume, left 
carotid artery and jugular vein were cannulated with polyethyl-
ene catheters. Body temperature was kept between 36.5 and 
37.5  °  C using a heating pad. Donor livers were preserved by retro-
grade aortal flush with 15 ml of University of Wisconsin solution 
and stored at 4  °  C for 24 h (group 1) or 4 h (group 2/3). Before im-
plantation, livers were rinsed with 10 ml of Ringer’s lactate solu-
tion at 4   °   C via portal vein (hydrostatic pressure: 10 cm H 2 O). 
Orthotopic liver transplantation was performed according to the 
cuff technique described by Kamada and Calne  [15] . Grafts were 
rearterialized and simultaneously reperfused via portal vein and 
Table 1.  Study groups
Group Donor Recipient Treatment CIT, h
1: fa/– veh fa/– fa/– veh 24
2: fa/fa veh fa/fa fa/– veh 4
3: fa/fa GSH fa/fa fa/– GSH 4
CIT = Cold ischemia time; veh = vehicle. 
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hepatic artery as described by Post et al.  [16] . Portal clamping 
times never exceeded 20 min. Five minutes after declamping, all 
rats received 0.5 ml of albumin (5%) and 0.5 ml of sodium bicar-
bonate to maintain blood pressure and physiological pH values. 
After 120 min of reperfusion, animals were sacrificed and liver 
weight was determined.
 Quantification of Bile Synthesis 
 To quantify liver function during the reperfusion period, bile 
flow was quantified as previously described  [17] . The common 
bile duct was cannulated with a polyethylene tube during donor 
surgery. Cumulative bile flow (  l/g/min) was calculated from to-
tal bile volume secreted between start of reperfusion and end of 
experiment (120 min).
 Determination of GSH and GSSG 
 As opposed to other plasma parameters, determination of 
GSH (reduced GSH prior to oxidation, administered form) and 
GSSG (oxidized form of GSH following radical scavenging or 
spontaneous oxidation) in plasma requires a separate isolation 
procedure as described previously by Jaeschke et al.  [18] . A total 
of 500   l of whole blood is required for determination of total 
GSH (GSH total = sum of GSH and GSSG). For GSSG analysis, 
an aliqot (200   l) of blood was mixed immediately with 200   l 
of 10 mmol/l N-ethylmaleimide (NEM) in 100 mmol/l phosphate 
buffer (pH 6.5) containing 17.5 mmol/l EDTA. The remaining 
blood was centrifuged for 1 min. An aliquot (100   l) of plasma 
was pipetted into 100   l sulfosalicylic acid (5%) for determina-
tion of total GSH. To separate GSSG from NEM and NEM-GSH, 
an aliquot of NEM-treated plasma was passed through a Sep-
PakC18 cartridge (Waters, Framingham, Mass., USA) followed 
by 1 ml of 100 mmol/l phosphate buffer (pH 7.5). GSSG in the 
eluates and total GSH in acidified plasma samples was deter-
mined by an enzymatic test as described previously  [19] . GSH 
plasma concentrations were calculated as difference between to-
tal GSH and GSSG.
 Plasma Collection and Storage 
 Whole blood was obtained via arterial catheter line (approxi-
mately 1.5 ml) in microcentrifuge tubes (Microtainer, Becton 
Dickinson, Rutherford, N.J., USA) and centrifuged at 16,000  g for 
15 min at 4  °  C. Plasma was separated, placed in pyrogen-free mi-
crocentrifuge tubes, immediately frozen, and stored (–80  °  C) un-
til assayed for alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and lactate dehydrogenase (LDH).
 Assessment of Serum Aminotransferases 
 Serum aminotransferases were used as established markers of 
hepatic injury. AST and ALT were measured 2 h after reperfusion 
with a kinetic UV test using a serum multiple analyzer (Olympus 
AU 2700)  [20] .
 Assessment of Lactate Dehydrogenase 
 Systemic cellular damage was determined by assaying serum 
levels of LDH 2 h after reperfusion with a kinetic UV test using a 
serum multiple analyzer (Olympus AU 2700)  [21] .
 Histology 
 Representative histological sections (HE staining) of fatty liv-
ers were examined 2 h after reperfusion.
 Statistics 
 The results are presented as mean  8 SD. One-way ANOVA 
followed by the Student-Newman-Keuls test or Tukey test as a 
post hoc test for multiple comparisons was used to determine sig-
nificance of the differences between experimental means. p  ! 
0.05 was considered to be significant.
 Results 
 Plasma GSH and GSSG 
 Plasma GSH was determined in rats receiving steatot-
ic organs and treated with vehicle or GSH at time of re-
perfusion (t = 0 min) and 15, 30, 60 and 120 min thereaf-
ter ( fig. 1 ). GSH-treated rats displayed systemic peak GSH 
levels 15 min after reperfusion. Plasma GSH levels were 
significantly increased in GSH treated rats throughout 
the whole experiment compared to vehicle-treated ani-
mals (p  ! 0.05).
 Plasma GSSG levels were significantly elevated 60 and 
120 min after reperfusion in GSH-treated animals com-
pared to non-treated rats (p  ! 0.05;  fig. 2 ).
 Plasma Aminotransferases (ALT/AST) 
 Alanine Aminotransferase 
 ALT levels were significantly increased in recipients of 
steatotic livers compared to recipients of lean livers after 
0 15 30 60 120
Minutes
G
SH
 (μ
M
)
0
100
200
300
400
500 *
*
* *
fa/fa veh
fa/fa GSH
 Fig. 1. Plasma GSH levels determined at time of reperfusion (0) 
and 15, 30, 60, and 120 min after liver transplantation. Livers were 
explanted from lean (fa/–) or obese (fa/fa) rats. Prior to declamp-
ing, recipient animals received vehicle or GSH (200   mol/kg body 
weight/h). n = 5/group. Values are presented as mean  8 SD. Data 
were analyzed by one-way ANOVA.  *  p  ! 0.05 vs. fa/– veh. 
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reperfusion (p  ! 0.05;  fig.  3 ). In recipients of steatotic 
grafts, administration of GSH significantly reduced plas-
ma ALT levels compared to administration of vehicle
(p  ! 0.05).
 Aspartate Aminotransferase 
 Plasma AST levels were significantly enhanced in ve-
hicle-treated recipients of fatty livers compared to rats re-
ceiving lean organs (p  ! 0.05;  fig. 4 ). In recipients of stea-
totic livers, treatment with GSH was associated with a 
significant reduction of AST compared to administration 
of vehicle (p  ! 0.05).
 Lactate Dehydrogenase 
 LDH, a non-organ-specific marker of IRI, was signifi-
cantly higher in recipients of fatty livers treated with ve-
hicle compared to recipients of lean livers following liver 
transplantation (p  ! 0.05;  fig. 5 ). In recipients of steatotic 
livers, the administration of GSH significantly reduced 
serum LDH levels compared to the administration of ve-
hicle (p  ! 0.05).
 Bile Flow 
 Two hours after reperfusion, cumulative bile flow (a 
sensitive marker of liver function) was significantly di-
minished in steatotic livers receiving vehicle compared to 
lean grafts (p  ! 0.05;  fig. 6 ). GSH treatment, however, sig-
nificantly increased bile flow in steatotic grafts compared 
to treatment with vehicle (p  ! 0.05).
 Histology 
 Histological sections (HE staining) demonstrated a 
50–80% degree of steatosis (data not shown). Two hours 
after liver transplantation, no alterations between the 
groups and due to IRI were evident.
 Discussion 
 The critical organ shortage for liver transplantation 
has resulted in the routine acceptance of steatotic organs. 
In the general population, steatosis occurs with a preva-
lence of 13–50%  [1, 2] . Steatotic livers substantially con-
tribute to the donor pool, thereby partially compensating 
for organ shortage. Clinical and experimental studies 
have shown that steatotic livers are more susceptible to 
IRI than lean livers  [3, 4, 22–25] . This results in increased 
plasma aminotransferases and diminished liver function 
in the early postoperative phase following transplanta-
tion  [3, 4] . Other risk factors, including cold ischemia 
time and donor age  [26, 27] , have been shown to exhibit 
additive detrimental effects on organ function and sur-
vival following liver transplantation. Steatosis is a par-
ticularly relevant risk factor for IRI due to its increasing 
prevalence. Moreover, in contrast to risk factors such as 
cold ischemia time, steatosis cannot be affected by chang-
ing allocation procedures. Nonetheless, future experi-
mental studies should consider other risk factors beside 
steatosis to better mimic the clinical situation.
 Due to the clinical importance of steatosis for outcome 
following liver transplantation, animal models of steato-
sis have been established  [2] . Genetically obese Zucker 
rats have been shown to develop liver steatosis mimicking 
non-alcoholic fatty liver disease  [2, 28] . Interestingly, the 
pathophysiological mechanisms associated with reperfu-
sion injury after orthotopic liver transplantation have 
been shown to be different between lean and steatotic 
Zucker rats  [11] . Lean rats tend to develop hepatic apop-
tosis following ischemia-reperfusion whereas necrosis is 
the predominant form of cell death in steatotic organs 
 [11] . Moreover, steatotic livers exhibit an increased pro-
duction of reactive oxygen species (ROS) following warm 
and cold ischemia and reperfusion  [5, 29] . These results 
collectively suggest that steatosis has to be considered 
when investigating new therapeutic strategies in liver 
transplantation.
G
SS
G
 (μ
M
)
0
10
20
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40
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0 15 30 60 120
Minutes
* *
fa/fa veh
fa/fa GSH
 Fig. 2. Plasma GSSG levels determined at time of reperfusion (0) 
and 15, 30, 60, and 120 min after liver transplantation. Livers were 
explanted from lean (fa/–) or obese (fa/fa) rats. Prior to declamp-
ing, recipient animals received vehicle or GSH (200   mol/kg body 
weight/h). n = 5/group. Values are presented as mean  8 SD. Data 
were analyzed by one-way ANOVA.  *  p  ! 0.05 vs. fa/– veh. 
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 The present data indicate that steatotic livers harvest-
ed from genetically obese Zucker rats develop signifi-
cantly more organ injury compared to lean allografts. In-
terestingly, increased organ injury following transplanta-
tion of fatty organs was evident despite a reduction in 
cold ischemia time from 24 h in lean to 4 h in steatotic 
organs. These findings are supported by previous results 
demonstrating increased organ damage and diminished 
organ function in fatty compared to lean organs follow-
ing IRI  [30, 31] . Cold ischemia time of 24 h for healthy 
donor organs was based on previous studies, demonstrat-
ing significant IRI in recipient animals  [13, 17] . For stea-
A
LT
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6,000
8,000
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#
*
fa/– veh fa/fa veh fa/fa GSH
 Fig. 3. Serum ALT levels determined 2 h after liver transplanta-
tion. Livers were explanted from lean (fa/–) or obese (fa/fa) rats. 
Prior to declamping, recipient animals received vehicle or GSH 
(200   mol/kg body weight/h). n = 5/group. Values are presented 
as mean  8 SD. Data were analyzed by one-way ANOVA.  *  p  ! 
0.05 vs. fa/– veh; # p  ! 0.05 vs. fa/fa veh. 
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 Fig. 4. Serum AST levels determined 2 h after liver transplanta-
tion. Livers were explanted from lean (fa/–) or obese (fa/fa) rats. 
Prior to declamping, recipient animals received vehicle or GSH 
(200   mol/kg body weight/h). n = 5/group. Values are presented 
as mean  8 SD. Data were analyzed by one-way ANOVA.  *  p  ! 
0.05 vs. fa/– veh; # p  ! 0.05 vs. fa/fa veh. 
 Fig. 5. Serum LDH levels determined 2 h after liver transplanta-
tion. Livers were explanted from lean (fa/–) or obese (fa/fa) rats. 
Prior to declamping, recipient animals received vehicle or GSH 
(200   mol/kg body weight/h). n = 5/group. Values are presented 
as mean  8 SD. Data were analyzed by one-way ANOVA.  *  p  ! 
0.05 vs. fa/– veh; # p  ! 0.05 vs. fa/fa veh. 
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 Fig. 6. Bile flow (  l/g liver weight/min) during 2 h of reperfusion. 
Livers were explanted from lean (fa/–) or obese (fa/fa) rats. Prior 
to declamping, recipient animals received vehicle or GSH (200 
  mol/kg body weight/h). n = 5/group. Values are presented as 
mean  8 SD. Data were analyzed by one-way ANOVA.  *  p  ! 0.05 
vs. fa/– veh; # p  ! 0.05 vs. fa/fa veh. 
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totic organs, cold ischemia time was substantially re-
duced to avoid deleterious organ damage  [7] .
 In healthy organs, continuous administration of GSH 
protects liver tissue from reperfusion injury after warm 
and cold ischemia  [9, 10, 32] . Endogenous GSH is concen-
trated in the intracellular space  [33] . It reacts with oxi-
dants released during reperfusion resulting in formation 
of oxidized GSH (GSSG)  [34] . Its effect on ischemia-re-
perfusion injury in steatotic grafts, however, remains un-
known. In the present study, GSH was administered at a 
dosage of 200   mol/kg body weight/h to provide stea-
totic organs with supraphysiological GSH levels. This 
dosage has been shown to ameliorate IRI following trans-
plantation of lean liver allografts  [30] and resulted in 
peak plasma GSH levels below the limit of toxicity in hu-
mans (500   M )  [35] . As has been found in lean organs, the 
administration of GSH at the beginning of reperfusion 
significantly decreased early liver injury (plasma amino-
transferase levels) and ameliorated liver function (bile 
flow) in steatotic grafts.
 Determination of the exact mechanisms which are re-
sponsible for the beneficial effects of GSH in steatotic or-
gans was beyond the scope of our study. Nonetheless, 
GSSG levels, the oxidized form of GSH, were increased in 
GSH-treated recipients of fatty grafts. This suggests that 
intravenously applied GSH was mostly oxidized. Oxida-
tion of GSH is known to be associated with detoxification 
of detrimental ROS  [36, 37] . In addition, the metabolism 
of GSH produces glycine  [35] , which also has protective 
properties against liver reperfusion injury  [14] . It has 
been proposed that the GSH-induced reduction of ROS is 
associated with improved sinusoidal perfusion, signifi-
cant decrease of leukocytes sticking to sinusoids, as well 
as prevention of sinus endothelial cell injury in lean or-
gans  [10, 32] . Steatotic livers are characterized by de-
creased sinusoidal blood flow due to swollen hepatocytes 
which may induce chronic hypoxia  [38] and ATP deple-
tion  [39] . Moreover, ischemia-reperfusion injury in fatty 
organs is associated with enhanced leukocyte adhesion 
and microcirculatory failure, potentially based on an in-
creased ROS release  [23, 25, 29, 40] . These studies collec-
tively suggest that GSH may also decrease ROS in fatty 
organs following cold storage and transplantation, there-
by improving microcirculation and preventing endothe-
lial damage, at least during the early reperfusion period 
which was of particular interest in this study.
 In summary, the present study demonstrated in-
creased IRI in transplanted, fatty allografts. Continuous 
postischemic infusion of GSH, a ROS scavenger, amelio-
rated early hepatocellular injury and improved liver func-
tion in fatty organs. The protective effects of GSH were 
associated with an increase in oxidized plasma GSSG, in-
dicating detoxification of ROS by GSH. Since no severe 
side effects of GSH administration have been reported, 
this peptide has significant potential to be a useful and 
safe means of improving the function of steatotic organs 
following liver transplantation in humans. A prospective 
randomized trial is required to verify these promising ex-
perimental results in the clinical arena.
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Liver TransplantationResults of theTOPStudy:ProspectivelyRandomized
Multicenter Trial of an Ex Vivo Tacrolimus Rinse
Before Transplantation in EDC Livers
Sebastian Pratschke, MD,1 Hannah Arnold, MD,1 Alfred Zollner, MD,2 Michael Heise, MD,3 Andreas Pascher, MD,4
Peter Schemmer, MD,5 Marcus N. Scherer, MD,6 Andreas Bauer, MD,7 Karl-Walter Jauch, MD,1 JensWerner, MD,1
Markus Guba, MD,1 and Martin K. Angele, MD1
Background.Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with
increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacro-
limus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of
ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. Methods. A prospective randomized multicenter trial
comparing ex vivo perfusion of marginal liver grafts (≥2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL)
or histidine-tryptophane-ketoglutarate solution (control) was carried out at 5 German liver transplant centers (Munich
Ludwig-Maximilians University, Berlin, Heidelberg, Mainz, Regensburg) between October 2011 and July 2013. Primary end-
point was the maximum alanine transaminase (ALT) level within 48 hours after transplantation. Secondary endpoints
were aspartate transaminase (AST), prothrombine ratio, and graft-patient survival within an observation period of 1 week. After
an interim analysis, the study was terminated by the scientific committee after the treatment of 24 patients (tacrolimus n = 11,
Control n = 13). Results. Tacrolimus rinse did not reduce postoperative ALT peaks compared with control (P = 0.207; tacro-
limus: median, 812; range, 362-3403 vs control: median, 652; range, 147-2034). Moreover, ALT (P = 0.100), prothrombine ratio
(P = 0.553), and bilirubin (P = 0.815) did not differ between the groups. AST was higher in patients treated with tacrolimus
(P = 0.011). Survival was comparable in both groups (P > 0.05). Conclusions. Contrary to experimental findings, tacrolimus rinse
failed to improve the primary endpoint of the study (ALT). Because 1 secondary endpoint (AST) was even higher in the intervention
group, the study was terminated prematurely. Thus, tacrolimus rinse cannot be recommended in transplantation of EDC livers.
(Transplantation Direct 2016;2: e76; doi: 10.1097/TXD.0000000000000588. Published online 4 May 2016.)The organ shortage represents one of the biggest challengesin transplantation medicine today and has resulted in an
increasing acceptance of extended donor criteria (EDC) graftsReceived 29 March 2016.
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have revealed protective effects of tacrolimus precondition-
ing.3,4 The authors recently demonstrated a reduction of
IRI after an ex vivo tacrolimus rinse in a model of experi-
mental liver transplantation in rats.5 In the clinical arena,
controversial data have been published on the effectiveness
of a tacrolimus rinse before liver transplantation6,7: within
a phase 1 trial, St Peter et al6 showed a significant reduction
of aminotransferase levels in the transplantation of non-
EDC livers after a tacrolimus rinse. In contrast to these
findings, Kristo et al7 recently failed to show a reduction
of alanine transaminase (ALT) levels through such a treat-
ment after transplantation of nonmarginal livers. Never-
theless, the authors demonstrated a distinct reduction of
precursors of proinflammatory enzymes on RNA level af-
ter a tacrolimus rinse in those patients. However, as both of
these studies investigated the transplantation of nonmarginal
organs, their relevance to the setting of EDC organ transplan-
tation is limited.
Therefore, the present prospectively randomized multi-
center trial (tacrolimus organ perfusion [TOP] study; Trial
register: EUDRACTnumber: 2010-021333-31, ClinicalTrialsFIGURE 1. CONSORT flow diagram TOP study.ID: NCT 01564095) included exclusively marginal livers with
2 or more EDC according to Eurotransplant's guidelines for
marginal liver grafts. The aim of the TOP study was to deter-
mine whether an ex vivo rinse of such organs with tacrolimus
results in a decreased IRI, thereby improving liver function
and organ survival. The study outline has been published
previously.8MATERIALS AND METHODS
Study Design
The TOP study was designed as an investigator-initiated,
prospectively randomized, multicenter trial according toGerman
Medicines Act (Section 42b, Abs. 1 Arzneimittelgesetz German
Pharmaceuticals Act). Patients were randomized into 2 groups
within this placebo-controlled, nonblinded study:(A) Ex vivo perfusion ofmarginal liver grafts with tacrolimus
(20 ng/mL) solved in 1000 mL histidine-tryptophane-
ketoglutarate (HTK) (tacrolimus + HTK)
(B) Ex vivo perfusion of marginal liver grafts with 1000 mL
HTK (HTK-alone)
© 2016 Wolters Kluwer Sebastian et al 3The observation period was 1 week. The inclusion period
for this trial was between October 2011 and July 2013. Be-
sides Munich Ludwig-Maximilians University as the initiat-
ing center, 4 German transplant departments participated in
this trial: Berlin-Charité, Heidelberg, Mainz, and Regensburg.
Twenty-five patients were enrolled in the study fromOctober
31, 2011 (first patient in) until July 9, 2013 (last patient out).
One patient was included and randomized but not transplanted
due to medical reasons. Eleven patients were treated with tacro-
limus + HTK and 13 with HTK alone (Figure 1, CONSORT
flow diagram). The study was terminated by the scientific com-
mittee in July 2013 after an interim analysis due to missing evi-
dence of the effectiveness of the study medication (20-ng/mL
tacrolimus in 1000-mLHTK) relative to the comparison group
(1000-mLHTK) concerning the primary endpoint of the study,
themaximummeasured ALT values on the first 2 postoperative
days. Moreover, potentially even harmful action was evident
when analyzing another secondary endpoint of the study,
postoperative aspartate transaminase (AST).
Protocol version 2.1 was approved by the local ethic com-
mittees of the ethics committee of the University of Munich.
The study complied with the Declaration of Helsinki and
Good Clinical Practice Guidelines. Informed consent was ob-
tained from each patient in written form before randomization.
Inclusion and Exclusion Criteria
Recipients with end-stage chronic liver disease older than
18years receiving their first organ transplantwere evaluated for in-
clusion in this trial. Only patients receiving livers with 2 or more
EDC following the definition of EDC by Eurotransplant9
(Table 1) were finally included in this trial. All recipient and
donor inclusion and exclusion criteria are outlined in Table 1.
Surgical Procedure/Perfusion Procedure
Tacrolimus was dissolved in 1000-mL HTK (concentra-
tion, 20 ng/mL) in the treatment group; in the control group,TABLE 1.
Inclusion/Exclusion criteria TOP study
Inclusion criteria
Recipient
Chronic end-stage liver disease, age > 18 years, first organ transplant
Exclusion criteria
Recipient
• Multiorgan transplantation
• High urgency listing
• Extrahepatic tumor diseases
• Pregnancy
• Denial or withdrawal of consent by the patient or his relatives
• Accommodation in an institution due to governmental or judicial authorities
• Missing knowledge of German language, no understanding of information not guaranteedthe rinse solution consisted of 1000-mLHTK-only. The rinse
was administered sequentially to the portal vein and the com-
mon hepatic artery (500 mL each) at the end of back-table
preparation via a 12-gauge cannula from a height of 100 cm
without additional pressure using polyvinyl chloride–free in-
fusion sets (Braun Melsungen AG, Germany). The duration
of the perfusion procedure was 16 minutes (median) versus
18.1 ± 7.3 minutes (mean ± SD) and was similar between
the groups (P > 0.05). Cava sparing liver transplantation was
performed afterward. Immunosuppression and postoperative
care were carried out according to center-specific standards.
Primary and Secondary Endpoints
The primary endpoint was the maximum ALT level (U/L)
within the first 48 hours after liver transplantation.
Secondary endpoints were ALT and AST levels (U/L)
and graft function (prothrombine ratio/quick (%), biliru-
bin (mg/dL) on postoperative days 1, 2, 4, and 7. Within
the follow-up, organ and patient survival was monitored.
Donor and Recipient Characteristics
The following data were collected for each donor and re-
cipient, respectively: height, bodyweight, body mass index
(BMI)/graft steatosis, age and diagnosis. In addition, the du-
ration of intensive care, cold ischemia time, donor risk index
(DRI) (according to Feng et al10) and the number and type of
EDC were captured (Tables 2 and 3).
Recipients' diagnoses were classified as follows: alcoholic
cirrhosis, malignancy, viral hepatitis, primary biliary cirrhosis,
and others. Based on the preoperative serum creatinine, biliru-
bin, and international normalized ratio levels, laboratorymodel
for end-stage liver disease (MELD) scores were calculated as
described previously.11
Statistic Evaluation/Sample Size Calculation
The sample size estimation was based on previous findings
published by St Peter et al6 in which nonmarginal grafts hadDonor
• Donor age >65 years
• Macrovesicular steatosis >40% (secured macroscopically or by biopsy)
• BMI >30
• Na >165 mmol/L
• Intensive care and mechanical ventilation >7 d
• Cold ischemia time >13 h
• AST >99 U/L
• ALT >105 U/L
• Bilirubin >3 mg/dL (>51 μmol/L)
• Application of epinephrine
Donor
Hepatitis B or hepatitis C infection
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4 Transplantation DIRECT ■ 2016 www.transplantationdirect.combeen transplanted. An effect size of approximately 0.7 was
considered appropriate for the sample size calculation pre-
suming higher postoperative ALT levels and a more pro-
nounced reduction in marginal liver grafts.8 The power of
the test was 80% at a significance level of 0.05. Therefore,
sample size estimation (nQuery Advisor 6.1; Statistical Solu-
tions, Saugus, MA) for 2 unpaired samples using theWilcoxon
rank-sum test with an expected dropout rate of 15% resul-
ted in an estimated sample size of 86 patients (43 tacroli-
mus + HTK vs 43 HTK-only). The randomization was
performed in blocks of variable length, stratified according
to the transplant centers. The Hodges-Lehman estimator
was used to estimate effects on the primary endpoint (ALT).
Secondary endpoints were calculated using the multivari-
ate rank-sum test by O'Brien. The portion of EDC in both
groups was compared by Fisher exact test, the absolute num-
bers of these parameters were analyzed using the Mann-
Whitney U test. The statistical analysis was performed using
statistical software Predictive Analysis SoftWare statistics
18.0.0 (SPSS Inc., Chicago, IL).
For all statistical tests, a test wise α-level of 5% was used.
P values less than 0.05 were considered statistically significant.RESULTS
Donor Characteristics
The number and type of EDC as a basis for patient inclu-
sion did not differ between the study groups. In this respect,
the average number of EDC (which represent the inclusion
criteria to the study) was 2.75 in both groups. The most
prevalent EDC were high donor age older than 65 years
(n = 9/24), an intensive care unit stay longer than 7 days
(n = 7/24), obesity (BMI > 30) (n = 10/24), and elevated
liver enzymes (AST > 105 U/L) (n = 9/24). The portion of
donors which met these inclusion criteria was similar in
both groups (Table 2). These factors also did not differ in
absolute numbers (median vs mean ± SD; Table 2).
The donor risk index was not different whether grafts had
been treated with tacrolimus or control/HTK (tacrolimus:
median, 1.9; mean ± SD, 2.0 ± 0.4; control: median, 1.8;
mean ± SD, 1.8 ± 0.3) (P = 0.35).When analyzing the donors'
cause of death, 10 donors had died of cerebral hypoxia and
14 of an intracerebral bleeding. These diagnoses had the
same portion in both groups.
Recipient Characteristics
Recipient characteristics did not differ between the 2 study
groups. Relevant prognostic factors were comparable in pa-
tients randomized to tacrolimus or control (ie, laboratory
MELD scores, BMI, age; P >0.05) (Table 3). Fifteen patients
were transplanted due to malignant diseases (hepatocellular
carcinoma, n = 14; cholangiocellular carcinoma, n = 1) and
2 for a cryptogenic liver cirrhosis. The remaining indications
were classified as follows: hepatitis C (n = 1), autoimmune
hepatitis (n = 1), PSC (n = 1), and α1-AT deficiency (n = 1).
Primary Endpoint: Maximum ALT
Perfusion of marginal livers with tacrolimus resulted in no
statistically significant effect on the maximum ALT values
measured within the first 2 postoperative days after trans-
plantation compared with HTK-only (tacrolimus + HTK:
TABLE 3.
Recipient characteristics: tacrolimus + HTK versus HTK-only is compared by using Mann-Whitney U test
Overall Tacrolimus Control P (tacrolimus + HTK vs HTK-only)
Recipient age 60 (58.5 ± 7.7) 63 (59.8 ± 8.1) 55 (57.5 ± 6.5) 0.26
BMI 27.4 (27.2 ± 4.9) 25.3 (26.6 ± 4.7) 27.4 (27.7 ± 4.8) 0.52
Laboratory MELD 13 (14.3 ± 6.9) 13 (13.3 ± 4.9) 13 (15.2 ± 8.2) 0.69
FIGURE 2. Serum ALT levels (U/L) on the first, second, fourth,
and seventh postoperative days with respect to an ex vivo organ per-
fusion with tacrolimus (20 ng/ml) or with HTK-only. P = 0.100; multi-
variate rank sum test by O'Brien. Tacrolimus + HTK, white column;
HTK-only, grey column.
© 2016 Wolters Kluwer Sebastian et al 5median, 812 U/L; range, 362-3403 U/L vs HTK-only: me-
dian, 652 U/L; range, 147-2034 U/L) (P = 0.207). The
Hodges-Lehman estimator for the 95% confidence interval
for the median difference was (−178 to 1166).
On the first postoperative day, the maximum ALT was in
median, 607 U/L (mean ± SD, 790.4 ± 714.4 U/L) in the ta-
crolimus group compared with 544 U/L (544.8 ± 326.9
U/L) in the control group, respectively (P = 0.56). On the
second postoperative day, the maximum ALT levels were
in median, 726 U/L (mean ± SD, 1010.5 ± 634.9 U/L) for ta-
crolimus versus median, 425 U/L (mean ± SD, 613.9 ±
439.8 U/l) for control (P > 0.05).
Secondary Endpoints
Alanine Transaminase
No statistically significant effect was evident when com-
paring tacrolimus + HTK versus HTK-only on postoperative
days 1, 2, 4, and 7 (P = 0.100, multivariate rank sum test ac-
cording to O'Brien). For example, the median ALT was
607 U/L (tacrolimus + HTK) versus 497 U/L (HTK-only)
on day 1 and 726.5 U/L (tacrolimus + HTK) versus 400 U/L
(HTK-only) on the second postoperative day (Figure 2).
Aspartate Transaminase
Patients whose grafts had been treated with tacrolimus
showed increased systemic AST levels in the postoperative
course. When comparing AST on postoperative days 1, 2,
4, 7, a P value of 0.011 was evident (multivariate rank sum
test according to O'Brien). For illustration, on postopera-
tive day 1, the maximum AST was 1196 U/L (median) in
grafts treated with tacrolimus versus 802 U/L (control). On
the second postoperative day, the median ASTwas 1030 U/L
(tacrolimus) compared with control: 390 U/L (Figure 3).
Bilirubin
A tacrolimus rinse did not alter the postoperative bilirubin
levels during the observation period of 1 week (P = 0.815). In
grafts flushed with tacrolimus, the median bilirubin was
4 mg/dL versus 2.75 mg/dL (control) on the first postopera-
tive day and 3.3 versus 3.05 mg/dL on the second postopera-
tive day, respectively (Figure 4).
Prothrombine Ratio/Quick (%)
No statistically significant effect was evident when com-
paring tacrolimus and control on postoperative days 1, 2,
4, and 7 (P = 0.553). For example, the median of this param-
eter was 53.5 (tacrolimus) versus 57.5 (control) on postopera-
tive day 1 and 55.5 versus 63 on postoperative day 2 (Figure 5).
Survival
Organ and patient survivals as well as the number of re-
jections were equal in both treatment arms (p = 1.000). Nostudy patient died or underwent retransplantation within
the observation period of 7 days.
DISCUSSION
Extended donor criteria liver grafts exhibit an increased
IRI during liver transplantation resulting in decreased graft
function and survival.12-14 Due to the current shortage of or-
gans from deceased donors and the declining number of liver
transplantations in Germany (n = 1192 in 2010, n = 884 in
2013), these grafts are increasingly used for transplantation.
In 2010, EDC organs made up more than 70% of all
transplanted livers in Germany, and the proportion of liver
grafts exhibiting 1 or more EDC increased from 29 % in
1997 to 73% in the year 2010 (data provided by Euro-
transplant). Thus, new therapies have to be developed to re-
duce IRI in EDC organs.
The hypothesis of the TOP study was that a single ex vivo
tacrolimus rinse reduces IRI in transplantation of marginal
liver grafts. In this respect, experimental data demonstrate a
protective role of the calcineurin inhibitor tacrolimus on the
hepatic IRI after warm and cold ischemic periods.5,15 For
the present trial, an ex vivo tacrolimus rinse in EDC liver
grafts has been chosen as study medication. This dosage
form is based on previous experimental5 and clinical6,7 data
indicating protective effects of a single ex vivo tacrolimus
treatment in the cold liver graft: St Peter et al6 described a sig-
nificant reduction of postoperative aminotransferase levels
after a tacrolimus rinse in transplantation of normal,
FIGURE 3. Serum AST levels (U/L) on the first, second, fourth
and seventh postoperative days with respect to an ex vivo organ per-
fusion with tacrolimus (20 ng/ml) or with HTK-only. P = 0.011; multi-
variate rank sum test by O'Brien. Tacrolimus + HTK, white column;
HTK-only, grey column.
FIGURE 5. Serum ALT levels (U/L) on the first, second, fourth, and
seventh postoperative days with respect to an ex vivo organ perfu-
sion with tacrolimus (20 ng/mL) or with HTK-only. Tacrolimus + HTK,
white column; HTK-only, grey column.
6 Transplantation DIRECT ■ 2016 www.transplantationdirect.comnonmarginal liver grafts. The second trial by Kristo et al7
could not reproduce a clinical reduction of IRI but showed
a decreased expression of inflammatory cytokines through
such a treatment. In both studies, however, nonmarginal liver
grafts were included. Thus, the results of these trials do not
reflect the current clinical problem of organ shortage and
marginal liver grafts.
With respect to the current study design it must be stated
that the metabolism of the graft is certainly reduced during
the ex vivo rinse treatment of the cold liver. As a calcineu-
rin inhibitor, tacrolimus requires active T cells to develop its
effect which are not present during the ex vivo perfusion.
Nevertheless, tacrolimus may exert its therapeutic effectsFIGURE 4. Serum bilirubin levels (mg/dL) on the first, second, fourth
and seventh postoperative day with respect to an ex vivo organ per-
fusion with tacrolimus (20 ng/mL) or with HTK-only. P = 0.815; multi-
variate rank sum test by O'Brien. Tacrolimus + HTK, white column;
HTK-only, grey column.throughout the gradual warming of the graft during reperfu-
sion. Furthermore, a local treatment is supposed to supply
higher concentrations of tacrolimus compared with a sys-
temic treatment of the recipient. In an experimental setting,
the authors were also able to demonstrate a relevant decline
of the tacrolimus concentration in the perfusate after passing
the ischemic graft.5
In an attempt to provide protective action of tacrolimus
from the beginning of reperfusion, most of the previous ex-
perimental models have performed a systemic donor precon-
ditioning.16,17 Despite their promising results, the clinical
implementation of these models is problematic due to the
organ allocation policy of Eurotransplant generating a con-
fusing group of recipients.Whether a systemic recipient treat-
ment before organ implantation would improve the effectivity
of tacrolimus should be considered in further studies.
The hepatic IRI is triggered by innate immune activa-
tion and is characterized by proinflammatory cytokines, neu-
trophil infiltration, and diminished microcirculation. In this
respect, potential mechanisms for the effects of tacrolimus
on the hepatic IRI have been described, including an impact
on inflammatory processes, a decrease of neutrophil infil-
tration and apoptosis as well as an improved microcir-
culation.4,16,18-21 Because tacrolimus has its effects primarily
through a downregulation of IL-2 and a consecutively dimin-
ished activation of T cells, this pathway may also account for
the postulated action of a tacrolimus rinse besides the well-
known anti-inflammatory properties of this substance. In this
respect, Khandoga et al have reported a novel concept for the
development of IRI demonstrating a pivotal of T cells in those
pathophysiological processes.22-24
In the TOP study, an organ rinse with tacrolimus dissolved
in HTK was compared with HTK-only (control group). This
study design was also chosen because the rinse procedure it-
self may have protective effects on ischemia-reperfusion in
liver transplantation. In this respect, experimental and clini-
cal studies demonstrate that perfusion with Carolina Rinse
or warm Ringer lactate exerts protective effects in terms of
© 2016 Wolters Kluwer Sebastian et al 7graft damage and survival.25,26 In contrast to these findings,
a recent prospective trial by Heise27 incorporating 264 patients
failed to show protective effects when performing an ex situ
perfusion of the hepatic artery with HTK solution.
The inclusion criteria (Table 1) chosen for this trial were
based on their association with decreased graft function and
survival. The study proposal has been published previously.8
The prevalence of 2 or more EDC was the central inclu-
sion criterion because some authors describe that even trans-
plantation of grafts from extremely extended criteria donors
may not negatively influence the long-term outcome as long
as only a single-donor risk factor is present (ie, donor age
>70 years).28 Instead, certain combinations of donor and re-
cipient factors seem to be of higher prognostic value than the
existence of single risk factors. For instance, a high donor age
and hepatitis C in the recipient29 or the combination of a
worsening MELD score (D-MELD) and the presence of ≥ 2
EDC in organ donors14 may decrease survival after liver
transplantation. Therefore, the TOP study only included
marginal liver grafts exhibiting 2 or more EDC.
The design of the TOP study resulted in a clinically rele-
vant reduction of graft quality to prove therapeutic effects
of the study medication. In this respect, the median DRI
was 1.9 in all organ donors whose grafts had been used for
the TOP study. The average number of EDC did not differ be-
tween the study groups. Although the DRI represents a rating
system for graft quality developed specifically for the United
States,10 it is also a valid marker for graft quality within the
Eurotransplant allocation system.30 The relevance of the
DRI is further emphasized by a previous analysis conducted
by our group which included 448 patients from our institu-
tional liver transplant database, which showed a DRI of
1.25 or greater to be a highly prognostic marker in multivar-
iate analysis with a hazard rate ratio of 3.2.31
The prognostic relevance of the hepatic IRI and other
nonimmunological pathomechanisms, however, is the sub-
ject of ongoing discussion.32-34
Acute effects of IRI include the generation of reactive oxy-
gen species and the release of inflammatory cytokines which
result in microcirculatory disturbance causing graft damage
and potentially graft loss.35 Ischemia-reperfusion injury also
correlates with the initial organ function.36,37 Therefore, clin-
ical markers of hepatic IRI (ALT, AST) were chosen as end-
points in the TOP study. Although IRI is a diagnosis mainly
made by histologic staining,38 the primary endpoint of the
study, ALT, correlates well with intrahepatic changes charac-
teristic for reperfusion associated liver damage.39
Moreover, IRI may be associated with chronic alter-
ations of the graft. In this respect, some authors suggest
an interaction between nonimmunological and immuno-
logical factors thereby influencing the long-term outcome
of liver grafts: O'Leary et al40,41 have shown a correlation
between organ damage and the generation of donor spe-
cific HLA-antibodies.
In the present study, a tacrolimus rinse at a concentration
of 20 ng/mL did not reduce postoperative ALT levels. Even
a trend toward slightly higher levels of ALT seems to be evi-
dent in grafts treated with tacrolimus, and this observation
reaches statistical significance in AST in the postoperative
course (P = 0.011). Nevertheless, based on the present results
suggesting no therapeutic effect also if larger numbers of pa-
tients had been recruited or even harmful action of a tacrolimusrinse the TOP study was terminated in July 2013 according
to a decision of the scientific committee.
Conflicting data on ALT and AST levels after tacroli-
mus rinse before liver transplantation have been published.6,7
Similar to our results, Kristo et al7 reported no effect of tacro-
limus on AST and ALT levels in nonmarginal organs. On the
molecular level, a reduction of precursors of inflammatory
markers using highly sensitive gene chip array analysis after
a tacrolimus rinse with 20 ng/mL in liver transplantation
was evident. These findings argue against a hepatotoxic ef-
fect of tacrolimus.
Altogether, previous data suggest that tacrolimus could
also exert protective effects in marginal liver grafts which ex-
hibit an increased IRI.
To analyze potential effects of a rinse treatment in mar-
ginal liver grafts itself, the results of the present study were
compared with placebo using the liver transplant database
of our hospital. For this purpose, 24 recent consecutive trans-
plantations of livers exhibiting 2 or more EDC were ana-
lyzed. Preoperative ALT/AST values did not differ between
study patients and placebo (P > 0.05). When analyzing post-
operative ALT/AST values (days 1, 2, 4, 7), no differences
were evident between study patients that had received an
ex situ rinse and placebo (Mann-Whitney U test, P >0.05).
In summary, the study medication failed to decrease IRI
and partially even increased graft damage in transplantation
of marginal livers. Only a small number of patients (n = 24)
has been included in this study, which limits its significance.
Nevertheless, missing evidence of the effectiveness of the
study medication must be presumed based on the present
data. Whether varying the dosage of tacrolimus in the rinse
solution or new approaches (ie, adding tacrolimus to a con-
tinuous machine perfusion) will increase its effectiveness
should be addressed in future trials.
CONCLUSIONS
Critical organ shortage contributes to decreased graft
quality which is associated with an increase in IRI as well
as reduced survival after liver transplantation. Experimental
and clinical data indicate a protective role of a tacrolimus
rinse in healthy, nonmarginal liver grafts. The aim of the
TOP study was to reduce hepatic IRI with a single ex vivo ta-
crolimus rinse before reperfusion in EDC liver grafts. The
present data do not indicate a protective role of tacrolimus
rinse of marginal organs in liver transplantation rather dem-
onstrating harmful effects. Thus, ex vivo tacrolimus rinse is
contraindicated as an approach to decrease IRI after trans-
plantation of marginal livers.
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Letter to theEditorThe Authors’ Reply
Sebastian Pratschke, MD1 and Martin K. Angele, MD1Thank you very much for your comment on our manu-script “Results of the TOP Study: Prospectively Ran-
domized Multicenter Trial of an Ex Vivo Tacrolimus Rinse
Before Transplantation in EDC Livers.”1 We would like to
take the opportunity to respond to the valuable comments
of Kobayashi.2
In the tacrolimus organ perfusion (TOP) study marginal
liver grafts exhibiting ≥ 2 extended donor criteria (EDC)
were randomly flushed ex situ with Tacrolimus (20 ng/mL)
dissolved in histidine tryptophane ketoglutarate (HTK) solu-
tion or with HTK only (control) to reduce ischemia reperfu-
sion injury. Kobayashi suspects a potential warming of the
grafts and harmful effects through this procedure. Facing this
criticism, the authors state that the temperature of the rinse
solution was 4°C at the beginning of the treatment (though
it was not measured at the end of the perfusion as suggested
by Kobayashi) and the procedure took on an average of
18 minutes only. Although the plastic bags containing the
rinse solution were not cooled during the procedure (analo-
gously with the systemic perfusion at organ harvesting),
grafts undergoing the study treatment were continuously
stored on ice until the beginning of implantation. Therefore,
the authors assume a warming of the graft and a subsequent
initiation of the hepatic metabolism to be extremely unlikely.
Moreover, Kobayashi questions the anastomosis time and as-
sumes that warm ischemia could counteract the protective ef-
fects of a rinse treatment. In this respect, he suggests a new in
situ technique of organ perfusion. The authors would like to
state that changes in the surgical procedure were beyond the
scope of the TOP Study. Moreover, the rinse treatment itselfReceived 14 July 2016. Revision requested 9 December 2016.
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Transplantation DIRECT ■ 2017was not the point of interest in our study, but to investigate
the effects of Tacrolimus in a rinse of 1000 ml HTK com-
pared to 1000 ml HTK only. Cava sparing transplantation
including anastomoses was performed after the rinse treat-
ment according to center specific standards in both groups.
Therefore, the study treatment did not affect the time for vas-
cular reconstruction. To the authors' best knowledge, a sim-
ple study treatment in combination with routine surgery is
required to generate valid data in a multicentric trial in liver
transplantation.
Kobayashi presents an interesting concept of an in-situ
perfusion. The authors greatly appreciate any attempts (ie,
organ preperfusion) to improve the utilization of EDC grafts.
In this respect, an additional in situ flush of the graft may
have protective effects. Nonetheless, this procedure does
not represent an established procedure and would need to
be evaluated in a prospective trial. Since the TOP study failed
to show protective effects of Tacrolimus compared with con-
trol, this concept must be reevaluated and the authors suggest
further analyses of this substance due to its proven anti-
inflammatory effects. Therefore, an adjunct of Tacrolimus to
an in-situ perfusion as described by Kobayashi or to machine
perfusion could be an option to reduce ischemia reperfusion
injury especially in EDC grafts thereby increasing the limited
donor pool, which represents the most pressing problem in to-
day’s transplantation medicine.
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Originally submitted March 22, 2011; accepted for publication July 29, 2011Objective. To characterize the immunosuppressant
tacrolimus as a protective antioxidant in rat liver
transplantation.
Methods. Livers of male Lewis rats underwent 24 h
of hypothermic preservation in UW solution and were
rinsed with tacrolimus or placebo directly before
transplantation. Markers of liver injury, such as en-
zymes and bile flow, were determined during a 2 h re-
perfusion period. Concentrations of reduced (GSH)
and oxidized (GSSG) glutathione were analyzed in
plasma, bile, and liver tissue for estimation of oxidant
stress caused by reactive oxygen species (ROS).
Results. Administration of tacrolimus (10 ng/mL) re-
sulted in decreased ALT plasma levels (1740 ± 1169 U/l
versus 3691 ± 1144 U/l; P < 0.05) at 2 h of reperfusion.
While endogenous intracellular GSH concentrations
remained unchanged, GSSG, the oxidation product of
GSH, was markedly decreased at 2 h of reperfusion in
preconditioned livers (47.0 ± 10.4 nm/g versus 71.8 ±
30.6 nm/g; P < 0.05). Correspondingly, GSSG bile con-
centrations (0.19 ± 0.04 mM versus 0.13 ± 0.04 mM; P <
0.05) as well as plasma GSSG levels (2.4 ± 0.3 mM versus
1.4 ± 0.2 mM; P < 0.05) were significantly increased
upon reperfusion. These findings suggest that tacroli-
mus impacts post-ischemic GSH metabolism when ad-
ministered as a rinse solution for liver allografts
through an unknown pathway.
Conclusion. Hepatocellular injury following trans-
plantation was significantly decreased by precondi-
tioning with tacrolimus. One possible mechanism of
action is the detoxification of ROS through the1 To whom correspondence and reprint requests should be ad-
dressed at Department of Surgery, Klinikum Grosshadern of the
LMU, Marchioninistr. 15, 81377 Munich, Germany. E-mail:
sebastian.pratschke@med.uni-muenchen.de.
309preservation of cytosolic and extracellular GSH/GSSG
ratios.  2012 Elsevier Inc. All rights reserved.
Key Words: ischemia/reperfusion injury; liver trans-
plantation; glutathione; tacrolimus.INTRODUCTION
Ischemia-reperfusion injury (IRI) as a consequence of
liver preservation has considerable effects on the out-
come of patients after liver transplantation. Primary al-
lograft dysfunction remains, therefore, a serious
problem, resulting in high patient morbidity and mor-
tality rates [1–3]. There is substantial evidence that
activation of Kupffer cells (KC), the generation of intra-
and extracellular reactive oxygen species (ROS), and
disturbances of the hepatic microcirculation are in-
volved in reperfusion injury [4, 5]. Therefore, therapeu-
tic strategies which reduce IRI remain to be
established.
A large number of investigations using antioxidant
interventions support the pivotal role of ROS in the de-
velopment of reperfusion injury following warm or cold
liver ischemia [3, 6, 7]. Recent studies examined the
therapeutic potential of the endogenous antioxidant
glutathione (GSH), a compound which is of particular
clinical interest due to its low toxicity in humans [8].
Furthermore, GSH is able to react spontaneously with
nearly all oxidants formed during inflammation and re-
perfusion, resulting in the formation of oxidized gluta-
thione (GSSG). In liver cells, the concentration of
GSH is 10mMand thus 1000-fold higher than in the ex-
tracellular space (10 mM), i.e., the sinusoids [9]. Re-
cently, we could demonstrate that GSH effectively0022-4804/$36.00
 2012 Elsevier Inc. All rights reserved.
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when given intravenously during the reperfusion pe-
riod [10, 11]. Upon reperfusion of ischemic livers, intra-
cellular GSH is released into the sinusoidal space as
well as into the bile through active transporters
found on hepatocytes, and can thus act as an endoge-
nous defense system against ROS in these compart-
ments [12, 13].
Since the mid-1980s, the calcineurin inhibitor tacro-
limus (FK 506) has been amainstay in immunosuppres-
sive regimens following organ transplantation [14, 15].
Specific T-cell inhibition seems to be responsible for the
immunosuppressive properties of tacrolimus. In addi-
tion, tacrolimus has been shown to result in ameliora-
tion of ischemia-reperfusion injury in various organs.
Its ability to reduce IRI is the cumulative result of ef-
fects on free radical metabolism, microcirculation,
calcium-activated pathways, inflammatory cascades,
and others [16]. Several experimental studies have
demonstrated a beneficial impact on ROS-mediated
cell damage upon ischemia and reperfusion [17, 18]. Al-
though it seems plausible that the protective effect of
tacrolimus is due to the suppression of free radicals fol-
lowing liver ischemia and reperfusion, the molecular
mechanisms responsible for this effect remain largely
unclear. Recently, an interesting human study was
able to demonstrate a protective effect on reperfusion
injury, when liver allografts were flushed with tacroli-
mus directly before the implantation procedure [19].
This procedure resulted in a significant decrease of
postoperative peak ALT levels; however, this study
did not investigate potential mechanisms underlying
this important observation.
On the basis of these results, and the knowledge that
glutathione is an important endogenous antioxidant in
IRI, we hypothesized that the application of tacrolimus
as a rinse solution for liver allografts may have an influ-
ence on the GSH/GSSG metabolism during rat liver
transplantation.METHODS
Animals and Preparation
All studies were performed with the permission of the government
authorities and in accordance with the German legislation on labora-
tory animal experiments. Syngeneic, male Lewis rats (donors: 210 6
14 g; recipients 2846 18 g bodyweight) were fasted 12 h prior to donor
and recipient operations, which were performed as described earlier
[20]. Prior to the implantation procedure, the livers were either
rinsed with cold saline solution alone or with the addition of tacroli-
mus (Astellas Inc., Deerfield, IL) via the portal vein. Portal clamping
time during transplantation was less than 20 min in all experiments
(17 6 1.5 min).
The common bile duct of the graft was cannulated with a PE-tube
and bile was collected in Eppendorf cups. Plasma samples (500 mL)
were obtained in the recipient before hepatectomy and during 120
min of reperfusion of the transplanted liver. The volume of the blooddrawn was replaced by saline. Five min after starting reperfusion, all
rats received 0.5 mL of albumin (5%) and 0.5 mL sodium bicarbonate
in order to maintain blood pressure and physiologic pH. To avoid ma-
jor fluid loss and drying of the liver, the abdominal cavity was covered
with cling wrap throughout the operation. After 120 min of reperfu-
sion, experiments were terminated and the liver weight was
determined.Experimental Groups
Two intervention groups (n¼ 6 each) were comparedwith a control
group (n¼ 6) and a sham-operated group (only laparotomy; n¼ 5). In
control animals, saline (20 mL at 4C; constant pressure 10 cm H2O)
was infused via the portal vein to wash the preservation solution
from the liver allograft before implantation. Intervention groups re-
ceived 10 or 50 ng/mL of tacrolimus, which was added to 20 mL of
saline.Analytical Methods
GSH and GSSG
Total soluble glutathione (GSH and GSSG) was measured in
plasma and bile as well as in the acidic homogenate from freeze-
clamped livers as described in detail elsewhere [21]. For GSSG anal-
ysis an aliquot (200 mL) of bloodwasmixed immediatelywith 200 mL of
10 mM N-ethylmaleimide (NEM) in 100 mM phosphate buffer (pH
6.5) containing 17.5 mM EDTA [21]. The remaining blood (300 mL)
was centrifuged at full speed for 1 min. An aliquot of (100 mL) of
plasma was pipetted into 100 mL sulfosalicylic acid (5%) for determi-
nation of total glutathione. To separate GSSG from NEM and NEM-
GSH adduct, an aliquot of NEM treated plasma was passed through
a Sep-PakC18 cartridge (Waters, Framingham, MA) followed by 1
mL of 100 mM phosphate buffer (pH 7.5). GSSG in the eluates and to-
tal glutathione in plasma and acidic homogenateswere determined by
an enzymatic test as described previously [21, 22]. GSH plasma con-
centrations were calculated as the difference between total glutathi-
one and GSSG. Bile concentrations of GSH and GSSG were
measured as described above; however, these samples underwent di-
lution (1:1000 in phosphate buffer) before analysis.
Serum Markers of Liver Cell Damage
Serumaminotransferaseswere used as establishedmarkers of liver
injury. Aspartate aminotransferase (AST) and alanin aminotransfer-
ase (ALT) were measured 2 h a fter reperfusion using a serum multi-
ple analyzer (Hitachi917; Roche, Mannheim, Germany).Liver Function
Liver function upon transplantation was estimated from the
amount of bile produced during the 2 h reperfusion period. Bile
flow was determined by collecting the bile in 30 min intervals
(mL/min/g) and the cumulative bile flow was calculated from total
bile volume produced during 2 h of reperfusion per gram of liver
(mL/2 h/g).Statistical Analysis
All data are expressed as mean and standard error. Statistical dif-
ferences between groups were calculated using paired or unpaired
Student’s t-test for randomly distributed data and the Mann-
Whitney U test for nonparametric data following analysis of variance
(ANOVA). Differences were considered significant at P < 0.05.
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Tacrolimus Absorbance in the Liver Allograft
It was important to document the extent to which ta-
crolimus can be absorbed by an isolated graft when it
was flushed by 20 mL of saline with 10 and 50 ng/mL
of the immunosuppressant at physiologic hydrostatic
pressure. For that purpose, the tacrolimus concentra-
tion in the effluate from the hepatic veins was mea-
sured after rinsing the livers with the tacrolimus
solution. Interestingly, we found that very little of the
tacrolimus in the rinse solution remained unabsorbed.
Approximately 100% and 88% of the administered ta-
crolimus dosages of 10 and 50 ng/mL, respectively,
were absorbed during rinsing, indicating successful in-
corporation by the liver tissue (Fig. 1).Cell Injury and Liver Function after Liver Transplantation
Injury of parenchymal liver cells after liver trans-
plantation was assessed by the release of ALT and
AST at 120 min of reperfusion. Parenchymal cell dam-
age in untreated animals (controls) was indicated by
a 34- and 40-fold increase of ALT- und AST serum
levels, respectively, compared with sham-operated ani-
mals (Table 1). Rinsing of the allografts with tacrolimus
at a concentration of 10 ng/mL resulted in a significant
(P < 0.05) reduction in AST- and ALT-levels of almost
40% and 50%, respectively, whereas the administration
of 50 ng/mL of tacrolimus seemed to be less effective
(Table 1).
The function of the liver allografts was estimated by
the recovery of bile flow during reperfusion. The bile
flow of donor livers was approximately 1 mL/min/gTac 10ng/ml
rinse    effluate
Tac 50 ng/ml
rinse   effluate
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FIG. 1. Tacrolimus (Tac) concentrations in rinse solution with ei-
ther 10 ng/mL or 50 ng/mL as substitute to 20 mL of saline. Black col-
umns indicate tacrolimus concentration as measured in the effluate,
sampled from liver veins. Almost 100% uptake following 10 ng/mL
and about 88% uptake following 50 ng/mL of tacrolimus was
determined.(Table 1). Hypothermic preservation and the transplan-
tation procedure dramatically decreasedmaximum bile
flow upon reperfusion to approximately 50% of baseline
values. The post-ischemic bile flow was significantly
higher in those allografts, which had been rinsed with
10 ng/mL tacrolimus (P < 0.05). The administration of
50 ng/mL of tacrolimus showed no substantial effect
on the functional recovery of the transplant as mea-
sured by the cumulative bile flow during 2 h of reperfu-
sion (Table 1).
Effect of Tacrolimus on GSH and GSSG Tissue Levels
Samples of frozen liver tissue for determination of
GSH and GSSG concentrations were taken at the end
of the 2 h reperfusion period. Preconditioning with
the tacrolimus flush solution did not significantly influ-
ence the total intracellularGSH content (GSHþGSSG)
as shown in Fig. 2A. However, livers that had been
rinsed with the 10 ng/mL tacrolimus solution showed
significantly lower levels of GSSG following transplan-
tation (47.9 6 8.9 mmol/g versus 71.2 6 12.2 mmol; P <
0.05). This decrease was less pronounced in livers
which had been rinsed with the 50 ng/mL solution
(63.8 6 9.8 mmol/g; Fig. 2B). Moreover, similar results
were evident when GSSG was normalized to percent
of total GSH levels (data not shown). Tacrolimus
seemed to mediate an increase in the reduced form of
hepatocellular glutathione (GSH), in particular at the
cytoprotective dose of 10 ng/mL.
Effect of Tacrolimus on GSH and GSSG Bile Concentrations
Quantification of the bile concentrations of GSH and
GSSG during the reperfusion period showed a substan-
tial I/R-mediated decrease in controls compared with
the sham group (Fig. 3). Tacrolimus preconditioning
of liver allografts with 10 ng/mL significantly increased
the GSH concentration compared with untreated con-
trols (320 6 123 mM versus 109 6 19 mM; P < 0.05),
whereas 50 ng/mL was less effective (191 6 84 mM;
Fig. 3A). An important fraction of the total GSH content
in the bile was represented by the oxidized form of GSH
(GSSG), as shown by GSSG concentrations of 0.19 6
0.02 mM and 0.15 6 0.03 mM after 10 ng/mL and 50
ng/mL tacrolimus flush, respectively, whereas controls
exhibited GSSG bile concentrations of only 0.13 6 0.04
mM (Fig. 3B), indicating a substantially accelerated ex-
port of GSSG from liver cells into the bile during reper-
fusion of transplants.
Effect of Tacrolimus on GSH and GSSG Plasma Concentrations
Total plasma glutathione levels were significantly
increased after the procedures of organ harvest,
24 h of hypothermic preservation, and orthotopic
TABLE 1
Hepatocellular Injury and Liver Function Following Transplantation
Sham [n ¼ 5] Control [n ¼ 6] Tac 50 [n ¼ 6] Tac 10 [n ¼ 6] P value [*versus control]
ALT [U/l] 108 6 12 3691 6 1444 2213 6 816* 1740 6 736* <0.05
AST [U/l] 72 6 9 2854 6 676 2312 6 412* 1470 6 812* <0.05
BF baseline [mL/min/g] 1.03 6 0.6 1.1 6 0.4 0.9 6 0.3 1.1 6 0.5 -
BF maximum [mL/min/g] 1.05 6 0.2 0.43 6 0.1 0.52 6 0.08 0.68 6 0.12* <0.05
BF cumulative [mL/2 h/g] 111.5 6 4.8 34.7 6 5.9 41.2 6 4.2 53.4 6 6.1* <0.05
Sham operated animals underwent only laparotomy, but had open abdomen for the same time period as necessary for transplantation and
reperfusion time. Tac 50¼ 50 ng/mL and Tac 10¼ 10 ng/mL tacrolimus added to rinse solution. ALT andAST serum levels were analyzed at the
end of the 2 h reperfusion period. BF ¼ bile flow; baseline values represent bile flow as measured in donors.
*P < 0.05 versus controls.
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controls versus 9.46 0.3 mM in sham-operated animals;
P < 0.05). Preconditioning of allografts with 10 ng/mL
tacrolimus resulted in a further increase in the to-
tal GSH concentration to 20.3 6 1.2 mM (P < 0.05
versus controls), but only to 17.9 6 0.9 mM followingG
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FIG. 2. Total GSH (GSHþGSSG) (A) and GSSG (B) concentra-
tions in liver tissue of allografts at the end of reperfusion period
(2 h). Donor organs were perfused and preserved with University of
Wisconsin (UW) solution for 24 h at 4C before transplantation. Sig-
nificant increase of GSH and GSSG compared with sham group
(grey column) indicates recruitment and oxidation of cytosolic GSH
upon free radical formation. Pretreatment of livers with tacrolimus
leads to a slight decrease of cellular GSH content, but to significantly
reduced GSSG concentrations when 10 ng/mL were administered.
Controls: white column; tacrolimus 50 ng/mL: striped column; tacro-
limus 10 ng/mL: black column). *P < 0.05 versus control.preconditioning with 50 ng/mL of tacrolimus. More-
over, plasma GSSG increased to significantly higher
levels (2.4 6 0.3 mM and 2.1 6 0.4 mM, respectively)
compared with untreated controls (1.46 0.2 mm) or an-
imals of the sham group (0.86 0.1 mM) as demonstrated
in Fig. 4B (P < 0.05 each). These findings suggest that
tacrolimus also influences glutathione homeostasis in
the extracellular space, i.e., the sinusoids of liver grafts.DISCUSSION
There is substantial experimental evidence for ROS-
mediated cell damage as a central pathomechanism of
reperfusion injury of the liver after warm and cold is-
chemic periods [4, 7, 23]. Therefore, antioxidant strate-
gies are thought to be a promising approach for the
prevention of hepatic reperfusion injury in trans-
planted organs. In the present study, we used tacroli-
mus to precondition rat liver allografts directly before
implantation, based on earlier work showing antioxida-
tive properties of that immunosuppressant in liver I/R
[16, 19]. Our results confirm the antioxidative proper-
ties of tacrolimus in the setting of liver transplantation.
We found that (1) the use of tacrolimus as flush solution
significantly reduces hepatocellular injury and en-
hances early transplant function within the first 2 h
of reperfusion, (2) tacrolimus reduces levels of toxic
GSSG in hepatocytes without affecting the total intra-
cellular GSH content, and (3) tacrolimus augments
the release of GSSG into the bile and also into sinusoids
through a still unknown mechanism, as measured by
plasma concentrations of oxidized GSH, resulting in
preservation of GSH/GSSG ratios.
Liver transplantation is the therapy of choice in an
increasing number of liver diseases, however the organ
pool is limited and 5%–30% of human allografts exhibit
severe postoperative dysfunction and frequently re-
quire retransplantation [2, 24]. A comprehensive un-
derstanding of the mechanisms underlying graft
failure is essential to improving success rates in this
clinical setting. From recent work, it seems clear that
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FIG. 3. Total GSH (GSHþGSSG) (A) and GSSG (B) concentra-
tions in bile of allografts at the end of reperfusion period (2 h). In
transplanted livers (controls, white column), bile concentration of
GSH was substantially elevated whereas GSSG was markedly
decreased compared with only laparotomy (sham, grey column).
Significant increase of total GSH and GSSG export into the bile
when livers were preconditioned with 10 ng/mL of tacrolimus (black
column). *P < 0.05 versus controls.
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ing cold storage, presents the predominant problem
[25]. During reperfusion of warm and cold ischemic
livers, activated Kupffer cells (KC) produce mediators
of inflammation, including tumor necrosis factor a, in-
terleukins, and chemokines, and release ROS into the
sinusoidal space, which in turn result in liver damage
[26]. There is no doubt that I/R-mediated intracellular
oxygen radical formationmay contribute to hepatic fail-
ure [6, 23, 27]. In addition, we were recently able to
demonstrate that the generation of KC-derived ROS
may act as extracellular signal molecules, rendering
also the sinusoidal space to an ‘‘oxidative’’ environment
[3, 8, 20]. Besides other effects, extracellular ROS
action was associated with a dramatically impaired he-
patic microcirculation upon reperfusion of transplanted
livers which could be significantly improved by post-
ischemic intravenous glutathione [11, 28] or glycine ad-
ministration [29, 30].
Thus, we speculated that altered glutathione metab-
olism may contribute to the beneficial effects of tacroli-
mus rinse. Nonetheless, the possible role of othermechanisms, for instance a decreased inflammatory re-
sponse, should also be considered in future studies.
The concept of flushing liver grafts after hypothermic
storage with Carolina rinse solution containing antiox-
idants, adenosine, calcium blocker, energy substrates,
and glycine resulted in new insights into preventive
mechanisms of endothelial cell killing, Kupffer cell acti-
vation and ROS-release [31]. Because pharmaceutical
preconditioning of liver grafts is more feasible in the
clinical setting than donor preconditioning [32–35] or
post-ischemic treatment [11, 36], we studied the addi-
tion of a calcineurin inhibitor (tacrolimus; FK506) to
the rinse solution. We chose tacrolimus because of re-
cent work demonstrating beneficial effects of this im-
munosuppressant on reperfusion injury in human
liver transplantation [19].
In our study, we could observe a significant decrease
in postoperative ALT- and AST-levels of 40% and 50%,
respectively (Table 1), following 10 ng/mL of tacrolimus
rinse. This effect was weaker after administration of
the higher dosage of 50 ng/mL. The trend towards a re-
duction in efficacy at the higher 50 ng/mL dosage com-
pared with the 10 ng/mL dosage did not reach
statistical significance. However, the benefit of the 10
ng/mL dosage compared with the control group was sta-
tistically significant. The surprisingly poor protective
activity of the higher tacrolimus dosage may be related
to increased toxicity. In humans, the daily dosage of ta-
crolimus applied intravenously lies between 0.01 and
0.05 mg/kg/d. The corresponding tacrolimus dose calcu-
lated for a 300 g rat would be between 3 and 15 mg per
day. For comparison, the total amount of tacrolimus ap-
plied with the flush solution is 0.2 mg (10 ng/mL) and
1 mg (50 ng/mL), respectively. In humans, plasma levels
of tacrolimus range from 5 to 15 ng/mL, according to the
patient’s condition. Therefore, one reason for the more
pronounced effects of tacrolimus at 10 ng/mL could be
that this dosage better represents the therapeutic
range of this drug. The 50 ng/mL dosage is clearly
much higher than would be expected in a clinical set-
ting, and may have resulted in toxicity in our model of
liver transplantation.
Furthermore, tacrolimus-mediated preservation of
hepatocellular integrity was associated with better
bile flow during 2 h of reperfusion (Table 1), which is
also consistent with postoperatively reduced bilirubin
levels in the above mentioned study [19]. Although
changes in aminotransferases better reflect early path-
ophysiologic alterations following ischemia-reperfusion
injury, bile production also represents an important
factor to characterize potential beneficial effects of
tacrolimus rinse.
Looking at possible underlying mechanisms of graft
protection by tacrolimus, it is relevant to note that sim-
ilar results showing IRI protection were obtained when
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JOURNAL OF SURGICAL RESEARCH: VOL. 176, NO. 1, JULY 2012314KC were blocked upon reperfusion [20, 37, 38], or when
antioxidants were given at various time points during
liver transplantation [11, 29, 39]. This suggests that
ROS, either released intracellulary or in the sinusoidal
space, might be a target for tacrolimus action [32, 40].
Currently, themost important clinical use of tacrolimus
is as an immunosuppressant, based on its ability to in-
activate T-cells [41]. However, additional effects of ta-
crolimus have been documented [32], in particular its
ability to prevent ischemic damage in tissues when ad-
ministered intravenously before ischemia, although the
mechanisms underlying these effects are not known
[42, 43]. Other investigators were able to demonstrate
the preservation of microvascular perfusion following
liver ischemia and reperfusion [44], and a substantial
decrease in free radical production in association with
improvement of IRI when tacrolimus is administered
before ischemia [18, 45, 46]. Because tacrolimus is
a highly lipophilic compound and, therefore, easily
crosses the plasmamembrane to gain access to intracel-
lular spaces [47], it seemed likely that the primaryantioxidative action of tacrolimus takes place within
the hepatocytes. This theory was supported by our re-
sults, which showed an extraction rate of tacrolimus
from the rinse solution via the portal vein of allografts
between 88% (50 ng/mL) and 100% (10 ng/mL; Fig. 1),
suggesting a nearly complete absorbance of the com-
pound by the cells of the liver.
Our analysis of intracellular levels of the important
endogenous antioxidant glutathione (GSH) revealed
that compared with the dramatically increased concen-
trations of the oxidized form of GSH (GSSG) in control
livers, GSSG levels could be significantly reduced by
the administration of 10 ng/mL tacrolimus rinse, while
the total GSH content remained unchanged (Fig. 2). In-
tracellular GSSG levels can be increased by the intra-
cellular generation of H2O2 at the monoamine oxidase
reaction upon reperfusion [9]. The prevention of
a high reducing environment inside the cell, i.e., GSH/
GSSG ratio by tacrolimus may thus contribute to free
radical elimination during reperfusion [9, 48]. This is
supported by earlier observations that demonstrated
an improved hepatocyte oxidation/reduction following
tacrolimus administration, with improved ketone
body ratios, and the prevention of ATP content depriva-
tion under hypoxic conditions [46].
The tacrolimus-induced preservation of hepatocellu-
lar GSH/GSSG redox state was likely the result of an
enhanced excretion of GSSG into the bile (Fig. 3)
and to the sinusoids (Fig. 4). Total glutathione
(GSHþGSSG) bile concentrations were markedly in-
creased in preconditioned animals, but based on the sig-
nificantly higher cytosolic GSH levels [49], the relative
fraction of biliary GSSG translocation seems to play the
key role under these conditions [50], although ATP-
dependent GSH release into the extacellular space
under hypoxic conditions has also been previously re-
ported [50, 51].
In contrast, it is well known that GSH is not taken up
by cells [52], which in our study resulted in a slight post-
ischemic increase in reduced GSH, including in the si-
nusoids that may enhance extracellular antioxidative
capacity. As shown in Fig. 4, reperfusion of trans-
planted livers was associated with a significant in-
crease in plasma GSH of about 35% compared with
sham-operated animals, and tacrolimus precondition-
ing augmented total GSH plasma concentrations,
even compared with untreated controls. Similarly,
GSSG plasma concentrations were simultaneously in-
creased upon reperfusion (Fig. 4). This observation is
best explained by either an enhanced active release of
GSSG into sinusoids as a consequence of hepatocellular
detoxification of hydroperoxides [52], or by GSH oxida-
tion upon free radical formation in the hepatic micro-
vasculature [3, 4, 20], thus reducing extracellular
vascular stress. Because both phenomena may be
PRATSCHKE ET AL.: TACROLIMUS DURING LIVER TRANSPLANTATION 315critical to the preservation of liver cell integrity upon I/
R, the ability of tacrolimus preconditioning to produce
high GSH/GSSG ratios in liver cells as well as in sinu-
soids is likely an important feature leading to the effica-
cious defense of free radical action [9]. Nevertheless,
the exact mechanisms behind this observation still re-
main unclear.
In summary, this study provides some new insights
into the antioxidative properties of the immunosup-
pressant tacrolimus on I/R-mediated liver injury. How-
ever, the impact on GSH/GSSG metabolism by
tacrolimus may only be one facet of multiple intercon-
nected mechanisms involved in liver IRI, as tacrolimus
is also known to have effects on themicrocirculation, in-
hibition of calcium-dependent pathways, inhibition of
inflammatory response, and modification of cellular re-
sponses to injury. Also, we are not able to fully explain
the lower efficacy of the higher dosage (50 ng/mL) in the
prevention of IRI, in particular as this dosage was effec-
tive in an ex vivo model of hypothermic I/R (Bilzer M.,
unpublished data). In this respect, further analysis of
the underlying mechanisms of a tacrolimus rinse and
its interconnectionswith the observed changes in gluta-
thione metabolismmust be performed. Moreover, those
effects must be confirmed in a long-term model in the
future. Nevertheless, liver allograft preconditioning
with tacrolimus appears to be a promising alternative
for the prevention of oxygen radical- mediated reperfu-
sion injury after liver transplantation.ACKNOWLEDGMENT
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Background: Critical organ shortage results in the utilization of extended donor criteria (EDC) liver grafts. These
marginal liver grafts are prone to increased ischemia reperfusion injury (IRI) which may contribute to deteriorated
graft function and survival. Experimental data have shown that the calcineurin inhibitor tacrolimus exerts protective
effects on hepatic IRI when applied intravenously or directly as a hepatic rinse. Therefore, the aim of the present
study is to examine the effects of an ex vivo tacrolimus perfusion on IRI in transplantation of EDC liver grafts.
Methods/Design: The TOP-Study (tacrolimus organ perfusion) is a randomized multicenter trial comparing the
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IRI, potentially improving organ survival following transplantation of EDC livers. The study includes livers with two
or more EDC, according to Eurotransplant International Foundation’s definition of EDC livers. Prior to implantation,
livers randomized to the treatment group are rinsed with tacrolimus at a concentration of 20 ng/ml in 1000 ml
Custodiol solution and in the placebo group with Custodiol alone. The primary endpoint is the maximum serum
alanine transamninase (ALT) level within the first 48 hours after surgery; however, the study design also includes a
1-year observation period following transplantation. The TOP-Study is an investigator-initiated trial sponsored by the
University of Munich Hospital. Seven other German transplant centers are participating (Berlin, Frankfurt, Heidelberg,
Mainz, Münster, Regensburg, Tübingen) and aim to include a total of 86 patients.
Discussion: Tacrolimus organ perfusion represents a promising strategy to reduce hepatic IRI following the
transplantation of marginal liver grafts. This treatment may help to improve the function of EDC grafts and
therefore safely expand the donor pool in light of critical organ shortage.
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Organ shortage represents a critical problem in trans-
plantation medicine. In 2010, 1192 liver transplantations
were performed in Germany as opposed to 1846 new en-
tries on the waiting list (German Organ Transplantation
Foundation (Deutsche Stiftung Organtransplantation,
DSO), Annual Report, 2010). As a consequence of this
discrepancy, there is a noticeable trend towards the
utilization of extended donor criteria (EDC) grafts. Data
provided by the Eurotransplant International Foundation
indicate that the proportion of liver grafts exhibiting one
or more EDC increased from 29% in 1997 to 73% in
2010 (Axel Rahmel, Medical Director, Eurotransplant,
personal communication). The proportion of grafts with
two or more EDC increased from 4% up to 28% over the
same time period.
Ischemia reperfusion injury (IRI) is a complex inflam-
matory, allogen-independent process commonly seen
following graft transplantation; however, it is particularly
pronounced in marginal organs [1-3], and may contrib-
ute to poor graft function and reduced survival in these
recipients [4,5]. During ischemia and reperfusion,
proinflammatory cytokines such as IL-6 or TNF-α are
released into the systemic circulation by Kupffer cells
and migrating neutrophils [6]. These molecules induce a
complex inflammatory cascade and trigger the gener-
ation of reactive oxygen species (ROS) thereby affecting
the redox status of the cell [7]. In turn, increased intra-
cellular levels of oxidized glutathione contribute to
impairment of the liver’s antioxidative defense system
[8]. In addition to sinusoidal congestion caused by
endothelial sticking of migrating neutrophils, an imbal-
ance between vasoconstrictive (endothelin-1) [9] and
vasodilatatory substances (NO) [10] may directly dis-
turb the hepatic microcirculation. This is considered to
be a central pathomechanism for organ dysfunction
and primary nonfunction [9,10], especially in marginalTable 1 Tacrolimus and ischemia reperfusion injury experime
Author Cold vs warm
ischemia
Ischemic time Species
Sakr et al., 1991 [15] Warm 45 minutes Rat
Kawano et al., 1995 [16] Warm 60 minutes Rat
Kawano et al., 1996 [17] Cold 80 minutes Rat
Garcia-Criado et al., 1997 [18] Warm 90 minutes Rat
Takeichi et al., 2009 [19] Warm 50 minutes Rat
Huser et al., 2009 [20] Cold 120 minutes Rat
Pratschke et al., 2012 [14] Cold 24 hours Rat
LDH, lactate dehydrogenase; ROS, reactive oxygen species; TAC, tacrolimus.liver grafts [11,12]. Besides poor graft quality, the recip-
ients’ health status (model for end-stage liver disease
(MELD) score) may also influence the outcome after
liver transplantation [13]. The combination of extended
criteria donors and poor recipient condition may be re-
sponsible for a reduction of graft survival following
liver transplantation. In 2011, the 5-year graft survival
rate in Germany was 52.6% compared to the inter-
national mean of 66.2% (data provided by DSO, Collab-
orative Transplant Study (CTS)).
Therefore, strategies must be developed to improve the
function and survival of EDC organs. Several experimental
models have shown that tacrolimus preconditioning be-
fore liver transplantation has protective effects (Table 1).
The authors have recently demonstrated that an ex vivo
tacrolimus flush reduces IRI in a model of experimental
liver transplantation in rats [14]. Based on these experi-
mental findings, a study protocol of a single ex vivo ta-
crolimus rinse prior to reperfusion in marginal livers
was developed (Trial register: EudraCT number: 2010-
021333-31, ClinicalTrials.gov identifier: NCT 01564095).
The aim of the TOP-Study (tacrolimus organ perfusion) is
to reduce hepatic IRI and improve long-term organ
survival following transplantation of marginal livers.
Hypothesis and endpoints
The hypothesis of the study is that a single ex vivo ta-
crolimus perfusion prior to reperfusion reduces IRI and
improves long-term graft survival. The primary end-
point is the maximum alanine transaminase (ALT) level
within the first 48 hours following liver transplantation.
Secondary endpoints are ALT and aspartate transamin-
ase (AST) levels, graft function (prothrombin time, bili-
rubin), and creatinine on days 1, 2, 4 and 7. In addition,
the study documents graft and patient survival, histo-
logically confirmed rejection, as well as ischemic-type
biliary lesions (ITBL).ntal animal studies
TAC-application: End points P
Systemic vs organ
rinse
Systemic Survival, aminotransferases, LDH <0.05
Systemic Microcirculation, aminotransferases <0.05
Systemic Lipid peroxidation, aminotransferases <0.05
Systemic Survival <0.01
ROS, cytokines, aminotransferases,
neutrophil infiltration
<0.05
Systemic Aminotransferases, neutrophil activation <0.05
Systemic Aminotransferases, histology 0.001
Organ rinse Aminotransferases, glutathione metabolism <0.05
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The TOP-Study is an investigator-initiated, prospective,
randomized trial comparing the ex vivo perfusion of
marginal livers with tacrolimus to placebo prior to trans-
plantation. The main inclusion criterion is the presence
of two or more EDC. IRI is assessed by serum ALT and
AST levels over a period of 7 days. Following this period,
organ and patient survival, bile duct complications, rejec-
tions and organ function are monitored for 1 year. The
TOP-Study is sponsored by the University of Munich
Hospital with financial support provided by a grant from
Astellas Pharma GmbH, München, Germany. Research
and organizational support is provided by the contract
research organisation (CRO) DABIO Gesellschaft für
Auftragsforschung mbH, Höhenkirchen, Germany.
Inclusion and exclusion criteria
The study includes patients undergoing liver transplant-
ation in the participating centers who meet the following
criteria: chronic terminal liver failure, over 18 years of
age, first liver transplantation, and informed, signed con-
sent by the recipient. Donor organs exhibiting two or
more EDC according to the Eurotransplant Manual for
extended criteria liver donors (Table 2) are included
[21].
Patients receiving split liver and multiorgan trans-
plantations are excluded as well as those undergoing
retransplantation, high urgency transplantation or pediatric
transplantation. In addition, recipients with extrahepatic
malignant diseases, and organs from donors with hepatitis
B or C infection, are excluded.
Perfusion procedure
Livers are perfused with 1000 ml of the rinse solution
from a height of 100 cm without additional pressure
using polyvinylchloride (PVC)-free infusion systems with
a 12 gauge cannula. The portal vein and the commonTable 2 Extended donor criteria (EDC)
Criteria
Donor age >65 years
Macrovesicular steatosis >40% (macroscopy or biopsy)
BMI >30
Sodium >165 mmol/l
ICU stay and ventilation >7 days
Cold ischemia time >13 hours
AST >99 u/l
ALT >105 u/l
Bilirubin >3 mg/dl (>51 μmol/l)
Application of epinephrine
Criteria according to the Eurotransplant Manual for EDC in liver grafts [21].
BMI, body mass index; EDC, extended donor criteria; ICU, intensive care unit;
ALT, alanine transaminase; AST, aspartate transamianse.hepatic artery are flushed sequentially, with 500 ml each.
In the test arm, tacrolimus is added to 1000 ml
Custodiol histidine-tryptophan-ketoglutarate (HTK) so-
lution at a concentration of 20 ng/ml. A total of 20 μg
tacrolimus is applied. In the placebo group livers are
perfused with 1000 ml Custodiol. The perfusion proced-
ure is performed at the end of the back-table preparation
at least 1 hour before reperfusion. The duration of the
perfusion does not exceed 15 minutes (Figure 1). Prior
to reperfusion livers are flushed in situ with 500 ml of
the recipients’ blood.Liver transplantation and postoperative
immunosuppressant regimen
Liver transplantation is performed according to the stand-
ard clinical practice at each center. Immunosuppression
during the first 7 postoperative days is tacrolimus-based.
Thereafter, a tacrolimus-based immunosuppressive regimen
is suggested but not mandatory. Additional immunosup-
pression, that is, corticoids, is administered at the discretion
of the treating clinician.Follow-up
The present trial includes a 7-day interventional
study regulated by the German Pharmaceuticals Act
(Arzneimittelgesetz, AMG) and a non-interventional
study (NIS) over 1 year (Figure 2). During the entire study
period, the monitoring of safety and data is performed
according to Good Clinical Practice (GCP) guidelines.
Data management and CRO duties are performed by
the DABIO Gesellschaft für Auftragsforschung mbH,
Höhenkirchen, Germany.Study visits
To characterize IRI and graft function serum ALT/AST,
prothrombin ratio and bilirubin are measured on postop-
erative days 1, 2, 4, 7, as well as 6 and 12 months following
liver transplantation (Figure 2). Moreover, graft and pa-
tient survival, bile duct complications and histologically
confirmed rejections are assessed.In vivo
donor
in vivo
recipient
Ex vivo 
donor
Explantation
Cold 
ischemia
Back table 
preparation,
Randomisation
Implantation
HTK 1000 ml
Tacrolimus (20 ng/ml)
HTK 1000 ml
2 ≥ EDC:
Organ
Perfusion
Figure 1 Flow chart of tacrolimus organ perfusion. EDC,
extended donor criteria; HTK, histidine-tryptophan-ketoglutarate.
TOP-Study Non interventional study
d=1 2     4  7 Discharge
from hospital
6 months
Liver 
transplantation
Ex vivo Tacrolimus
Perfusion
12 months
Donor Recipient
Figure 2 Study visits TOP-Study (tacrolimus organ perfusion).
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The primary endpoint of the study is the maximum
serum ALT level within 48 hours following liver trans-
plantation, which reflects the degree of acute hepatocel-
lular injury. Non-parametric analysis using Wilcoxon
rank-sum test is performed to compare the maximum
ALT levels in grafts treated with tacrolimus versus
placebo. Based on a previous study using non-marginal
healthy grafts, an effect size of approximately 0.5 was
calculated [22]. In experimental studies, therapies for the
treatment of IRI were more effective in steatotic livers
[23,24]. Since recipients of marginal organs are incorpo-
rated in the present study, the predicted improvement in
postoperative ALT levels should be higher than in non-
marginal grafts. Thus, an effect size of 0.7 was consid-
ered appropriate for the sample size calculation. The
power of the test is 80% at a significance level of 0.05.
Therefore, sample size estimation (nQuery Advisor 6.1,
Statistical Solutions, Saugus, MA, USA) for two un-
paired samples using the Wilcoxon rank-sum test with
an expected dropout rate of 15% results in an estimated
sample size of 86 (43 tacrolimus vs 43 placebo).
To homogenize the patient collective only marginal
organs with two or more EDC are included. Nonethe-
less, all EDC may affect the primary endpoint. Since
documentation of EDC is required for patient inclusion,
those parameters will be analyzed as potential con-
founders. Moreover, recipient age will also be registered.
Participating centers
The Departments of Surgery of the following German
university hospitals are participating in this trial: Charité
Campus Virchow-Klinikum, Berlin; Johann Wolfgang
Goethe-University, Frankfurt am Main; Johannes Gutenberg
University, Mainz; Westphalian Wilhelms-University,
Münster; Ruprecht-Karls-University, Heidelberg; University
of Regensburg; Eberhard Karls University, Tübingen; and
Campus Grosshadern, Ludwig-Maximilians-University,
Munich.
Ethics and safety
Protocol version 2.1 has been approved by the local ethic
committees of the ethics committee of the university ofMunich. The study complies with the Declaration of
Helsinki and GCP guidelines. Informed consent is
obtained from each patient in written form prior to
randomization. The patient is informed about the na-
ture, duration and possible consequences of the trial by
an investigator specifically registered for this trial.
Current status (October 2012)
Study permission by the Federal Institute for Drugs and
Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte, BfArM) was received on 29 July 2011
and ethics committee approval on 23 August 2011.
Version 2.1 of the protocol is active. To date (October
2012), seven centers (Berlin, Frankfurt, Heidelberg,
Mainz, Munich, Regensburg and Tübingen) have been
initiated and 17 patients have been recruited for the
study. Estimated closure for recruitment for the study
will be 31 December 2013. One year thereafter the study
will be closed. Data calculation will require 6 months. A
finalized report of the study is expected for July 2015.
Discussion
Organ shortage and the consecutive transplantation of
EDC grafts remain an unsolved problem in organ trans-
plantation. Marginal organs are increasingly accepted,
which is associated with increased acute IRI [4,23] and
diminished graft survival [5,25,26]. An increased suscep-
tibility of marginal organs to the pathomechanisms of
IRI is discussed as a potential cause for the impaired
outcome of these grafts [2,3]. Thus, clinically relevant
strategies must be developed to prevent IRI in marginal
organs.
Several experimental studies have demonstrated protect-
ive effects of tacrolimus on IRI following liver transplant-
ation [14,17,20]. Despite their promising results, these
models were based on systemic donor preconditioning,
which is logistically difficult to incorporate into clinical
practice due to the existing organ allocation practice in the
Eurotransplant zone.
An ex vivo tacrolimus treatment may represent a solu-
tion to this problem. Recent experimental data indicates
a protective effect of an ex vivo tacrolimus rinse in a
model of experimental liver transplantation in rats [14].
Preservation of intracellular glutathione levels was sug-
gested as a potential mechanism in this study. The
calcineurin inhibitor tacrolimus acts through a blockade
of the intracellular calcineurin-calmodulin complex. This
blockade inhibits the calcium-dependent phosphoryl-
ation of the nuclear factor of activated T cells (NFAT).
As a consequence, IL-2, which is normally involved in
the activation of CD4+ and CD8+ T cells, and the IL-2
receptor are downregulated. Thus, the inactivation of T
cells is regarded as the central mechanism in the im-
munosuppressant properties of tacrolimus [27,28].
Table 3 Clinical studies of tacrolimus rinse in liver
transplantation
Author Number of
patients
Result P
Tacrolimus Placebo
St Peter et al., 2003 [21] 20 AST (IU/l) AST (IU/l) 0.02
day 1: 604 day 1: 1294
day 2: 683 day 2: 934
Kristo et al., 2011 [38] 26 ALT (IU/l) ALT (IU/l) 0.88
day 6: 79 day 6: 101
ALT, alanine transaminase; AST, aspartate transaminase.
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independent hepatic IRI, which is characterized by the
release of a complex cascade of cytokines including IL-6
and TNF-α, the generation of ROS, the accumulation
and transmigration of different cell types (that is, lym-
phocytes, neutrophils, platelets), as well as alterations of
the microcirculation potentially causing graft dysfunc-
tion or even non-function [6]. In this respect, T cells
have been shown to be critically involved in the induc-
tion of IRI of the liver [29-32]. A rapid recruitment of
CD4+ T cells in hepatic sinusoids as early as 30 minutes
after reperfusion is followed by their migration through
the endothelial barrier to injured hepatic tissue [30].
Although CD4+ T cells themselves are not cytotoxic,
they release a panel of cytokines, chemokines and adhe-
sion molecules which are potentially harmful to the
organ. Moreover, CD4+ T cells interact with platelets
and Kupffer cells which further aggravate IRI [33]. How-
ever, it has yet to be determined whether tacrolimus
affects IRI after liver transplantation via CD4+ T cells.
Neutrophils are also actively involved in hepatic IRI.
The accumulation of neutrophils congests hepatic sinu-
soids and leads to the release of proinflammatory cyto-
kines (that is, TNF-α and IL-6), as well as ROS [34].
Adhesion molecules such as P-selectin and ICAM-1 are
involved in the process of neutrophil recruitment [35].
The application of tacrolimus decreases the expression
of these adhesion molecules, thereby attenuating neutro-
phil recruitment [36,37]. In addition, direct suppressive
effects of tacrolimus on the activation of Kupffer cells,
which also release proinflammatory cytokines have been
demonstrated in vitro [38]. This anti-inflammatory effect
of tacrolimus was also evident in human liver biopsies
after the transplantation of organs rinsed with tacroli-
mus [39].
With respect to the microcirculation, direct effects of
tacrolimus on the expression of vasoconstrictive sub-
stances (endothelin-1) in endothelial cells have been
shown, which might further improve hepatic microcircu-
lation [40]. Increased levels of ROS are known to be in-
volved in the pathogenesis of IRI. The application of
tacrolimus in vivo is associated with a reduction of ROS
[18]. Recently, a rat model of liver transplantation dem-
onstrated that tacrolimus increases glutathione metabol-
ism, which in turn may protect organ function by reducing
ROS toxicity [14]. Tacrolimus has also been found to
exert anti-apoptotic effects by preventing Fas-induced
apoptosis in human hepatocytes in vitro [41], as well as
in an in vivo model of IRI in rats [42]. A decrease in
liver apoptosis may contribute to persisting protection
of cellular integrity. In summary, several potentially
synergistic mechanisms for the protective effects of ta-
crolimus in the setting of ischemia-reperfusion injury
have been proposed.Preliminary clinical data have shown beneficial results
of tacrolimus preconditioning in human liver transplant-
ation (Table 3). In addition, the tacrolimus rinse proced-
ure has been tested clinically in a phase I trial (Table 3).
In a previous trial, Peter et al. demonstrated a significant
reduction of aminotransferase levels following the trans-
plantation of normal livers rinsed with 20 ng/ml tacrolimus
[22]. Although the results of this trial were promising, the
clinical impact was limited by the small number of patients
included (n = 20). In a similar clinical study, Kristo et al.
recently failed to show a reduction in ALT levels on day 6
after transplantation [39]. However, the study population
was relatively small, and, as most patients received healthy
organs, the results cannot be directly compared to a study
of marginal grafts. Postoperative aminotransferase levels in
the Kristo et al. study were generally quite low, with serum
ALT levels in the control group reaching almost normal
levels 6 days after transplantation [39]. Nevertheless, the
authors showed an impressive reduction in precursors of
proinflammatory enzymes following tacrolimus rinse [39].
In the TOP-Study, livers are treated with a single
ex vivo tacrolimus rinse prior to implantation, with the
aim of reducing graft damage and secondarily improving
the long-term course of EDC grafts. The maximum ALT
level within the first 48 hours following liver transplant-
ation was chosen as a clinical marker of hepatic injury
and used to estimate the degree of IRI. Aminotransfer-
ases have been shown to be an appropriate marker of
hepatic IRI in a number of studies. Puhl et al. demon-
strated an inverse correlation between microcirculation,
a key factor in the development of IRI, and serum ALT/
AST levels in human liver transplantation [43]. More-
over, EDC organs, which are associated with increased
levels of IRI, display significantly elevated ALT/AST
levels [4]. In addition to assessing acute IRI, the TOP-
Study assesses graft survival during a 1-year follow-up
period. Although the impact of acute graft injury on
long-term survival is discussed controversially in the
literature, there is strong evidence that IRI correlates
significantly with long-term graft survival [44].
The tacrolimus concentration of 20 ng/ml was chosen
in the present trial based on safety data from previous
Pratschke et al. Transplantation Research 2013, 2:3 Page 6 of 7
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to the tacrolimus treatment have been reported. The
20 μg of tacrolimus dissolved in 1000 ml of Custodiol to
form the rinse solution represents a minute fraction of
the 1.75 × 103 μg per day of tacrolimus administered
intravenously to a 70 kg adult. If even 80% of the tacroli-
mus in the rinse solution reached the systemic circula-
tion, the drug level would be below the detection limit
of 3 ng/ml. Therefore, the rinse solution seems to have
local effects in the liver graft, rather than contributing to
systemic immunosuppression.
In summary, a tacrolimus rinse could represent a new
strategy to reduce IRI and improve organ survival in
EDC organs in liver transplantation. A reduction of
organ damage in marginal grafts may allow the accept-
ance of more EDC organs, even in patients with high
MELD scores, thereby safely expanding the donor pool
in liver transplantation.
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Summary
The role of intraoperative porto-caval shunts in orthotopic liver transplantation
(OLT) is controversial. Aim of this study was to analyze the effects of an intraopera-
tive, porto-caval catheter-shunt on graft function and survival following cava spar-
ing OLT. Four hundred and forty-eight piggy back liver transplantations with or
without a temporary spontaneous porto-caval shunt between 1997 and 2010 were
analyzed (shunt n = 274 vs. no shunt n = 174). Lab MELD scores and donor risk
indices (DRI) were calculated. Hepatic injury (ALT, AST), -function (bilirubin,
prothrombin ratio), postreperfusion liver blood flow and graft survival were regis-
tered [mean follow-up: 50.5 (0–163.0) months]. The impact of a shunt on graft sur-
vival was determined using multivariate analysis. Usage of a porto-caval shunt was
associated with reduced hepatic injury (ALT, AST), whereas graft function was not
affected. The shunt group showed a significantly increased portal venous blood
flow after reperfusion. Retransplantation rate was decreased (7.7% vs. 20.1%,
P = 0.001) and long-term graft survival was significantly increased with a porto-
caval shunt (hazard ratio 2.1, P < 0.001). This effect was even more pronounced
for marginal organs. Usage of intraoperative porto-caval catheter-shunts is benefi-
cial in cava sparing OLT and is associated with reduced ischemia-reperfusion injury
and improved organ survival in particular for recipients of marginal organs.
Introduction
Ischemia-reperfusion injury following orthotopic liver
transplantation (OLT) contributes to postoperative organ
dysfunction and may result in graft loss [1,2]. The use of
marginal livers, made necessary by an increasing shortage
of organ donors, further aggravates ischemia-reperfusion
injury [3]. The activation of Kupffer cells plays a pivotal
role in the pathophysiology of reperfusion injury [4,5].
Several experimental studies demonstrate that gut-derived
mediators are involved in the activation of Kupffer cells
during reperfusion following temporary occlusion of the
portal vein [6–9]. Portal hypertension during liver trans-
plantation may cause intestinal edema leading to increased
gut permeability and resulting in bacterial translocation
and the release of various mediators, that is chemokines,
cytokines, and endotoxin into the portal circulation [5,7].
Cava sparing surgical techniques for liver transplantation
(i.e. piggy back technique or side-to-side cavo-caval anasto-
mosis according to Belghiti [10]) have been developed to
minimize blood flow stasis in the inferior caval vein during
surgery [10–13]. This results in improved hemodynamic
stability during transplantation and reperfusion [11–13].
Combining cava sparing OLT or piggy back technique with
a temporary porto caval shunt [12,14,15] additionally
reduces venous stasis by connecting the portal venous
system with the inferior caval vein. This technique avoids
splanchnic congestion and therefore may decrease the
release of endotoxin and other mediators from the gut into
the graft and consecutively into the systemic circulation
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after reperfusion. Furthermore, a reduction in intraopera-
tive blood loss through preservation of the retroperitoneum
has been reported [15].
Tzakis and Belghiti described a temporary end-to-side
porto-caval anastomosis to establish a shunt for patients
with a lack of adequate portosystemic collaterals [14,15].
Alternatively, an extracorporeal spontaneous porto-caval
shunt-catheter can be inserted using a plastic tube to con-
nect the portal- to the femoral vein. This shunt technique,
which does not require anticoagulation or an additional
pump supply (Fig. 1), is commonly used at the transplan-
tation center of the University of Munich.
The aim of this study was to determine whether the use
of temporary porto-caval shunt-catheters reduces hepatic
injury, improves cardiovascular stability and intraoperative
blood loss, and improves short- and long-term organ sur-
vival during and after cava sparing OLT.
Methods
Study design
The study was performed at the surgical department of the
University of Munich – Campus Grosshadern, Munich,
Germany. The study period extended from January 1997 to
April 2010. A retrospective search of the liver transplant
database, including all consecutive patients who received a
cava preserving OLT was performed. Pediatric and split
liver transplantations were excluded. The retrospective data
analysis of the liver transplant database was approved by
the local institutional review board.
Surgical procedures
All patients included in this study received a cava
preserving OLT with an end-to-side or side-to-side caval
anastomosis. For the piggy back technique, it is attempted
to partially clamp the caval vein allowing blood flow to the
right atrium through the inferior caval vein. Shunt applica-
tion was performed by all transplant surgeons. Moreover,
insertion of the femoral and portal catheter is standardized
at our institution and carried out similarly by all surgeons
according to an standard opening procedure (SOP). This
minimizes the risk for heterogeneity within the groups
because of the surgical procedure. The use of temporary in-
traoperative spontaneous extracorporeal porto-caval shunts
was based on the transplant surgeons’ assessment of the
recipient’s general condition and the presence of adequate
porto systemic collaterals. In brief, a 17 F cannula (50 cm,
CB 96535 015; Medtronic Inc., Meerbusch, Germany) was
inserted into the femoral vein by direct puncture (Seldinger
technique). Another catheter was placed in the portal vein
and fixed by tourniquet ligation (24 F, 35 cm, CB 66124;
Medtronic Inc.). The catheters were connected, allowing
porto systemic blood pressure differences to establish spon-
taneous porto-caval blood flow. Insertion of the femoral
and portal catheter accounts for approximately 20 min,
which does not represent a relevant addition in operative
time to the transplantation. It should be emphasized that
this technique does not require a centrifugal pump or addi-
tional anticoagulation (Fig. 1).
Donor and recipient characteristics
The following data was collected for each donor and reci-
pient: Age, sex, blood group, United Network for Organ
Sharing (UNOS) status of the recipient [high urgency
versus T-status listing on the transplant list], retransplan-
tation, cold ischemia time, and type of graft preservation
solution [University of Wisconsin (UW)- or Histidine-
Tryptophan-Ketoglutarate (HTK)-solutions]. Based on
the preoperative serum creatinine, bilirubin, and INR lev-
els, the lab MELD Score was calculated as described pre-
viously [16]. Furthermore, the donor risk index (DRI)
was calculated according to Feng et al. [17]. The indica-
tions for liver transplantations were classified as follows:
alcoholic cirrhosis, malignancy, acute liver failure, viral
hepatitis, primary biliary cirrhosis, and others.
For the detection of graft steatosis, liver biopsies of
donor organs were routinely obtained after reperfusion
using a Menghini needle (Hepafix; Braun, Melsungen,
Germany) or wedge biopsy. In each biopsy, the percent-
age of hepatocytes showing macrovesicular steatosis, was
determined. For analysis, steatosis was classified as mild
(<30%) and moderate/severe (more than 30%). These
categories were based on a previous study in which
donor steatosis of more than 30% donor steatosis was
associated with impaired postoperative organ function
[18].
Figure 1 Intraoperative picture of a temporarily inserted porto-caval
shunt catheter after cava preserving hepatectomy prior to liver trans-
plantation.
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Intraoperative parameters
Continuous intraoperative hemodynamic monitoring was
performed according to standard hospital procedures.
Hepatic arterial and portal vein blood flow were measured
intraoperatively following reperfusion using transit time
flow measurement as described previously [19]. The aver-
age consumption of catecholamines (norepinephrine or
epinephrine) during the entire surgical procedure was used
as a surrogate marker for hemodynamic stability [20], and
intraoperative transfusion requirements were recorded
(substitution of red cell units and fresh frozen plasma con-
centrates).
Serum parameters
The prothrombin ratio [Quick (%)], AST, ALT, bilirubin-,
and serum creatinine levels were recorded on the first, sec-
ond, and seventh postoperative day as a measure of postrep-
erfusion liver injury, graft function, and renal function.
Short- and long-term outcome
Graft survival and the frequency of primary graft nonfunc-
tion (PNF) resulting in acute retransplantation within the
first postoperative month after initial transplantation were
assessed. Long-term organ survival status was registered for
all patients (median observation period: 32.0 months). In
addition, retransplantation rates caused by chronic organ
dysfunction were documented. To verify the effect of shunt
usage on long-term graft survival, the data werealso ana-
lyzed excluding patients with PNF.
Statistical analysis
The statistical analysis was performed using statistical soft-
ware PASW statistics 18.0.0 (SPSS Inc., Chicago, IL, USA).
For all statistical tests, a testwise a level of 5% was used.
P-values of <0.05 were considered statistically significant.
The effect of variables on cumulative organ survival was
assessed using the log rank test in Kaplan–Meier survival
analysis. In addition to hepatic and portal venous blood
flow other variables that may influence the outcome follow-
ing liver transplantation according to the survey of the
European database [21] were evaluated using univariate
analysis. Continuous variables, such as recipient and donor
age, were dichotomized based on the values published by
Adam et al. [21]. Variables were considered as potential
confounders in a multivariate analysis performed using
Cox proportional-hazard regression using the forward
Wald method. Besides gender and recipient and donor age,
those variables with a P-value of <0.05 in the univariate
analysis were entered into the multivariate analysis model.
The results of continuous variables are presented as
mean ± SEM. To determine the differences between the
values on day 1 and 2, the Mann–Whitney U-test was
applied. Categorical parameters, such as retransplantation
and complication rate, were compared using chi-square test
or the Fisher′s exact test, as appropriate.
Results
Within the observation period, a total of 448 liver transplan-
tations were performed in 392 patients [mean age 51.0
(±11.0) years, sex ratio m:f = 2.05:1]. A porto-caval shunt
was established in 274 patients (61%) vs. 174 patients (39%)
without a shunt. The morbidity rate due to the insertion of a
shunt was 0.73% with two lymphatic fistulas documented.
The mean follow-up was 50.5 [0–163.0] months.
Patient characterization with respect to shunt application
The median Lab MELD score and the rate of high urgency
transplantations did not differ whether a shunt was inserted
or not (Table 1). The average recipient age was lower in
patients receiving a shunt than in those without a shunt:
46.0 [10.0–84.0] vs. 52.0 [11.0–79.0] years, P < 0.001. Fur-
thermore, the percentage of indications within the com-
pared groups did not differ with respect to the insertion of
a shunt, except in the group of transplantations not classifi-
able to those categories (Table 1).
Intraoperative course
Transfusion requirement, vasopressor support, organ blood
flow
The number of transfused packed red blood cells did not
differ between the groups: 5.0 ± 4.0 (shunt) vs. 4.4 ± 5.0,
Table 1. Recipient characteristics.
Shunt
P-valueYes (n = 274) No (n = 174)
Recipient age 46.0 (10.0–84.0) 52.0 (11.0–79.0) <0.001
MELD Score 20 (2–40) 21 (5–40) 0.103
High urgency-
transplantation (%)
11 (44) 14 (56) >0.05
Indications for liver transplantation: N (% within groups shunt versus no
shunt)
Alcoholic cirrhosis 57 (20.8) 37 (21.3) 0.907
Malignancy 65 (23.7) 29 (16.7) 0.074
Acute liver failure 18 (6.5) 16 (9.2) 0.306
Viral hepatitis 65 (23.7) 32 (18.4) 0.182
Primary biliary
cirrhosis
30 (10.9) 16 (9.2) 0.551
Others 39 (14.2) 44 (25.3) 0.003
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(no shunt), P = 0.80. Moreover, the number of fresh frozen
plasma concentrates transferred could not be correlated
with the use of a shunt: 21.1 ± 1.2 (shunt) vs. 19.6 ± 1.1
(no shunt), P = 0.806.
Continuous infusion of vasopressors was significantly
reduced in patients receiving a shunt: The infusion rate of
norepinephrine in patients receiving a shunt was
1.60 ± 0.8 mg/h vs. 1.88 ± 1.0 mg/h without shunt,
P = 0.012. Similarly, the infusion rate of epinephrine was
decreased in patients receiving a shunt: 0.08 ± 0.03 mg/h
vs. 0.09 ± 0.02 mg/h, P = 0.002).
Intraoperative portal venous blood flow following reper-
fusion significantly correlated with the usage of a tempo-
rary porto-caval shunt-catheter and was elevated to
1727 ± 48 ml/min in patients with a shunt compared with
1431 ± 63 ml/min in patients without a shunt (P < 0.001).
In contrast, no such correlation was evident with respect to
hepatic arterial blood flow (P = 0.792) (Table 2).
Postoperative course
Hepatic cellular injury
ALT and AST levels were significantly decreased on the
first, second, and seventh postoperative day in patients
transplanted with a temporary porto-caval shunt
(P < 0.001) compared to patients without a shunt (Fig. 2a
and b).
Hepatic- and renal function
Establishment of an intraoperative shunt was associated
with a significant reduction in serum bilirubin levels on the
first day following liver transplantation (P = 0.023)
(Fig. 2c). In contrast, prothrombin ratio [Quick (%)] was
not affected by the usage of a shunt (Fig. 2d).
Serum creatinine levels measured on the first, second,
and seventh postoperative day were also not affected by the
application of a shunt (P > 0.05).
Causes of early graft loss
Within the study period, a total of 13 grafts failed within
the first postoperative month with consecutive retransplan-
tation. While 12 cases of early graft loss occurred in grafts
without a shunt, only one graft loss was apparent following
transplantation with a shunt (P < 0.001). The causes of
early graft loss were categorized into the following
subgroups: PNF, vascular and others. Graft losses were dis-
tributed as follows: No shunt: PNF 7 (58%), Vascular 4
(33%), others 1 (8%); shunt: PNF 1 (100%).
A subgroup analysis also indicates that patient and donor
characteristics were equal in patients undergoing retrans-
plantation with respect to the insertion of a shunt. DRI did
not differ significantly in patients retransplanted whether a
shunt was utilized or not (P = 0.484): 1.63 ± 0.08 (shunt)
vs. 1.74 ± 0.07 (no shunt) (mean ± SEM; Mann–Whitney
U test.). The lab MELD score did also not show differences
between the subgroups: 26 ± 2 (shunt) vs. 27 ± 2 (no
shunt), P = 0.729. According to univariate, not multivari-
ate regression analysis, the insertion of a shunt significantly
reduced the risk of graft loss within the early phase follow-
ing liver transplantation (P = 0.04). DRI and lab MELD
score did not affect early graft loss.
Retransplantation
Forty-three retransplantations were performed during the
whole observation period after the first month. Within this
period, significantly less retransplantations were evident in
patients receiving a shunt compared to those transplanted
without a shunt [n (%)]: 20 (7.3) vs. 23 (13.2), P = 0.038.
Altogether, 56 patients underwent retransplantation over
the entire observation period. Within this group, 35 reo-
perations (20%) were performed in patients that had been
initially operated without a shunt compared with 21 reo-
perations in patients that had not been receiving a shunt.
Graft survival
Univariate analysis revealed an increased long-term graft
survival when a porto-caval shunt was applicated with a
mean survival (CI) of 106 [98.0–115.7] months vs. 86.5
[73.5–99.5] months, P = 0.001 (Table 3; Fig. 3a). When
patients with PNF were excluded from the analysis, these
results did not change: 108.0 [99.1–116.9] vs. 88.5
[75.4–101.6] month, P = 0.002 (Table 3).
In 2007, the MELD score was introduced in the Euro-
transplant allocation system. Therefore, the study period
was divided into periods from 1997 till 2006 and 2007 till
2010. In this respect, the mean survival did not differ
between the periods (Table 3).
A subgroup analysis with respect to recipients’ lab MELD
scores (MELD <35 vs.  35) and the application of a shunt
revealed an increased graft survival in patients with a
MELD Score  35 when a shunt was established. Mean
survival increased from 39.9 [21.5–58] months to 101.2
[73.2–129.1] month, P = 0.049 (Fig. 3b; Table 3). More-
over, in recipients with a MELD Score <35 graft survival
rose from 70.9 [60.8–80.9] to 110.0 [100.1–113.9] month,
when a shunt was inserted, P (log rank) = 0.001 (Fig. 2b).
According to CRT-analysis, grafts were divided into
groups with a donor risk index < or  1.25 with regard to
Table 2. Application of a shunt and correlation with liver blood flow.
Shunt No shunt
P (Mann–Whitney
U-test)
n (%) 274 (61.2) 174 (38.8)
Portal vein 1724 ± 48 1431 ± 63 <0.001
Hepatic artery 205 ± 8 205 ± 10 0.792
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the application of a shunt. In this respect, graft survival
increased from 77.7 [62.7–92.7] to 99.6 [88.9–110.3]
months in grafts with a donor risk index  1.25 if a shunt
had been applicated, P = 0.002 (Fig. 3c).
Other potential confounders: multivariate analysis
Associations of collected variables with long-term graft sur-
vival (Cox model) in the univariate analysis are shown in
Table 3. Donor age (>65 years), recipient age (>60 years),
degree of steatosis, type of preservation solution (UW ver-
sus HTK), high urgency transplantation, malignancy, epi-
nephrine treatment in donor, total ischemic time  12 h,
or a lab MELD Score  35 did not affect survival
(P > 0.10).
Potential confounders with a p value <0.05 in the univar-
iate analysis were included in the multivariate model: re-
transplantation, arterial flow <100 ml/min, no use of a
shunt and a DRI  1.25. No shunt, hepatic arterial blood
flow <100 ml/min as well as a donor risk index  1.25 were
identified as independent risk factors for decreased graft
survival in the covariate–adjusted model (Table 4).
Discussion
Cava sparing liver transplantation in piggy back technique
in combination with partial cava clamping during implan-
tation may provide better hemodynamic stability as com-
pared with full cava clamping in conventional technique
[10]. Early division of the recipient portal vein substantially
facilitates hepatectomy in piggy back technique. However,
prolonged portal venous clamping during hepatectomy
may lead to portal venous hypertension and splanchnic
congesting with this technique. To decompress the portal
venous system during hepatectomy, two principal shunting
techniques have been established: (i) In situ portal venous
shunt by an temporary end-to-side anastomosis of the the
PV to the infrahepatic vena cava (ii) a spontaneous ex situ
shunt. In animal models, an interruption of portal flow for
up to 90 min resulted in increased permeability of splanch-
nic vessels, intestinal edema of the gut, and the accumula-
tion of acute inflammatory cells with evidence of mucosal
cell damage [22,23]. In light of those pathophysiological
changes caused by an acute rise in portal venous pressure,
the use of a temporary porto-caval shunt has been
described by Tzakis et al. [14]. In those studies, a tempo-
rary end-to-side anastomosis was formed between the reci-
pient’s portal vein and the infrahepatic inferior vena cava.
In contrast, an extracorporal shunt catheter is used at our
institution, which is directly placed in the portal vein after
dissection and connected to a catheter previously placed in
the femoral vein to establish a spontaneous temporary
porto-caval blood flow. Utilization of temporary porto-
caval shunts was initially recommended for patients with
portal hypertension caused by acute or subacute liver fail-
ure who are expected not to have adequate portosystemic
venous collaterals [14]. Surprisingly, a subgroup analysis of
patients transplanted for acute liver failure revealed no sta-
tistical difference in organ survival compared with patients
transplanted for chronic liver diseases (data not shown).
The small number of transplantations for acute liver failure
(n = 34) may account for the lack of statistical significance.
Therefore, experimental studies are required to further
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clarify the underlying mechanisms of the protective effects
of intraoperative shunts. The routine use of temporary
porto-caval shunts in liver transplantation, however, is
Table 3. Univariate analysis.
n (%)
Mean survival
[months] [CI]
P (log rank)
univariate
analysis
Total 448 (100)
Recipient age
<60 years 377 (84.2) 99.6 [91.7–107.5] 0.494
60 years 71 (15.8) 92.9 [74.8–111.0]
High urgency
No 423 (94.2) 98.4 [90.9–105.8] 0.720
Yes 25 (5.8) 105.4 [78.0–132.7]
Retransplantation
1. LTx 381 (85.0) 102.8 [95.0–110.6] 0.003
Re-LTx 67 (15.0) 73.6 [54.0–93.1]
Shunt
No 174 (38.8) 86.5 [73.5–99.5] 0.001
Yes 274 (61.2) 106.8 [98.0–115.7]
Shunt (excl. primary graft nonfunction)
No 170 (38.5) 88.5 [75.4–101.6] 0.002
Yes 108.0 [73.5–99.5]
Time period
1997–2006 303 (67.6) 97.6 [89.3–105.9] 0.537
2007–2010 145 (32.4) 31.8 [28.9–34.7]
Total ischemia time
<12 h 339 (81.7) 99.6 [91.3–108.0] 0.831
12 h 76 (18.3) 98.3 [80.8–115.8]
Donor age
<65 years 324 (81.4) 100.4 [92.1–108.7] 0.367
65 years 74 (18.6) 95.3 [75.1–115.6]
Resuscitation donor
No 353 (86.9) 100.0 [91.8–108.1] 0.986
Yes 53 (13.1) 90.8 [71.6–109.9]
Shock donor
No 313 (77.5) 101.2 [92.6–109.9] 0.538
Yes 91 (22.5) 87.9 [73.9–101.9]
LabMELD Score
<35 317 (79.4) 101.4 [92.9–110.0] 0.023
35 82 (20.6) 85.6 [68.1–103.0]
Shunt and LabMELD Score
I:
Shunt/MELD < 35
207 (51.9) 110.0 [100.1–119.9] I vs. II 0.001
II: No
Shunt/MELD < 35
141 (35.3) 70.9 [60.8–80.9]
III:
Shunt/MELD  35
28 (7.0) 101.2 [73.2–129.1] III vs. IV 0.049
IV: No
Shunt/MELD  35
23 (5.8) 39.9 [21.5–58.3]
Donor risk indices (DRI)
DRI < 0.125 88 (20.0) 125.6 [112.3–138.9] <0.001
DRI  0.125 351 (80.0) 90.4 [81.9–98.8]
Shunt and DRI
I. Shunt/DRI < 1.25 201 (45.8) 123.7 [108.2–139.3] III vs. IV 0.002
II. No
Shunt/DRI < 1.25
150 (34.2) 106.3 [86.1–126.4]
III.
Shunt/DRI  1.25
66 (15.0) 99.6 [88.9–110.3]
IV. No
Shunt/DRI  1.25
22 (5.0) 77.7 [62.7–92.7]
III: Shunt/MELD ≥ 35 
IV: No Shunt/MELD ≥ 35
I: Shunt/MELD < 35 
II: No Shunt/MELD < 35 
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Figure 3 (a) Cumulative graft survival (10 years) after liver transplanta-
tion with regard to the insertion of a spontaneous porto caval shunt.
Shunt (gray line), no shunt (black line). 106.8 [98.0–115.7] vs. no shunt
88.5 [73.5–99.5] months; P = 0.001. (b) Cumulative graft survival after
liver transplantation with regard to the insertion of a spontaneous porto
caval shunt and the recipients’ lab MELD Scores. I: Shunt andMELD < 35
(gray perforated line); II: shunt and MELD  35 (gray line); III: no shunt
and MELD < 35 (black perforated line); IV: no shunt and MELD 35
(black line). I vs. III: P = 0.001; II vs. IV: P = 0.049. C: Cumulative graft
survival after liver transplantation with regard to the insertion of a spon-
taneous porto caval shunt and the Donor Risk Index. I: Shunt and donor
risk indices (DRI) < 1.25 (gray perforated line); II: no shunt and
DRI < 1.25 (gray line); III: shunt and DRI  1.25 (black perforated line);
IV: no shunt and DRI  1.25 (black line). I: Shunt and DRI < 1.25 (gray
perforated line); II: no shunt and DRI < 1.25; III: shunt and DRI  1.25;
IV: no shunt and DRI  1.25. III vs. IV: P = 0,002. Values are presented
as mean ± SEM.
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discussed controversially in the literature [24]. Despite the
theoretical arguments in favor of a systematic use of porto-
caval shunts, their clinical benefit remains the subject of
controversy [25,26]. Hoffmann et al. [25] state in their
review that shunts are not required for successful liver
transplantation. Although this review analyzed utilization
of shunts during en bloc transplantation with resection of
the caval vein, it must be stated that the rationale for the
insertion of a shunt, a reduction in venous stasis, is the
same in both techniques. Nevertheless, basic differences
between cava sparing and cava resecting liver transplanta-
tion may account for the discrepancy in the results. In par-
ticular, the mechanisms and effects of portosystemic shunts
on hepatic injury remain unclear. Thus, it was the aim of
this study to determine whether usage of a temporary
porto-caval shunt-catheter may reduce liver damage after
ischemia reperfusion and affect long-term graft survival.
The use of a portal venous shunt was associated with
lower levels of aminotransferases for up to 7 days, suggest-
ing a lowered degree of postischemic injury in this group of
patients. In contrast, Ghinolfi et al. [26] could not show
such effects in their retrospective analysis in 148 cava spar-
ing liver transplantations. The smaller number of patients
compared to this study may account for this discrepancy.
Figueras et al. [12] also failed to demonstrate beneficial
effects of porto-caval shunts on postoperative aminotrans-
ferase levels. Four-months graft survival rates in this study,
however, were more than 97% in both groups suggesting
differences in the patient collectives in terms of donor and
recipient characteristics compared to the Eurotransplant
allocation area [27]. Moreover, only 80 patients were
included in this prospective trial. In addition to liver injury,
beneficial effects of porto caval shunt utilization on blood
product transfusion, intraoperative hemodynamics, and
ease of retrohepatic dissection with a shorter operative time
have been observed in liver transplantation with the use of
a porto-caval shunt [24,26]. The subjective surgeon’s
impression at our institution suggests that establishment of
a porto-caval shunt helps to control intraoperative blood
loss. This impression, however, was not reflected in reduced
blood product substitution in patients with porto-caval
shunt.
A recent study reports beneficial effects of porto-caval
shunting on postreperfusion hemodynamic instability,
which is associated with significantly adverse postoperative
outcome [28]. In this respect, increased organ survival in
recipients transplanted with a temporary shunt using mul-
tivariate analysis considering all known potential con-
founders was shown. The absence of an intraoperative
shunt in this study was identified as a significant risk factor
for diminished organ survival with a hazard ratio of 2.1. As
opposed to this finding, Ghinolfi et al. [26] failed to dem-
onstrate such an effect in multivariate analysis. Even
excluding patients with a primary nonfunction, this sur-
vival benefit was still present in our study. Our results
imply that intraoperative portal-caval shunting may be
associated with improved long-term survival.
Utilization of a temporary intraoperative porto-caval
shunt was based on subjective assessment of the responsible
surgeon, including personal preference or the presence of
potentially adequate portosystemic collaterals. This repre-
sents an obvious limitation. Despite significant effects of
the MELD score on organ survival in univariate analysis,
this parameter failed to reach statistical significance in mul-
tivariate analysis. One potential explanation could be that
the number of cases with a MELD score  35 is too small
(n = 82). Moreover, sick patients with a MELD score  35
generally receive grafts with good quality. This policy may
to some extent compensate for the reduced health condi-
tion of those patients.
The recipient age was significantly higher in patients
transplanted with a porto-caval shunt (52 vs. 46 years,
respectively). In uni- and multivariate analysis, however,
recipient age was not identified as a significant risk factor
for organ survival. Nonetheless, a potential bias cannot be
excluded in this study. In contrast to previous trials, a
donor age  65 years as well as a recipient’s age >60 years
did not influence graft survival in this study (P > 0.05). In
an analysis incorporating 22089 liver transplant patients,
Adam et al. [21] showed statistical significance for these
risk factors in multivariate analysis. A risk ratio of <1.3 was
evident for a recipient age  60 years (RR 1.29) and for a
donor age >55 years (RR 1.14). This relatively small effect
may suggest limited clinical relevance in light of critical
organ shortage. In this respect, the large number of patients
included in the study of Adam et al. could explain the dis-
crepancy in significance levels. Moreover, only a relatively
small number of older recipients and grafts has been trans-
planted compared to the rest of the population in this study
(recipients: 377 vs. 71; donors: 324 vs. 74), which may be
another explanation of the lack of statistical significance.
Previous studies indicate the importance of portal blood
flow and gradient measurements prior to hepatectomy in
deciding who should be selected for shunt utilization
[12,29]. Patients with high portal flow and elevated porto-
caval gradient benefited particularly on post-transplant
renal function when using a temporary porto-caval shunt.
Margarit et al. defined the cut-off for high versus low por-
tal flow prior to hepatectomy as 800 ml/min. Based on
Table 4. Multivariate analysis.
Prognostic factors Hazard rate ratio [CI] P
Transplantation without shunt 2.1 [1.4–3.0] <0.001
Flow hepatic artery <100 ml/min 2.1 [1.3–3.2] 0.001
DRI  1.25 3.2 [1.7–5.9] <0.001
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those findings, measurement of portal blood flow prior to
hepatectomy might represent an objective tool for selecting
patients who should be transplanted with a temporary
porto-caval shunt. This, however, should be clarified in a
prospective trial.
As liver transplantation faces serious problems concern-
ing extended criteria donors and recipients in poor condi-
tions represented by high MELD scores, a subgroup
analysis on the efficacy of shunt utilization was performed
in this study with respect to the donor risk index and the
recipients’ MELD score. Ghinolfi et al. [26] however,
failed to show such effects when stratifying the population
by low and high MELD scores. Interestingly, the applica-
tion of a shunt exhibited beneficial effects on graft survival
especially in high risk transplantations, that is with poor
graft quality (DRI  1.25) and a high Lab MELD score
( 35). Although the relevance of poor graft quality and
bad recipient conditions differs regionally, a general advice
for shunt utilization might be supported by the present
data. In contrast to our own results, Mehrabi et al. [30]
postulated that usage of porto-caval shunts is not required
when performing piggy back technique liver transplanta-
tion. This center, however, utilized porto-caval shunts in
only 1.4% of 500 patients. Thus, this manuscript does not
allow drawing valid conclusions of shunt utilization on
organ outcome.
The exact underlying mechanisms for the protective
properties of a temporary porto-caval shunt remain
unknown. Nonetheless, in our series, application of a
porto-caval shunt catheter was associated with significantly
increased portal blood flow following reperfusion. This
result may in part explain the beneficial effects of shunt
usage, as enhanced portal blood flow has been shown to be
associated with reduced liver injury previously [19]. Fur-
thermore, incidence of postreperfusion syndrome was
reduced after utilization of a temporary porto-caval shunt
[28]. Whether solely those improvements in hemodynam-
ics account for the ameliorated postoperative transaminase
levels in patients with porto-caval shunt remains unknown.
Alternatively, mediators released from the gut that is proin-
flammatory cytokines, endotoxin, chemokines etc. caused
by splanchnic congestion, may be responsible for the
observed liver injury in patients without a shunt. In this
respect, induction of inflammatory responses in the liver,
that is expression heat shock proteins [31] as well as remote
organ injury following portal vein occlusion have been
reported [32]. The implication of those potential mecha-
nisms for the beneficial effects of maintained portal drain-
age versus portal occlusion during liver transplantation,
however, has to be further investigated.
In summary, the insertion of a temporary porto-caval
shunt catheter reduces cellular damage in patients with cava
sparing liver transplantation. Shunt usage was associated
with increased portal blood flow following reperfusion,
which may in part explain the beneficial effects on hepatic
injury. Moreover, the insertion of a shunt was associated
with an improved graft survival. This effect was more pro-
nounced in recipients with high MELD scores and recipi-
ents of marginal donor organs. Therefore, the application
of a temporary porto-caval shunt catheter is advisable in
cava sparing OLT especially for recipients of marginal
organs. Nonetheless, a prospective randomized multicenter
trial should be initiated to confirm this important observa-
tion in light of an increased frequency of transplantation of
marginal grafts due to organ shortage.
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LETTER TO THE EDITORS
Response to Gastaca
doi:10.1111/tri.12158
Dear Sir,
Thank you very much for your comment on our manu-
script ‘Temporary intraoperative porto-caval shunt: useless
or beneficial in piggy back liver transplantation?’. We
would like to take the opportunity to respond to the valu-
able comments of Gastaca.
Gastaca pointed out that portal blood flow and pressure
prior to hepatectomy should be considered as confounders
when studying the effects of a temporary porto-caval shunt.
Unfortunately, this information was not available in our
prospectively conducted liver transplantation database.
Moreover, information on portal blood flow and pressure
prior to liver transplantation cannot be recruited retrospec-
tively and therefore was not content of the present study.
We certainly agree with Gastaca that this information
would be of tremendous relevance to prospectively identify
subgroups of patients who will have the highest benefit
from an intraoperative shunt application. We would specu-
late that patients with low portal pressure and high portal
blood flow prior to transplantation would profit most from
temporary shunt usage. In this subgroup, patients are not
used to portal venous stasis with consecutive intestinal
congestion and have less porto-systemic collaterals. None-
theless, we respectfully submit that investigating all consec-
utive patients transplanted with or without a porto-caval
shunt at out institution in the period from 1997 to 2010
revealed a significant survival benefit in multivariate
analysis. Potential confounders associated with poor
graft survival, i.e., steatosis, cold ischemia time, donor age,
etc., have been included in univariate and multivariate
analysis.
Based on our manuscript, a prospective multicenter ran-
domized trial within Germany will be initiated. In this trial,
portal pressure and blood flow as well as shunt time will be
considered as stratification criteria. This prospective study
will address the valuable comments of Gastaca and poten-
tially clarify whether the critical 90-min threshold for the
development of organ injury owing to interruption of portal
flow can be directly transferred into the clinical arena. Most
important, liver tissue will be collected for molecular analysis
further evaluating the underlying mechanisms for the amaz-
ingly positive results of intraoperative shunt application on
liver injury and organ survival after liver transplantation.
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ORIGINAL ARTICLE
Arterial Blood Flow Predicts Graft Survival in Liver
Transplant Patients
Sebastian Pratschke,* Georgios Meimarakis,* Stephan Mayr, Christian Graeb, Markus Rentsch,
Reinhard Zachoval, Christiane Josephine Bruns, Axel Kleespies, Karl-Walter Jauch, Florian Loehe,
and Martin Kurt Angele
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany
Proper liver perfusion is essential for sufficient organ function after liver transplantation. The aim of this study was to determine
the effects of portal and arterial blood flow on liver function and organ survival after liver transplantation. The arterial and portal
venous blood flow was measured intraoperatively by transit time flow measurement after reperfusion for 290 consecutive liver
transplants. The graft survival, hepatic cell damage (alanine aminotransferase and aspartate aminotransferase), and liver func-
tion (prothrombin ratio and bilirubin) were determined. Grafts were stratified into groups according to arterial blood flow meas-
urements [<100 mL/minute for arterial blood flow group I (ART I), 100-240 mL/minute for ART II, and 240 mL/minute for ART
III] and portal venous blood flow measurements (<1300 mL/minute for portal venous blood flow group I and 1300 mL/minute
for portal venous blood flow group II). With multivariate analysis, the impact of blood flow on graft survival was determined, and
potential confounders were considered. Decreased portal venous blood flow was associated with significantly less organ sur-
vival in univariate analysis but not in multivariate analysis. In contrast, the arterial blood flow was significantly correlated with
organ survival after liver transplantation in univariate and multivariate analyses [hazard rate ratio ¼ 2.5, confidence interval ¼
1.6-4.1, P < 0.001, median survival ¼ 56.6 (ART I), 82.7 (ART II), or 100.7 months (ART III)]. Moreover, low arterial blood flow
resulted in impaired postoperative organ function and higher rates of primary nonfunction. Biliary complications were not
affected by blood flow. Other risk factors for graft failure that were identified by multivariate analysis included retransplantation,
histidine tryptophan ketoglutarate solution versus University of Wisconsin solution, and donor treatment with epinephrine.
Impaired arterial blood flow after reperfusion represents a significant predictor of primary graft nonfunction and is associated
with impaired graft survival. Whether the intraoperative measurement of hepatic arterial flow is predictive of graft survival
should be evaluated in a prospective trial. Liver Transpl 17:436-445, 2011. VC 2011 AASLD.
Received August 10, 2010; accepted December 12, 2010.
Postoperative liver graft function is influenced by
extended donor criteria, such as prolonged cold ische-
mia times, graft steatosis, donor hypernatremia, and
advanced donor age.1,2 In addition, recipient-related
risk factors, such as the underlying cause of liver fail-
ure and the recipient’s age and general state of health,
may contribute to an impaired outcome.3-5 However,
the extent of perioperative organ injury is not pre-
cisely predictable. In addition to extended donor crite-
ria and recipient-related risk factors, postoperative
intensive care interventions such as the use of vaso-
active drugs and mechanical ventilation may alter the
organ blood flow and contribute to poor graft
function.6,7
Nasraway et al.8 reported that liver graft perform-
ance depends on stable hemodynamics, sufficient
Abbreviations: ALT, alanine aminotransferase; ART, arterial blood flow group; AST, aspartate aminotransferase; HTK, histidine
tryptophan ketoglutarate; ITBL, ischemic-type biliary lesion; PNF, primary nonfunction; PV, portal venous blood flow group;
TTFM, transit time flow measurement; UW, University of Wisconsin.
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organ blood flow, and prevention of venous stasis in
the liver. Experimental studies have indicated that
sufficient arterial blood flow is required for liver regen-
eration and recovery of organ function after trans-
plantation.9,10 In addition, disturbance of the arterial
capillary blood flow is thought to play a key role in
the pathogenesis of biliary complications.11,12 Patho-
physiological changes induced by ischemia/reperfu-
sion injury may enhance microcirculatory perfusion
failure via the activation of polymononuclear leuko-
cytes and increased leukocyte-endothelial interac-
tion.13,14 The influence of microcirculatory changes
on organ function was confirmed by Puhl et al.,15 who
demonstrated a correlation between initial microcircu-
lation and early graft function in human orthotopic
liver transplantation.
In order to evaluate the quality of the anastomosis,
blood flow is determined intraoperatively after reperfu-
sion with ultrasound-based transit time flow measure-
ment (TTFM). The prognostic value of intraoperative
blood flow measurements for graft survival has not yet
been determined. Studies assessing whether intraoper-
ative organ blood flow correlates with organ function
are still lacking. The aim of the present study was to
determine whether intraoperative blood flow measure-
ments of the hepatic artery, portal vein, or both could
predict graft function, graft survival, or both.
PATIENTS AND METHODS
Study Design
The study was performed at the Department of Surgery,
Klinikum Grosshadern, Ludwig-Maximilians University
(Munich, Germany). The study period extended from
January 1997 to December 2007. In this retrospective
analysis of our liver transplantation database, all consec-
utive whole organ liver transplants between 1997 and
2007 with documented arterial and portal blood flow
measurements after reperfusion were included. Split
liver recipients and pediatric recipients were excluded
from the analysis. The retrospective data analysis was
approved by the local institutional review board.
Measurement of Arterial and Portal Blood Flow
Portal and hepatic blood flow was measured with
TTFM at the end of the surgery (Medi-Stim AS, Oslo,
Norway). This method generates valid data and pro-
vides reliable measurements that are independent of
the examiner’s experience as well as environmental
conditions that cannot be controlled, such as the
measurement angle, blood temperature, and hemato-
crit level.16-18
For data analysis, the grafts were divided into 3 ar-
terial blood flow groups [<100 mL/minute for arterial
blood flow group I (ART I), 100-240 mL/minute for
ART II, and 240 mL/minute for ART III] and 2 portal
venous blood flow groups [<1300 mL/minute for por-
tal venous blood flow group I (PV I) and 1300 mL/
minute for PV II]. The threshold between the groups
was defined by classification and regression trees
analysis according to the chi-square automatic inter-
action detector algorithm.
Surgical Technique
All patients underwent cava-sparing liver transplanta-
tion. Operative procedures did not change during the
observation period. In particular, anastomosis techni-
ques related to the portal vein and hepatic artery were
not modified. Thus, it appears unlikely that the
results of this analysis were affected by changes in
the arterial or portal venous blood flow related to
changes in the surgical technique.
Donor and Recipient Characteristics
The following information was collected for each donor-
recipient pair: donor age, sex, and blood group; recipi-
ent age, sex, blood group, and United Network for
Organ Sharing status; high-urgency listing versus reg-
ular listing for transplantation; underlying hepatic dis-
ease; cold ischemia time; and graft preservation solu-
tion [University of Wisconsin (UW) solution or histidine
tryptophan ketoglutarate (HTK) solution]. The condi-
tion of the donor, which was based on the need for
epinephrine, evidence of shock, or need for cardiopul-
monary resuscitation, was also documented. The clas-
sification of the donor’s condition was based on defini-
tions derived from Eurotransplant’s standardized
donor data sheet, which was completed by the regional
organ coordinator before organ retrieval. In this setting,
shock is defined as a positive shock index over a pro-
longed period of time, resuscitation is defined by me-
chanical cardiopulmonary resuscitation, and epineph-
rine donor is defined as a donor requiring the
continuous application of epinephrine in addition to
norepinephrine to maintain adequate blood pressure.
Moreover, donors 60 years and donors with 30%
macrovesicular steatosis were flagged as having poten-
tial risk factors for poor graft function.19 Because most
authors regard macrovesicular steatosis in liver grafts
to be more clinically relevant than microvesicular stea-
tosis, only macrovesicular steatosis was included in the
analysis.20 In a previous article,21 we conducted an
extensive analysis of macrovesicular steatosis in the
same patient cohort (1997-2005). For the purposes of
the present study, the documented results of the more
recent routine liver biopsies (2006-2007) were retro-
spectively confirmed by an additional pathologist. Do-
nor organ biopsy samples were routinely obtained after
reperfusion with a Menghini needle or by wedge biopsy.
The tissue was stained with hematoxylin and eosin and
was evaluated with light microscopy.
Acute Graft Function, Hepatic Cell Damage, and
Complication Rate
For the characterization of the postoperative liver
function, the prothrombin ratios (Quick percentages)
and bilirubin levels were registered on the first,
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second, and seventh postoperative days. For the
determination of hepatic cell damage, alanine amino-
transferase (ALT) and aspartate aminotransferase
(AST) levels were measured. Furthermore, the fre-
quency at which primary nonfunction (PNF) of the
graft resulted in acute retransplantation within the
first 14 postoperative days was determined.
Long-Term Results
Patient follow-up was continued until March 1, 2009.
Biliary complications [ie, bile duct stenosis, leakage,
or ischemic-type biliary lesions (ITBLs)] requiring
reoperation or endoscopic retrograde cholangiopan-
creatography were documented prospectively at the
time of occurrence, as was the need for retransplanta-
tion due to chronic organ dysfunction (ITBLs, hepati-
tis reinfection, or chronic rejection).
Statistical Analysis
The statistical analysis was performed with SPSS 17.0
statistical software (SPSS, Inc., Chicago, IL). For all sta-
tistical tests, we used a testwise a level of 5%. P values
less than 0.05 were considered statistically significant.
The effects of variables on cumulative organ survival
were assessed with the log-rank test in Kaplan-Meier
survival analysis. In addition to hepatic and portal ve-
nous blood flow, other variables that might influence
outcomes after liver transplantation according to the
survey of the European database19 were evaluated by
univariate analysis. Continuous variables (ie, recipient
age and donor age) were dichotomized according to the
values published by Adam et al.19 Variables were con-
sidered potential confounders in a multivariate analysis
performed by Cox proportional hazards regression with
the forward Wald method. Variables with a P value <
0.10 in the univariate analysis were entered into the
multivariate analysis model.
The results of continuous variables are presented as
means and standard errors of the mean. To determine
the differences between the values on days 1 and 2, the
Mann-Whitney U test was applied. Categorical parame-
ters (ie, retransplantation and complication rates) were
compared with the chi-square test or Fisher’s exact test.
For the analysis of the effects of hepatic and portal
venous flow on the occurrence of PNF or retransplan-
tation, Fisher’s exact test or the chi-square test and
also binary logistic regression with the forward Wald
method were performed.
RESULTS
During the observation period, 290 liver transplants
were performed in 261 patients [age ¼ 48.7 6 11.0
years (mean 6 standard deviation), male/female ratio
Figure 1. (A) Serum bilirubin
levels, (B) ALT levels, (C) AST levels,
and (D) prothrombin ratios (Quick
percentages) were determined after
liver transplantation on posto-
perative days 1, 2, and 7, and the
grafts were categorized into 3
groups according to the arterial
organ blood flow: <100 (white), 100
to 240 (gray), and 240 mL/minute
(black). Values are presented as
means and standard errors of the
mean. (C) *P ¼ 0.019 for ART I
versus ART III. (D) *P ¼ 0.020 for
ART I versus ART III, #P ¼ 0.005 for
ART II versus ART III, §P ¼ 0.006
for ART I versus III, and þP ¼ 0.005
for ART II versus ART III.
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¼ 2.1:1]. The median observation period was 43.0
months (range ¼ 0-129.9 months).
Effect of Organ Blood Flow on Acute Graft
Injury and Function
Bilirubin
Bilirubin levels were elevated above physiological lev-
els on the first, second, and seventh postoperative
days in all study groups (Figs. 1A and 2A). Variations
in the intraoperative arterial and portal venous blood
flow had no significant effect on the bilirubin
concentration. An increase in the serum bilirubin level
 20% was associated with diminished organ survival
in multivariate analysis (Table 1).
ALT
ALT levels were increased during the first postopera-
tive week in all groups in comparison with physiologi-
cal levels. There was a trend toward a reduction of
ALT levels with increasing arterial (Fig. 1B) and portal
venous blood flow (Fig. 2B), although this effect did
not reach statistical significance (P > 0.05).
AST
Peak AST levels on the first and second postoperative
days were ameliorated with increasing arterial blood
flow levels (Fig. 1C). This decrease was significant
between ART I and ART III (P < 0.05). The portal ve-
nous blood flow had no significant effect on postoper-
ative AST levels (Fig. 2C).
Prothrombin Ratio (Quick Percentage)
In comparison with physiological levels, the Quick
percentage was reduced on the first and second post-
operative days in all groups (Figs. 1D and 2D). The
Quick percentage significantly increased because of
arterial blood flow in all study groups (P < 0.05 for
ART I versus ART III and for ART II versus ART III) on
days 1 and 2 (Fig. 1D). The portal venous blood flow
was not associated with such differences (Fig. 2D).
TABLE 1. Multivariate Analysis (Cox Proportional
Hazards Regression) of Prognostic Factors for Graft
Survival After Liver Transplantation (n 5 290)
Prognostic Factor Hazard Rate Ratio* P
Retransplantation 1.7 (1.0-3.1) 0.054
Preservation solution
(risk with HTK)
1.8 (1.1-3.1) 0.022
Postoperative bilirubin
elevation  20%
2.6 (1.7-4.0) <0.001
Epinephrine donor 2.0 (1.2-3.4) 0.011
Hepatic artery flow
< 100 mL/minute
2.5 (1.6-4.1) <0.001
Total flow
< 1400 mL/minute
2.0 (1.3-3.1) 0.002
*Confidence intervals are shown in parentheses.
Figure 2. (A) Serum bilirubin
levels, (B) ALT levels, (C) AST
levels, and (D) prothrombin ratios
(Quick percentages) were
determined after liver trans-
plantation on postoperative days
1, 2, and 7, and the grafts were
categorized into 2 groups
according to the portal venous
blood flow: <1300 (white) and 
1300 mL/minute (gray). Values
are presented as means and
standard errors of the mean.
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Effect of Organ Blood Flow on Organ Survival
Graft PNF
Low portal venous blood flow was associated with an
enhanced risk for PNF (7.1% for PV I versus 2.1% for
PV II, P ¼ 0.0487). An arterial blood flow < 100 mL/
minute was associated with significantly increased
rates of PNF (12.8% for ART I) in comparison with an
arterial blood flow  100 mL/minute (2.6% for ART II
and 1.1% for ART III, P ¼ 0.022). A similar result was
observed for the total flow (8.2% for <1400 mL/mi-
nute versus 2.0% for 1400 mL/minute).
Multivariate analysis revealed a significantly
increased risk of PNF in patients with an arterial
blood flow < 100 mL/minute (hazard rate ratio ¼ 7.4,
confidence interval ¼ 2.1-26.3, P ¼ 0.002) and a total
flow < 1400 mL/minute (hazard rate ratio ¼ 4.8, con-
fidence interval ¼ 1.3-17.6, P ¼ 0.017).
Long-Term Organ Survival
Portal Venous Blood Flow. The portal venous flow,
which was categorized into 2 groups (<1300 mL/mi-
nute for PV I and 1300 mL/minute for PV II), signifi-
cantly affected long-term organ survival in univariate
analysis (71.7 months for PV I versus 92.7 months for
PV II, P ¼ 0.007; Fig. 3A and Table 2). When the sub-
group of patients developing PNF (n ¼ 11) was
excluded, the portal blood flow also significantly influ-
enced mean organ survival (77.2 months for PV I versus
94.7 months for PV II, P ¼ 0.040; Fig. 3C). Multivariate
analysis did not display a significant effect of the portal
flow on short- or long-term survival.
Arterial Blood Flow. Arterial blood flow, which was
categorized into 3 groups (<100 mL/minute for ART I,
100 to <240 mL/minute for ART II, and 240 mL/
minute for ART III), significantly affected long-term
organ survival after liver transplantation (Fig. 3B and
Table 2). The mean organ survival was 100.7 months
for ART III, 82.7 months for ART II, and 56.6 months
for ART I (P < 0.001). Diminished organ survival in
recipients with an arterial blood flow < 100 mL/mi-
nute was reflected in decreased median follow-up
(15.0 versus 36.5 months, respectively). Moreover,
graft survival and blood flow rates did not change
within the study period (data not shown). When
patients developing PNF (n ¼ 11) were excluded, the
arterial blood flow still significantly affected survival
(65.1 months for ART I versus 85.0 months for ART
II), which reached 101.8 months in grafts with an ini-
tial arterial blood flow  240 mL/minute (P ¼ 0.016;
Fig. 3D). Multivariate analysis revealed a significant
effect of an arterial blood flow < 100 mL/minute on
organ survival (for ART I, hazard rate ratio ¼ 2.5, con-
fidence interval ¼ 1.6-4.1, P < 0.001; Table 1). A total
organ blood flow < 1.400 mL/minute was associated
with significantly decreased survival (hazard rate ratio
¼ 2.0, confidence interval ¼ 1.3-3.1, P ¼ 0.002).
Other Potential Confounders: Multivariate Analysis. As-
sociations of collected variables with long-term graft
survival (Cox model) in the univariate analysis are
Figure 3. Cumulative graft
survival 10 years after liver
transplantation with respect to (A)
the portal venous blood flow, (B)
the arterial blood flow, (C) the
portal venous blood flow (patients
with PNF were excluded), and (D)
the arterial blood flow (patients
with PNF were excluded). (A,C)
The portal venous blood flow was
1300 (black line) or <1300 mL/
minute (gray line). (B,D) The
arterial blood flow was  240 (top
black line), 100–240 (gray line), or
less than 100 ml/minute (bottom
black line).
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TABLE 2. Univariate Analysis of Prognostic Factors for Graft Survival After Liver Transplantation
Prognostic Factor n (%) Mean Survival (Months)* P†
Total 290 (100.0) 86.7 (79.7-93.8)
Sex 0.890
Female 95 (32.8) 83.2 (5.9-71.7)
Male 195 (67.2) 86.2 (4.4-77.6)
Sex match 0.485
Yes 113 (39) 83.0 (5.7-71.8)
No 176 (61) 87.5 (4.5-78.7)
Recipient age 0.836
<60 years 246 (84.8) 86.5 (3.9-78.8)
60 years 44 (15.2) 84.4 (8.4-67.9)
High urgency 0.883
No 286 (98.6) 95.0 (31.0-64.0)
Yes 4 (1.4) 290.0 (94.0-196.0)
Malignancy 0.883
No 195 (67.2) 86.8 (4.4-78.1)
Yes 95 (32.8) 77.0 (5.3-66.6)
Retransplantation 0.030
First transplantation 252 (86.9) 87.2 (3.7-80.0)
Retransplantation 38 (13.1) 73.7 (10.7-52.8)
Preservation solution 0.072
HTK 69 (23.8) 69.6 (8.4-53.2)
UW 221 (76.2) 89.4 (3.9-81.8)
Total ischemia time 0.903
<12 hours 248 (85.8) 86.5 (3.9-78.9)
12 hours 41 (14.2) 78.4 (8.0-62.6)
Recipient blood group 0.950
0 109 (38.1) 85.5 (5.6-74.5)
A 115 (40.2) 81.2 (5.6-70.2)
B 35 (12.2) 83.4 (9.7-64.4)
AB 27 (9.4) —
Macrovesicular steatosis 0.504
<30% 215 (79.9) 87.9 (4.1-79.8)
30% 54 (20.1) 79.2 (7.9-63.8)
Postoperative bilirubin elevation <0.001
<20% 218 (75.2) 93.1 (3.9-85.5)
20% 72 (24.8) 65.4 (7.0-51.6)
Donor age 0.499
<60 years 211 (77.6) 85.4 (4.0-77.7)
60 years 61 (22.4) 85.1 (8.4-68.7)
Resuscitation donor 0.997
No 246 (86.3) 86.8 (3.9-79.1)
Yes 39 (13.7) 74.3 (8.3-58.0)
Shock donor 0.798
No 206 (72.8) 86.1 (4.3-77.7)
Yes 77 (27.2) 77.0 (5.8-65.6)
Epinephrine donor 0.047
No 246 (87.2) 89.7 (3.8-82.1)
Yes 36 (12.8) 67.1 (10.0-47.6)
Hepatic artery flow <0.001
ART I: <100 mL/minute 47 (16.2) 56.6 (41.2-72.0)
ART II: 100-240 mL/minute 153 (52.8) 82.7 (73.4-92.1)
ART II: 240 mL/minute 90 (31.0) 100.7 (89.3-112.1)
Portal venous blood flow 0.007
PV I: <1300 mL/minute 98 (33.8) 71.7 (6.2-59.6)
PV II: 1300 mL/minute 192 (66.2) 92.7 (4.2-84.4)
Total flow 0.002
<1400 mL/minute 85 (29.4) 69.1 (6.6-56.2)
1400 mL/minute 204 (70.6) 93.3 (4.1-85.3)
NOTE: For some factors, data were not available for all patients.
*Confidence intervals are shown in parentheses.
†Log-rank values from the univariate analysis.
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shown in Table 2. Donor age, recipient age, gender
mismatch, steatosis degree, recipient or donor age
 60 years, high-urgency listing, malignancy, cold
ischemia time  12 hours, and liver steatosis  30%
did not significantly impact survival (P > 0.10).
Potential confounders with P < 0.10 in the univari-
ate analysis were included in the multivariate model
[retransplantation, bilirubin elevation  20%, type of
preservation solution (UW versus HTK), donor treatment
with epinephrine, arterial flow < 100 mL/minute,
portal flow <1300 mL/minute, and total flow < 1400
mL/minute]. In addition to arterial and total blood
flow, retransplantation, preservation solution (HTK),
serum bilirubin elevation  20%, and donor treatment
with epinephrine were identified as independent risk
factors for decreased survival in the covariate-
adjusted model (Table 1).
Retransplantation Rate
The retransplantation rate correlated with arterial
flow measurements (21.3% for ART I, 8.5% for ART II,
and 5.6% for ART III, P ¼ 0.010). Multivariate analy-
sis revealed a significantly increased risk for retrans-
plantation in patients with a blood flow < 100 mL/mi-
nute (hazard rate ratio ¼ 3.4, confidence interval ¼
1.4-7.9, P ¼ 0.005).
Biliary Complication Rate
Within the observation period (mean ¼ 43 months),
33.9% of all grafts developed biliary complications
requiring intervention. Differences in the arterial
flow did not significantly affect biliary complications
(31.9% for ART I, 26.4% for ART II, and 48% for
ART III).
DISCUSSION
The organ blood supply is thought to play a pivotal
role in organ function after liver transplantation. Ex-
perimental studies have indicated that sufficient arte-
rial blood flow is required for liver regeneration and
recovery of organ function.22,23 However, the rele-
vance of arterial and portal blood flow to liver function
after transplantation remains unknown. TTFM reli-
ably detects portal venous and arterial blood flow af-
ter the reperfusion of hepatic grafts. Previous studies
have indicated that this method generates reproduci-
ble and valid data.16-18,24 Therefore, the aim of the
present study was to determine the effects of portal
venous, arterial, and total blood flow on postoperative
organ function, complication rates, and graft survival.
Using a covariate-adjusted model, we considered
other potential risk factors for diminished organ func-
tion, including liver steatosis, donor age, and pro-
longed cold ischemia times, as confounders of the
blood flow effect.
From 1997 to 2007, TTFM was performed routinely
within 2 hours after reperfusion on 290 liver grafts.
When reduced arterial or portal flow macrovascular
perfusion was optimized via resuturing of the anasto-
mosis or thrombectomy, blood flow values after vascu-
lar reconstruction were used for further analysis.
This study failed to demonstrate a statistically sig-
nificant correlation between organ blood flow and
postoperative hepatic cell injury (AST and ALT levels)
or graft function (Quick percentage and bilirubin
level). In this respect, the consumption of coagulation
products did not significantly vary between the study
groups (data not shown). Thus, it appears unlikely
that differences in the substitution of coagulation
products accounted for the disparities in the postop-
erative Quick percentage measurements with respect
to hepatic blood flow. In contrast, diminished arterial
flow was associated with an increased rate of PNF and
impaired survival. As cutoff points for arterial flow,
100 and 240 mL/minute were identified with classifi-
cation and regression trees analysis. Most impor-
tantly, arterial blood flow was independent of other
confounders and was associated with a clinically rele-
vant hazard rate ratio of 2.5 for poor outcomes (Table
1). Although portal flow significantly correlated with
graft survival, this parameter was not proven to be
significant in multivariate analysis. This demonstrates
the key role of arterial flow in graft function after liver
transplantation and correlates well with data from
Abbasoglu et al.,24 who observed reduced initial arte-
rial flow in patients who later developed vascular com-
plications. In their study, an arterial blood flow < 400
mL/minute was chosen as a risk factor.24 The authors
focused on the impact of blood flow on arterial throm-
bosis; they excluded information on organ function
and survival, and this may explain the discrepancy in
the cutoff values versus those of the present study.
Moreover, potential confounders within the groups
were not considered. In contrast, Lisik et al.25 sug-
gested a correlation between portal flow and early
liver function. This analysis, however, included only
15 patients, and this may limit its clinical relevance.
In this trial, information on organ blood flow was
limited to macrovascular measurements, which
potentially missed changes in microvascular perfu-
sion and interactions between those factors. Microcir-
culatory disturbances occur during reperfusion and
play a key role in the pathogenesis of ischemia/reper-
fusion injury.26,27 A relevant study by Puhl et al.15
demonstrated a significant correlation between the
initial microcirculation and early graft function after
human liver transplantation. Studies have demon-
strated that measurements of the microcirculation via
laser Doppler flowmetry on the liver graft surface cor-
relate with macrovascular blood flow.28 Moreover, sys-
temic hemodynamics (eg, the mean arterial pressure,
venous drainage, and right ventricular heart failure)
may influence liver perfusion.29 To analyze the effects
of systemic cardiovascular function on hepatic blood
flow, the intraoperative use of norepinephrine, epi-
nephrine, and dopamine was examined with respect
to hepatic arterial blood flow during liver transplanta-
tion. Although norepinephrine and dopamine did not
significantly affect arterial hepatic blood flow, the use
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of epinephrine was significantly correlated with dimin-
ished arterial blood flow (data not shown).
Potential interactions between macrocirculation and
microcirculation after liver transplantation were
beyond the scope of the present study. Despite the
lack of information on microvascular perfusion, our
data strongly emphasize the clinical relevance of mac-
rovascular graft perfusion.
Nonetheless, further investigations analyzing the
underlying causes of diminished hepatic flow are
required, and they may contribute to the development
of therapeutic approaches to optimizing organ blood
flow. In this respect, the intraoperative application of
nitric oxide, a microvascular vasodilator playing a key
role in hepatic ischemia/reperfusion injury,30,31 may
represent a promising strategy.
It could be argued that stenosis and technical difficul-
ties contribute significantly to diminished arterial flow af-
ter transplantation. Indeed, a previous study has demon-
strated decreased arterial flow in patients developing
long-term vascular complications.32 In that study, how-
ever, the intraoperative arterial blood flow was >400mL/
minute, and this argues against an initial vascular steno-
sis. The present analysis demonstrates a detrimental
effect of decreased arterial blood flow on long-term organ
survival even when PNF is excluded. This further sup-
ports arterial blood flow as a relevant risk factor for poor
graft survival beyond initial vascular difficulties. In our
study, blood flow measurement was limited to a single
time point. In addition, transcutaneous Doppler meas-
urements were routinely performed on the first postoper-
ative day and in patients with clinical symptoms. This
procedure identifies vascular complications that may not
be evident by intraoperative TTFM.
In the present study, biliary complications (including
ITBLs, strictures, and leakage requiring intervention or
retransplantation) were included; the overall rate was
33.9%. In the literature, biliary complication rates of 1%
to 19% have been reported.11,33,34 In those studies, the
term biliary complication was mostly restricted to
patients who developed ITBLs. Recently, Welling et al.35
systematically reviewed 256 consecutive liver trans-
plants and detected a bile leak rate of 18% and a stricture
rate of 23%. Interestingly, no correlation was found
between diminished arterial blood flow and the occur-
rence of biliary complications in the present study. Even
though the biliary complication rate (48%) was highest in
livers with an arterial blood flow > 240 mL/minute (ART
III), no statistically significant correlation between biliary
complications and hepatic blood flow could be found.
Higher rates of early death or the need for retransplanta-
tion due to PNF in patients with an arterial blood flow <
100mL/minute (12.8%) could bias this analysis because
these patients undergo retransplantation or die before
the development of biliary complications.
Several studies have found a correlation between
ITBLs and diminished arterial blood flow.11,36 Moench
et al.12 postulated that insufficient perfusion and the
high viscosity of the preservation solution are poten-
tial mechanisms of biliary complications due to
obstruction of the arterial microcirculation.
In addition to organ blood flow, the type of organ
preservation solution, a postoperative increase in bili-
rubin > 20%, and donor treatment with epinephrine
have been identified as risk factors for poor organ
survival in multivariate analysis. Similarly, previous
studies have demonstrated protective properties of
UW solution versus HTK for organ function.19
Because other studies have failed to demonstrate
such effects, it appears unrealistic that the common
use of HTK for organ preservation will be changed in
the near future.37,38 An increase in bilirubin levels >
20% within the postoperative course as a risk factor
for poor organ survival is appealing because it repre-
sents an additional prognostic parameter during the
postoperative course.
A recent study by Sainz-Barriga et al.39 has shown
negative effects of organ risk factors (eg, macrovesicular
steatosis> 30% and warm ischemia time) on organ blood
flow. In contrast, using TTFM, Angele et al.21 demon-
strated that macrovesicular steatosis does not affect he-
patic blood flow. In the present analysis, the warm ische-
mia time did not influence the hepatic arterial blood flow
(data not shown). Moreover, widely accepted risk factors
such as donor age, cold ischemia times, and organ stea-
tosis did not correlate significantly with diminished
organ survival.1,19 In contrast, an analysis of the Euro-
transplant database, which incorporated 22,089 liver
transplant patients, displayed statistical significance for
those risk factors.19 The risk ratio for most parameters in
the analysis of Adam et al.19 was less than 1.4, and this
suggested limited clinical relevance in light of the organ
shortage. Solely for the parameters retransplantation
and transplantation for malignancy, a risk rate ratio > 2
was evident. In the present study, retransplantation was
associated with a similar hazard risk ratio, which almost
reached statistical significance (P ¼ 0.054). The huge
number of patients incorporated into the study of Adam
et al. may explain the discrepancy in significance lev-
els.19 In this respect, single risk factors such as high do-
nor age are less clinically significant than the combina-
tion of donor and recipient characteristics.40 Therefore,
marginal organs are primarily accepted for recipients
without further risk factors, and this could result in a
bias in the present data. Therefore, intraoperative blood
flow measurement represents a predictive parameter
combining donor and recipient characteristics after liver
transplantation.
In summary, the results of the present study indi-
cate that impaired arterial blood flow after reperfusion
is a significant predictor of increased graft injury as
well as PNF and is associated with diminished long-
term graft survival. Thus, intraoperative TTFM of the
hepatic artery may allow us to identify organs at risk
for poor outcomes. Whether the intraoperative mea-
surement of the hepatic arterial flow may predict graft
survival should be evaluated in a prospective trial.
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Liver Transplantation Reduce Intraoperative Blood Loss
and Improve Postoperative Transaminases and Renal Function:
A Meta-Analysis
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Abstract
Background The value of temporary intraoperative porto-caval shunts (TPCS) in cava-sparing liver transplantation
is discussed controversially. Aim of this meta-analysis was to analyze the impact of temporary intraoperative porto-
caval shunts on liver injury, primary non-function, time of surgery, transfusion of blood products and length of
hospital stay in cava-sparing liver transplantation.
Methods A systematic search of MEDLINE/PubMed, EMBASE and PsycINFO retrieved a total of 909 articles, of
which six articles were included. The combined effect size and 95 % confidence interval were calculated for each
outcome by applying the inverse variance weighting method. Tests for heterogeneity (I2) were also utilized.
Results Usage of a TPCS was associated with significantly decreased AST values, significantly fewer transfusions of
packed red blood cells and improved postoperative renal function. There were no statistically significant differences
in primary graft non-function, length of hospital stay or duration of surgery.
Conclusion This meta-analysis found that temporary intraoperative porto-caval shunts in cava-sparing liver trans-
plantation reduce blood loss as well as hepatic injury and enhance postoperative renal function without prolonging
operative time. Randomized controlled trials investigating the use of temporary intraoperative porto-caval shunts are
needed to confirm these findings.
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Abbreviations
ALT Alanine aminotransferase
AST Aspartate aminotransferase
CI Confidence interval
DCD Donation after cardiac death
DRI Donor risk index
FFP Fresh frozen plasma
ICU Intensive care unit
IV Inverse variance
LOS Length of hospital stay
MELD Model for end stage liver disease
PNF Primary non-function
PRBC Packed red blood cells
RCT Randomized controlled trial
TPCS Temporary intraoperative porto-caval shunt
Introduction
For many years, liver transplantation was routinely per-
formed with portal venous and cavo-caval bypass systems
in order to reduce venous stasis in the splanchnic circula-
tion and the lower half of the body, especially in orthotopic
liver transplantation.
In this respect, cava-sparing liver transplantation (i.e.,
piggy back) was introduced to avoid interruption of blood
flow in the inferior vena cava (IVC), to maintain venous
return to the heart with consequent hemodynamic better
stability and to reduce IVC pressure and renal congestion.
This technique was first described by Calne in 1968 [1] and
became clinical routine in the 1990s following publications
by Tzakis [2] and Belghiti [3] on this topic.
In order to decrease portal venous stasis during hepa-
tectomy, cava-sparing liver transplantation can be com-
bined with an additional spontaneous, extracorporeal porto-
caval shunt catheter or alternatively an intracorporeal,
surgical end-to-side porto-caval anastomosis. The combi-
nation of cava-sparing liver transplantation and a shunt has
beneficial effects: A remnant caval backflow is achieved by
partial clamping, and during hepatectomy this technique
allows early portal dissection and decompression of the
portal system and facilitates dissection of the retrohepatic
vena cava. As a mechanism, a porto-caval shunt trans-
plantation may alleviate gut edema, reduce bleeding by
reduction of portal venous pressure and improve hemody-
namic stability [4]. At our institution, a porto-caval shunt is
routinely used to facilitate hepatectomy in cava-sparing
liver transplantation [5].
In orthotopic, cava-resecting liver transplantation with
replacement of the inferior vena cava, this vessel and the
portal vein are usually clamped simultaneously and the
time for a shunt to develop its full effect is usually too
short.
Recent data from our group demonstrated beneficial
effects of a temporary porto-caval shunt (TPCS): Patients
undergoing cava-sparing liver transplantation showed
reduced graft damage as well as enhanced long-term graft
survival [5]. In the literature, however, heterogeneous data
have been published on the effects of a TPCS [6–8].
The aim of this study was to analyze the effects of a
TPCS in liver transplantation by performing a meta-anal-
ysis on selected outcomes from the current literature.
Methods
Search strategy and inclusion/exclusion criteria
A systematic search of MEDLINE/PubMed, EMBASE and
PsycINFO was performed to identify suitable studies.
Additionally, reference lists were hand-searched for the
relevant literature. The study was performed according to
the PRISMA statement for systematic reviews and meta-
analyses [9]. The used search terms were ‘‘liver trans-
plantation’’ combined with ‘‘portosystemic shunt,’’ ‘‘porto-
caval shunt’’ or ‘‘porto-caval anastomosis.’’ Different
spellings of the search terms were taken into account (e.g.,
portocaval vs. portacaval). Boolean operators (‘‘AND,’’
‘‘OR,’’ ‘‘NOT’’) were applied to combine the search terms.
A protocol of the review process may be obtained from the
contact author. The following outcomes of interest have
been defined: (1) hepatic injury [alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and primary non-
function (PNF)], (2) characteristics of the surgical inter-
vention [packed red blood cell (PRBC) requirement, fresh
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frozen plasma requirement (FFP), duration of operation],
(3) renal function (creatinine) and (4) health care utilization
[length of stay (LOS)].
All studies published in English or German up to
October 2014 were included for abstract screening. While
randomized controlled trials, clinical trials, and observa-
tional studies comparing liver transplantation with and
without TPCS were included, reviews, reports, comments,
case studies and case series were excluded. Split liver
transplantations, Domino- and DCD (donation after cardiac
death) grafts were not included in the analyzed studies. All
abstracts were independently screened by two researchers
(A. R. and M. K.). In case of disagreement, the corre-
sponding studies were discussed to achieve consensus. The
same procedure was conducted again with the selected full
texts. Here, studies were excluded in a first step if they did
not apply a TPCS or did not compare outcomes for a TPCS
versus no TPCS. In the final step, studies were excluded
when they did not investigate the outcomes of interest.
Appraisal of the quality of the studies
and publication bias
The checklist developed by Downs et al. [10] was applied
to rate the quality of the included studies. In this checklist,
26 items distributed over five subscales are used to assess
the quality of the study type, reporting bias, external and
internal validity, biases, and confounding. Both researchers
rated the quality independently. In case of disagreement, a
discussion led to consensus. Tests for publication bias were
not performed since for all outcomes not more than six
studies were included.
Data extraction and management
For each of the included studies, all outcomes were
extracted (type of outcome, measure of outcome, time-
point of measurement). Subsequently, all specific outcomes
were assigned to parent areas. In a consensus meeting, the
authors selected those outcomes for which meta-analyses
should be performed. For outcomes of interest for which
data were not reported completely, the corresponding
authors were contacted and asked to provide the missing
data.
Data synthesis
Depending on the type of data, effect sizes were calculated
either as mean difference (for outcomes reported as con-
tinuous data using the same scale in all studies), standard
mean difference (for outcomes reported as continuous data
using different scales across the studies) and odds ratio (for
dichotomous outcomes).
For all outcomes, a random-effect model as described by
Borenstein et al. [11] was applied. This model takes into
account that heterogeneity between the trials such as
variation in the study population or the implementation of
interventions exists, which was assumed for the included
studies.
For all meta-analyses, the following statistics were cal-
culated: For each single study, the effect size with its 95 %
confidence interval (CI) was calculated. The combined
effect size with its 95 % CI was calculated applying the
inverse variance weighting method (IV). To test the sig-
nificance of the overall effect size, a Z-transformation was
performed. The significance level was set as .05. To
describe heterogeneity among the studies, the variance of
the true effect size between the studies (s2), v2, degrees of
freedom (df) and a test for heterogeneity (I2) were calcu-
lated. An I2[ 50 % was considered as substantial hetero-
geneity [4]. For each meta-analysis forest plots were
created. Statistical analyses and generation of figures were
conducted using the statistic software RevMan 5.3. devel-
oped by the Cochrane Collaboration.
Results
The systematic search of the literature revealed 900
potentially suitable publications. An additional nine studies
were identified by hand search of the reference lists. After
abstract screening, 28 studies were included in the full-text
analysis. Of these, 11 studies were included in the quali-
tative analysis. Six studies addressed these outcomes and
were selected to be included in the meta-analysis (Fig. 1).
Table 1 depicts the characteristics of the included
studies. All studies were performed in Europe except one
performed in the USA and were published from 1999 to
2012. Five studies were conducted as retrospective data
analyses; one study was carried out as a randomized con-
trolled trial. The quality score showed a range from 9 to 20
across the studies. The mean age of the patients included in
the studies ranged from 46 to 58 years, and the total sample
sizes of the studies ranged from 65 to 448.
Effects of the temporary porto-caval shunt
on selected outcomes
Hepatic injury
For ALT and AST, data from two studies including a total
of 619 patients were available [5, 12]: The mean difference
in ALT (Fig. 2) assessed within the first three postoperative
days was considered. While Pratschke et al. [5] found
significantly lower ALT values for utilization of a TPCS,
Ghinolfi and colleagues failed to demonstrate such a
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difference [12]. Moreover, for the combined effect no
significant reduction was found anymore (mean difference:
-192.84; 95 % CI -801.97, 416.29; p = .53).
For AST (Fig. 3), the effect size was reported as the
mean difference measured at the seventh postoperative day.
In both studies [5, 12], lower AST values were found in the
TPCS group. While this difference was not significant in
each individual study, the combined analysis showed sig-
nificantly lower AST values (mean difference: -25.96;
95 % CI -50.90, -1.03; p = .04) in the TPCS group.
For PNF (Fig. 4), data from three studies [5, 12, 13]
including a total of 676 patients were included. The
occurrence of PNF was compared using odds ratios. In
each of three studies patients operated with a TPCS showed
reduced odds for PNF; however, a significant difference
was only found in the study by Pratschke et al. [5]. The
combined odds for PNF was reduced in the TPCS group;
however, statistical significance was not reached (odds
ratio 0.32; 95 % CI 0.09, 1.16; p = .08).
Characteristics of the surgical intervention
For duration of operation (Fig. 5), data from five studies
[4, 5, 14–16] including a total of 880 patients were eval-
uated. The mean difference in the duration of the operation
was used as effect size. The mean duration of operation
was shorter in all studies, but only Arzu et al. [15] found a
significant shorter duration for the TPCS group. The
combined effect did not reach statistical significance (mean
difference: -40.77; 95 % CI -83.48, 1.94; p = .06).
For analyses of the PRBC requirement (Fig. 6), data
from six studies [5, 12–16] comprising 1328 patients were
included. The standardized mean difference of transfused
PRBCs was used as effect size. Raw data described either
the number of packs or units of PRBCs required during
surgery. In five of the six studies, fewer PRBCs were
required in the TPCS group [5–9]. In three of these studies,
the difference was statistically significant [12, 14, 16].
Only Pratschke et al. found a decreased number of trans-
fused PRBCs in the group without TPCS [5]. Though in
this study the TPCS group required more PRBCs than the
group transplanted without a TPCS, the combined effect
suggests a lower transfusion requirement (standardized
mean difference: -0.30; 95 % CI -0.56, 0.03; p = .03)
during surgery with TPCS.
To analyze the FFP requirement (Fig. 7), data from five
studies comprising a total of 927 patients were included
[4, 5, 12, 14, 15]. The standardized mean difference was
used as effect size. Raw fundamental data described either
the number of packs, units or number of concentrates, or
milliliters of FFP required during surgery. While in three
studies the mean difference was lower for the TPCS group
[12, 14, 15], in two studies it was lower for the group
without TPCS [4, 5]. However, the lower need for FFP in
Publications identified through 
database search: n=900 
Publications included in full text  
analysis: n=27 
Abstracts excluded  
(n=881) 
Publications included in qualitative analysis: 
n=12 
Publications identified through 
hand search: n=9 
Publications included for abstract screening: 
 n= 909 
Full texts excluded 
(n=15) 
- no TPCS (8) 
- no comparison of TPCS vs. no 
TPCS (n=6) 
- same study population (n=1) 
Total publications included in meta-analyses: 
n=6 
Studies excluded 
(n=6) 
- no outcomes of interest 
compared for TPCS vs. no 
TPCS (n=2) 
- Different OLT-techniques 
(n=2) 
- no unpublished data available 
(n=2) 
Fig. 1 Flow diagram of systematic literature search according to the PRISMA statement [21]
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Fig. 2 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on alanine aminotransferase values.
The size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
Fig. 3 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on aspartate aminotransferase. The
size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
Fig. 4 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on primary non-function. The size of
the squares indicates the weighting of the studies. The diamond indicates the overall effect size
Fig. 5 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on the duration of operation. The size
of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
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the group without TPCS was only statistically significant in
the study by Pratschke et al. [5]. The combined estimate
suggests no effect of TPCS on FFP requirement (stan-
dardized mean difference: 0.09; 95 % CI -0.71, 0.88;
p = .83).
Renal function
Data from four studies [5, 12, 15, 16] comprising a total of
1206 patients were included to investigate the effect on
creatinine values (Fig. 8). The standardized mean
difference was used as effect size. Raw data described
either creatinine level (in mg/dl) or creatinine clearance in
the early postoperative phase (3rd day). In all studies,
lower creatinine values were found for the TPCS group,
although this difference was not significant in the study by
Pratschke et al. [5]. The combined data showed a signifi-
cant (standardized mean difference: -0.29; 95 % CI
-0.53, 0.04; p = .02) reduction of the creatinine values in
the TPCS group. No information was available on the
percentage of renal replacement therapy from the studies
analyzed.
Fig. 6 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on the requirement for packed red
blood cell transfusion. The size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
Fig. 7 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on the requirement for fresh frozen
plasma transfusion. The size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
Fig. 8 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on creatinine levels on the 3rd
postoperative day. The size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
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Length of hospitalization
For the LOS (Fig. 9), data from three studies [4, 12, 15]
comprising a total of 414 patients were included. The mean
difference for LOS in days was used as effect size. This
mean was lower for the TPCS group in all studies; how-
ever, none of the studies showed statistical significance.
The combined effect did not reach statistical significance
(mean difference: -2.18; 95 % CI -5.60, 1.24; p = .21).
Heterogeneity in the studies
For ALT, duration of operation, red blood cell requirement,
FFP requirement and creatinine the I2 values indicated
substantial heterogeneity (I2[ 75 %, p\ .05).
Discussion
Cava-sparing techniques as described by Belghiti et al. [3]
have been developed to maintain the venous return to the
heart, thereby improving hemodynamic stability and renal
perfusion [8]. Additionally, the dissection of the
retroperitoneum can be omitted which results in reduced
blood loss. Nevertheless, ischemia–reperfusion injury still
remains a considerable issue and cross-clamping of the
portal vein with subsequent splanchnic congestion, gut
edema, bacterial translocation and sudden cytokine release
after release of the portal venous blood flow substantially
contributes to ischemia–reperfusion injury [7, 17–19].
Tzakis [20] and Belghiti [21] described a temporary
porto-caval shunt (TPCS), which was primarily designed
for patients with a lack of sufficient porto-caval collaterals.
Subsequently, this technique was also applied in patients
with adequate porto-caval collaterals. A TPCS may be
established using a temporary end-to-side porto-caval
anastomosis [21] or using an extracorporeal porto-caval
shunt catheter connecting the portal to the femoral vein [5].
The latter does not require anticoagulation or roller pumps
and is the preferred procedure at our department. Due to
the small number of reports, a separate analysis considering
the technique (plastic tube or temporary anastomosis
between portal vein and caval vein) was not performed.
Only one study from the USA was included in this meta-
analysis. The higher acceptance of a porto-caval shunt in
Europe as compared to North America could be the result
of regional differences in the average DRI and MELD
score between both transplant communities. As the use of a
TPCS still remains controversial [22–24], we sought to
investigate the effect of a TPCS on posttransplant
transaminases, primary graft non-function, duration of the
operation, transfusion of blood products, posttransplant
renal function and length of hospital stay (LOS).
All studies included the transfusion of packed red blood
cells (PRBC) as a surrogate marker for intraoperative blood
loss. The use of a TPCS significantly decreased the amount
of transfused PRBCs. One may hypothesize that decom-
pression of the portal vein would reduce blood flow in
preexisting portosystemic collaterals and thereby facilitate
intraoperative hemostasis. Although the determination of
hemodynamic stability was beyond the scope of this study,
one would speculate that lower blood loss would result in
improved hemodynamic stability. This question, however,
needs to be evaluated in a prospective trial. In contrast to
PRBC substitution, there was no significant difference in
the transfusion of FFPs between both groups. This suggests
that the trigger for FFP substitution is multifactorial and
does not solely depend on intraoperative blood loss. Use of
a TPCS was associated with a nonsignificant trend toward a
shorter operation time which might be due to multiple
confounders influencing operation time which were not
analyzed in this study. Differences in operation time may
also affect other outcomes. For instance, a reduction in
intraoperative blood loss could be the result of reduced
operation time. Interestingly, none of the studies reported
an increase in time of operation.
The length of hospital stay as a surrogate marker for
postoperative morbidity was analyzed. The use of a shunt
did not influence LOS. It must be stated that the mean LOS
in the European studies was longer than in the American
Fig. 9 Forest plot for the meta-analysis of studies examining the effect of a temporary porto-caval shunt on the length of hospital stay in days.
The size of the squares indicates the weighting of the studies. The diamond indicates the overall effect size
World J Surg (2016) 40:2988–2998 2995
123
study by Ghinolfi et al. [12]. Therefore, it cannot be
excluded that different health systems or other confounders
may contribute to this observation. No sufficient informa-
tion on the length of ICU-stay was available from the
analyzed studies.
One may speculate that improved central venous filling
and thus enhanced renal perfusion would contribute to
improved kidney function in patients operated with a
TPCS. In this respect, the meta-analysis of studies report-
ing creatinine values on the 3rd postoperative day revealed
a significant advantage for patients operated with a TPCS.
Despite this observation, it cannot be excluded that portal
venous blood flow prior to hepatectomy may also influence
this effect. Margarit et al. [25] have shown that renal
function in patients with a portal venous flow greater than
800 ml/min prior to hepatectomy was particularly
improved following the use of a TPCS. Two of the studies
incorporated in this meta-analysis reported improved
postoperative serum creatinine levels in patients with an
increased portal venous blood flow, whereas the two others
did not investigate portal venous flow in detail. The present
studies do not provide information on renal replacement
therapy. Nonetheless, patients with renal replacement
therapy also exhibit elevated creatinine levels. Moreover,
this systematic mistake accounts for both groups. There-
fore, elevated creatinine levels reflect a diminished kidney
function despite the above-mentioned limitation. However,
no final conclusion can be drawn on the impact of the
portal venous flow on postoperative renal function in liver
transplantation with and without TPCS.
Hepatic injury and liver function must be considered as
important parameters when analyzing the effects of TPCS.
AST and ALT levels represent clinical indicators for hep-
atic injury as a result of ischemia–reperfusion injury
[26, 27]. In the present analysis, significantly reduced AST
values were evident in patients transplanted with a TPCS.
This suggests that the utilization of a TPCS is associated
with decreased liver injury in this setting. In contrast, ALT
levels were not significantly improved. These parameters
may also be subject to unspecific effects.
Although there was a trend toward a reduction of the
rate of PNF in patients operated with a shunt, this obser-
vation only reached statistical significance in one study but
not in the pooled analysis. Since other factors, i.e., reduced
graft quality [28], ischemia reperfusion injury [6], etc., are
known to affect the occurrence of PNF, those confounders
should be considered in a prospective randomized trial
evaluating the potentially protective effects of a porto-
caval shunt.
The results of this meta-analysis favor the use of a TPCS
and indicate that important intraoperative parameters as
wells as parameters of the early postoperative phase are
improved. Examination of the underlying mechanisms for
the protective effects of a TPCS in liver transplantation on
cardiovascular stability and liver injury was beyond the
scope of the present analysis. Several potential mechanisms
may act synergistically in mediating the protective effects of
a TPCS. Previously, we have been able to show that the use of
a TPCS in liver transplantation is associated with an
enhanced portal venous blood flow [5]. This finding is clin-
ically relevant as graft survival is impaired in patients with
decreased portal venous blood flow [29]. Moreover, shunts
have been shown to reduce the incidence of postreperfusion
syndrome which may reflect improved central venous filling
and thus improved cardiac function and oxygenation [30].
Alternatively, decreased release of endotoxin and pro-in-
flammatory mediators from the gut and liver due to reduced
bacterial translocation in the gut may contribute to hemo-
dynamic stability and reduced liver injury [17–19]. These
findings need to be evaluated in prospective trials.
This study has several limitations. The number of
identified studies is low which is due to the fact that the
evidence on the application of a TPCS in liver transplan-
tation is scarce. Moreover, no sufficient information on
long-term survival eligible for this meta-analysis was
available in the included studies. Furthermore, only one
randomized controlled trial (RCT) could be included. Due
to the paucity of available publications, the authors had to
combine non-RCTs with the one available RCT. In this
respect, the identified heterogeneity for some of the out-
comes suggests diversity regarding clinical, i.e., donor and
recipient characteristics (donor risk index, MELD score),
and methodological parameters among the studies which
cannot not be clarified from the present data. To address
this heterogeneity, we applied random-effect models,
which only allow the identification of an average inter-
vention effect compared to a best estimate of an inter-
vention effect when applying fixed-effect models. The
meta-analysis, however, contains heterogeneous data
which may bring a potential bias to the results but also
underlines the need for a prospective trial on this issue.
The present data indicate similar donor and recipient
conditions whether a shunt had been inserted or not. In this
respect, three studies demonstrate similar MELD scores
[5, 12, 15], three manuscripts indicate similar CHILD Pugh
scores [4, 14, 16], and all studies give more or less detailed
information on indications for liver transplantation which
do not seem to differ between the groups. Nevertheless, the
scarcity of information on potential risk factors for the
outcome after liver transplantation in all studies clearly
represents a limitation of this meta-analysis. Two studies
incorporated the DRI in their analysis [5, 12] suggesting
that no differences in the DRI between patients with or
without shunt were evident. Interestingly, these studies also
indicate a more pronounced impact of a shunt in trans-
plantation of grafts with high donor risk indices, but not in
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patients with high MELD scores. This suggests that besides
those risk factors mentioned above usage of a shunt affects
outcome after liver transplantation.
Nevertheless, this meta-analysis cannot provide infor-
mation about the rationale and the indications for the use of
a shunt: This is mainly due to the retrospective study
design of the included trials, and only one prospective trial
by Figueras et al. [4] was available. One could speculate
that patients with a lack of adequate collaterals (i.e., in
acute liver failure) would benefit most from a shunt. No
evidence can be found for this hypothesis from the present
data. Therefore, no recommendation can be given which
indications should preferably be treated with a shunt (i.e.,
chronic vs. acute liver diseases) currently.
Despite these limitations, the application of a TPCS
seems to exert beneficial effects in cava-sparing liver
transplantation. Since a selection bias in any retrospective
analysis cannot be excluded, the positive data of the pre-
sent meta-analysis have to be confirmed within a
prospective randomized trial.
Conclusion
Temporary porto-caval shunts are a simple and effective
technique to decrease blood transfusion, ameliorate post-
operative renal function and reduce hepatic injury in liver
transplantation. Since previous data show some limitations,
this method must be analyzed in a prospective trial.
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